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ABSTRACT 
Background:  Syphilis transmission remains a global problem with an estimated 12 million 
people infected each year. Ninety percent of syphilis cases occur in low income countries. 
Syphilis is a serious source of adverse pregnancy outcomes for both mother and infant. 
Ideally, syphilis screening should be provided as part of a package of maternal and newborn 
health-care services. This thesis reports on a pilot intervention study to develop, implement 
and evaluate a point of care test for syphilis in antenatal care services in rural Burkina Faso. 
 
Methods: This study used a pre post intervention mixed methods quasi-experimental design 
with a group of health facilities offering ANC services (primary health centers in rural area) 
as the sampling units. This study was conducted in three phases, which consisted of a 
situational analysis using qualitative methods (Phase 1), selecting an appropriate test through 
evaluating 4 candidate tests and the participatory design and implementation of an 
intervention that included onsite training, provision of supplies and medicines, quality control 
and supervision (Phase 2), and an evaluation combining review of record tools, interviews, 
time motion study and estimating incremental costs (Phase 3).  The conceptual framework 
draws on multilevel assessment (MLA), policy triangle framework, MRC framework for 
designing complex interventions and the Normalization Process Model (NPM). Methods 
included document review, seventy five interviews were conducted with health providers, 
district managers, facility managers, traditional healers, pregnant women, community health 
workers, and Non-Governmental Organizations (NGO) managers in phase I and fourteen in 
phase III, non-participant observation, time-motion study, incremental cost analysis, and 
sensitivity, specificity and ease of use analysis of four candidate point-of care tests.  Data 
were collected between 2012 and 2014. Qualitative data were analyzed through thematic 
analysis supported by Nvivo software. Quantitative data were analyzed through descriptive 
statistics such as frequency, mean and median supported by SPSS.  
 
Findings: Phase I identified barriers to implementation and uptake of syphilis testing at 
health provider and community levels. The most important barriers at provider level included 
fragmentation of services, poor communication between health workers and clients, failure to 
prescribe  syphilis test, and low awareness of syphilis burden. Cost of testing, distance to 
laboratory and lack of knowledge about syphilis were identified as barriers at community 
level. Phase II: Alere DetermineTM Syphilis was the most sensitive of the four point-of-care 
tests evaluated. The components of the intervention were successfully implemented in the 
selected health facilities.  Overall, phase III showed that it is feasible and acceptable to 
introduce a point of care test for syphilis in antenatal care services at primary health care 
level using the available staff. The intervention was reported as acceptable, but of 812 
pregnant women who came for their first visit 39% were screened during the study period. 
Rural facilities had higher coverage (66.8%) than the urban ones (25.6%). Quality control 
found no discordance between the rapid test and TPHA results. The average cost of ANC per 
unscreened pregnant woman was 3.11 USD (±0.14) vs 5.06 USD (±0.16) per screened 
woman. The main cost driver was the material costs notably the test itself.  The test’s cost is 
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comparable to HIV test costs, but funder support for integrating this additional test is less 
readily available than for HIV tests. 
 
Conclusions: The findings suggested that an intervention that introduces point of care test for 
syphilis at antenatal care services is feasible, acceptable, and of comparable costs to HIV 
screening in pregnancy. Nonetheless, instructions and supervision need to be clearer to 
achieve optimal levels of screening and quality control, and barriers identified by health 
workers need to be overcome. The point-of care test for syphilis is likely to be acceptable by 
health workers as a routine service and incorporated as a normal practice in Burkina Faso 
context. 
 
 
Keywords: Syphilis screening, antenatal care, prenatal diagnosis, point of care test, 
incremental cost, health policy and systems, primary health care, feasibility, Burkina Faso. 
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CHAPTER 1: Introduction 
 
1.1. Background 
 
Syphilis transmission remains a global problem with an estimated 12 million people infected 
each year (WHO, 2007b) . The prevalence ranges from less than 1% to 10% and ninety 
percent of syphilis cases occur in low income countries (Peeling & Mabey, 2004).  
 
Syphilis is a serious source of adverse pregnancy outcomes for both mother and infant (Di 
Mario, Say, & Lincetto, 2007)  and can also facilitate HIV acquisition and transmission 
(Mwapasa et al., 2006; Reynolds et al., 2006) . If left untreated, maternal syphilis infection 
has significant medical, economic, and societal consequences (Levin et al., 2007). Among 
infected pregnancies, a quarter will end in stillbirth or spontaneous abortion (S. Hawkes, 
2009). Neonatal deaths and prematurity or low birth weight are respectively 9.3% and 5.8% 
more frequent in untreated pregnant women with syphilis (Gomez et al., 2013).  
 
Congenital syphilis is also a consequence of undiagnosed, untreated, or inadequately treated 
maternal syphilis (D. G. Walker & Walker, 2002). Mother to child transmission of syphilis 
decreases from 100% at the early stage of the infection to up to 70% four years after the 
acquisition of the disease, to almost 0% at the late latent stage (Berman, 2004). Thus early 
detection and prompt treatment of maternal syphilis will reduce adverse pregnancy outcomes, 
avert costs of subsequent treatment of live born infants infected with syphilis, and benefit the 
mothers’ health  (S. J. Hawkes, Gomez, & Broutet, 2013). 
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However, maternal syphilis is an under-recognized health problem (D. G. Walker & Walker, 
2002). Health care systems increasingly concentrate on preventing infants from becoming 
infected by HIV.  The scale-up of programs for the prevention of mother-to-child 
transmission of HIV (PMTCT) has attracted the attention of new global funding initiatives in 
resource-poor countries (Thorne and Newell, 2003). In contrast, syphilis screening and 
prevention have been ignored by both national programmes and international funders, even 
though the prevention of maternal syphilis is inexpensive and cost effective and thus 
compares very favourably with PMTCT (F Terris-Prestholt et al., 2003).  
 
Screening and treatment of pregnant women for syphilis remain cost-effective even when the 
prevalence is low (Connor, Roberts, & Nicoll, 2000). Its management relies on serologic 
screening in pregnancy and treatment with injectable penicillin. Ideally, syphilis screening 
should be provided as part of a package of maternal and newborn health-care services (WHO, 
2007b). 
 
1.1.1. Accelerating global action for controlling congenital syphilis  
 
In the last ten years, publications on syphilis have increased, especially about maternal and 
congenital forms. This indicates a reawakening of concern and has led to the launch of a 
global initiative. In 2007, World Health Organization (WHO) launched a global initiative for 
the elimination of congenital syphilis. A five year plan (2010-2015) was developed, aimed at 
eliminating congenital syphilis in up ten countries which account for over 40% of the 1.2 
million adverse pregnancy outcomes related to syphilis in pregnant women (WHO, 2007b). 
The strategy of WHO rested on four pillars. Among these pillars screening and treatment of 
pregnant women and their partners is a key component. The process should be country-driven 
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taking into account contextual factors such as antenatal conditions. Each country has to 
define the best way for screening and treatment of pregnant women and their partner in an 
integrated approach for delivery a total package for maternal and newborn health care. 
 
1.1.2.  Need for effective comprehensive antenatal care package 
 
The philosophy of antenatal care is to detect and treat conditions in the mother and her fetus 
(es) which may threaten her pregnancy (Lumbiganon, 1998). In the early 2000s, WHO 
launched the focused ANC strategy that emphasized a limited number of evidence-based 
essential practices and screenings.   Most low and middle-income (LMIC) countries are 
implementing the focused antenatal care approach, in which early detection of existing 
diseases such as malaria, HIV, syphilis and other STIs is one of the goals. Many national 
policy and management of maternal care guidelines emphasize the importance of diagnosing 
and treating pregnant women for reproductive tract infections (RTIs) using the syndromic 
approach, and screening all women for syphilis with available tests. 
 
 In 2001, a study among 22 ministries of health in sub-Saharan Africa  found that 77% 
reported universal syphilis screening to be a national norm for pregnancy care (S Gloyd, 
Chai, & Mercer, 2001).     However, the levels of actual implementation of the syphilis 
component of the ANC package are low with on average 38%  (with a range of 1-92% ) of 
women with syphilis screened and treated (S Gloyd et al., 2001; Hoque, Hoque, & Kader, 
2008; Manabe et al., 2015).  
 
In most African countries, including Burkina Faso, blood pressure checks, urine tests for 
sugar and protein, testing for HIV and provision of medicines such as iron tablets and 
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sulfadoxine–pyrimethamine for intermittent preventive treatment of malaria are an integral 
part of ANC in many public primary health facilities. In contrast, screening for syphilis is 
largely restricted to facilities with laboratory services. Thus there are clearly unmet needs that 
need to be covered with a comprehensive ANC package for all pregnant women wherever 
they are. It is also important to identify the barriers and challenges to the implementation of 
the antenatal syphilis screening policy in the field. 
 
1.2. Rationale 
 
In Burkina Faso, syphilis remains an important public health problem, with significant 
regional variations. The National HIV/STI Sentinel Surveillance program has reported a 
national prevalence of 1.9% in 2011 with important sites variations from 0.2 to 7.3 % (figure 
2).   
 
Figure 1: Prevalence of sites surveillance in 2011 in Burkina Faso 
 
 
Source data: PSSLS-IST, report 2011 (PSSLS-IST, 2013) 
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Prenatal syphilis testing is not systematic even though the detection of STIs is listed in the 
national prenatal consultation guidelines. When it does occur, detection of syphilis and STIs 
in general, is based on syndromic management. At the early stage with genital ulcers, 
syndromic management works well. In general syndromic management is effective if 
symptoms are reasonably sensitive and specific indicators of STI (Colvin et al., 2006). In the 
case of syphilis, however, the primary lesions are often painless and unseen, and secondary 
syphilis is also often characterized by non-specific signs and symptoms (Nessa et al., 2008).  
 
Most pregnant women are treated presumptively, based on symptoms. This is particularly 
true at primary health care settings. In 2001, the assessment of this syndromic management 
approach which had theoretically been implemented since 1996, showed low rates of 
screening: 4 to 13% (Kouanda, Sama, Catraye, Nougtara, & Ki-Zerbo, 2003). These data 
suggest that policy makers, program managers and health professionals might benefit from 
knowing if there are other feasible and affordable strategies for detection of early maternal 
syphilis in order to prevent congenital syphilis. 
 
 A wide range of tests for diagnosis of syphilis are now available but there is no single 
optimal test (Ratnam, 2005). A number of laboratory test methods are used for syphilis 
diagnosis. The two tests most commonly used are the VDRL (Venereal Disease Research 
Laboratory) and the RPR (Rapid Plasma Reagin) tests (S Gloyd et al., 2001). In Burkina 
Faso, syphilis testing is laboratory-based- using VDRL and Treponame pallidum 
hoemagglutination assay (TPHA) tests that require appropriate laboratory instrumentation 
with trained personnel and a source of electricity. Access to laboratory based tests is 
restricted to facilities with laboratory services, mainly urban facilities. Generally laboratories 
are not available in primary health care settings. In addition this mode of testing  does not 
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allow providers and patients to get results and provision of treatment in the same day, 
resulting in additional direct and opportunity costs for returns to health facilities, as well as 
loss to follow up.  
 
 Recently, a number of simple and rapid tests have become commercially available. These 
tests are simple, robust, and affordable and can be stored and transported without need for 
refrigeration (Herring et al., 2006a). In addition they provide results in about 15 minutes, 
enabling immediate treatment (D Mabey et al., 2006). Both VDRL and rapid treponemal tests 
are cost-effective but the rapid test offers the potential to reach greater numbers of women, 
especially in areas where screening with VDRL is difficult to implement  (Rydzak & Goldie, 
2008; Watson-Jones et al., 2005).  
 
These rapid syphilis tests have been introduced in some countries in Africa ((Bonawitz et al., 
2015; Dassah, Adu-Sarkodie, & Mayaud, 2015; Stephen Gloyd et al., 2007) . They are also 
available in Burkina Faso but they are not used for antenatal screening in the health system. 
To our knowledge no study has provided evidence regarding which rapid syphilis tests could 
be used in the Burkina Faso context, nor on how they could be introduced as part of the ANC 
package.  
 
It is against this background that our study assessed the feasibility of integrating syphilis 
point-of-care diagnostic testing in the package of antenatal care, with the aim of guiding 
decision makers on a feasible, acceptable and affordable approach to adopt for maternal 
syphilis screening and treatment in order to enhance the prevention of congenital syphilis. 
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The following research questions were formulated: 
Is it feasible to introduce a rapid syphilis test in the package of antenatal care in limited 
resources countries at primary health care level (case of Kaya health district, Burkina Faso)?  
 
Subsidiary questions included: 
1. How do antenatal syphilis screening and treatment currently perform operationally in 
primary health care facilities in Kaya health district? 
2. What are the facilitators and barriers to introduce rapid syphilis tests in the package of 
antenatal care services at the rural primary health care facilities? 
3. What are the additional costs of introducing the rapid syphilis tests in the package of 
antenatal care services at the rural primary health care facilities? 
  
1.3. Overall aim and objectives of the research  
 
1.3.1.  Aim 
 
This study aimed to evaluate the feasibility of introducing an on-site test for maternal syphilis 
into the package of antenatal care services in order to improve practical responses to maternal 
and newborn health in Burkina Faso.   
 
1.3.2.  Objectives 
 
The main objective was to assess the constraints, acceptability and cost of introducing an on-
site test for maternal syphilis screening in the package of antenatal care services in rural 
primary health care in the district of Kaya in Burkina Faso. 
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The research was conducted in three phases with the following specific objectives of the 
study: 
PHASE I: Situation Analysis of the current strategy 
1. To examine health workers’ perspectives on strategies for managing antenatal syphilis 
screening.  
2.  To analyze the operational performance of the current antenatal syphilis screening 
and treatment strategy at primary health care facility level. 
3. To explore women’s perceptions and costs related to syphilis screening. 
 
PHASE II: Pilot test of the provision of onsite test of syphilis  
4. To design a model that integrates the provision of a point of care test of syphilis for 
antenatal care services. 
5. To implement the model of the provision of a point of care test of syphilis for 
antenatal care services. 
 
PHASE III: Evaluation of the provision of the onsite test of syphilis for antenatal care 
services and Costing 
6. To evaluate the effects of the provision of the on-site test of syphilis on antenatal care 
services and practices of health workers. 
7. To identify barriers and facilitators to introducing a point of care test of syphilis at 
primary health care facility level. 
8. To estimate the additional cost to introducing of the point of care test for antenatal 
services. 
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1.4.  Structure of the thesis 
The thesis is presented in eight chapters with four chapters of results in the form of 
manuscripts published or submitted to peer-reviewed journals.  Chapter 1 is an introduction 
which includes the aim and objectives of the research.   Chapter 2 presents the literature 
review and the theoretical framework developed for the study. Chapter 3 presents the 
methods used for the three phases of overall intervention study. In chapter 4, the situational 
analysis of antenatal syphilis screening is presented. Chapters 5 and 6 cover the design, 
implementation and evaluation of the intervention. This includes the barriers and facilitators 
to implementation of the intervention. Chapter 7 discusses the costing analysis of the 
intervention. Finally chapter 8 discusses the findings, contribution of the thesis, and 
recommendations.  
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CHAPTER 2: Literature review 
2.1. Overview of Maternal syphilis burden  
 
In a recent review of studies published between 1990-2011, syphilis prevalence estimates 
were 4.5% (3.9%-5.1%) in East and southern Africa and 3.5%(1.8%-5.2%)  in  West and 
Central Africa (Chico, Mayaud, Mabey, & Ronsmans, 2012).   
With respect to maternal syphilis, the World Health Organization (WHO) estimates that 2 
million pregnant women are infected with syphilis worldwide each year. Approximately 1.2 
million pregnant women with syphilis transmit the infection to their newborn (Kamb et al., 
2010).  The figure below illustrates the global distribution of new cases of syphilis per year. 
Sub-Saharan Africa and South and Southeast Asia bear the highest burden of the disease. 
The prevalence in developing countries ranges from less than 1% to 10%.  
 
African studies showed prevalence during pregnancy of 2% in Mali (WHO, 2007b), 5.3% in 
Kampala Hospital and rural ANC centers in Uganda (D. C. Mabey et al., 2012), 9.2% in 
Lusaka Hospital and rural ANC centers in Mongu District, Zambia (D. C. Mabey et al., 
2012), 9% in Sudan (Nagi, Allah, & Khalil, 2008), and 10.9% in 51 facilities in Tanzania (D. 
C. Mabey et al., 2012). In most of these countries, the prevalence of human 
immunodeficiency virus (HIV) is also high and syphilis facilitates its transmission. 
Dramatically increased HIV screening has not been accompanied by improved syphilis 
screening, so people are ‘avoiding HIV and dying of syphilis’ (Peeling & Mabey, 2004).  
 
In countries where prevalence is low, the question of whether routine antenatal screening for 
syphilis is still justified has been raised (Kiss, Widhalm, Geusau, & Husslein, 2004; Obi-
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nwosu, 2015) . However these figures have to be carefully interpreted because of differences 
in sources, samples size, type of testing, and health facilities levels. Moreover, most low and 
middle income countries without a functional syphilis screening program are unlikely to have 
a functional reporting system (Newman et al., 2013). 
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Figure 2: Percentage of antenatal care attendees positive for syphilis  
 
Source: WHO, 2014. (WHO, 2014) 
2.2. Overview of maternal syphilis in Burkina Faso 
 
Kirakoya et al (2010) conducted a serosurvey of 2,136 pregnant women from 98 healthcare 
facilities in 2003. The study showed a higher prevalence among pregnant women from semi-
urban areas (2.2%, 95% CI 1.0 to 4.5) compared with rural areas (1.7%, 95% CI 1.2 to 2.4, 
p=0.06). Age, marital status, location and education were not associated with syphilis 
infection (Kirakoya-Samadoulougou et al., 2011) .  
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A study carried out from 1995 to 1998 in three antenatal clinics in Bobo Dioulasso, the 
second largest city in Burkina Faso, also showed a low prevalence of syphilis infection 
among 10,980 pregnant women. Syphilis seroprevalence was 0.24% (95% confidence 
interval (CI): 0.15–0.35) without changes over time. HIV infection, illiteracy, and having 
casual sex partners were the independent risk factors for syphilis infection (Sombie et al., 
2000).  But Meda et al (1997) found a high prevalence of STDs in pregnant women in the 
two largest urban centers in Burkina Faso in 1994. A total of 645 consecutive pregnant 
women were enrolled and 32.4% presented at least one STD. Among them, 3.6% had recent 
syphilis (Meda et al., 1997).  
 
Nagot et al (2004) in a review of STI and HIV epidemiological data from 1990 to 2001 
suggests a decline and that it could be explained by the adoption of safer sex behavior, the 
introduction of the syndromic management (SM) approach, or the higher use of antibiotics 
(Nagot, Meda, & Ouangre, 2004). However, the more recent seroprevalence results (PSSLS-
IST, 2013)and the Kouanda et al (2003) evaluation of the syndromic management program 
suggest in contrast that syphilis remains a significant problem in Burkina Faso, and that 
existing policies and strategies face serious implementation gaps (Kouanda et al., 2003). 
 
2.3. Impact of syphilis on pregnant women and their babies 
 
Syphilis infection in pregnancy is associated with fetal and early infant death and adversely 
affects the issue of the pregnancy. The risk of vertical transmission could be up to 80% in 
early latent syphilis (WHO, 2007b).  Many studies in Africa demonstrated an association 
between syphilis and adverse pregnancy outcomes. Schulz et al. (1987) estimated that 5- 8% 
of all pregnancies surviving past 12 weeks will have an adverse outcome caused by syphilis, 
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such as spontaneous abortion, perinatal or infant death or a living infant with syphilis in 
Africa (Schulz, Cates, & O’Mara, 1987).  
 
Results from a study in Malawi have shown that  nearly 1 out of 4 stillbirths, 1 out of 9 
neonatal deaths, and 1 out of 25 post neonatal deaths were attributed to maternal syphilis 
(McDermott, Steketee, Larsen, & Wirima, 1993) . Gomez et al. (2013) conducted a 
systematic review and meta-analysis of reported estimates of adverse pregnancy outcomes 
among untreated women with syphilis. They found that among untreated pregnant women 
with syphilis, fetal loss and stillbirth were 21% more frequent, neonatal deaths were 9.3% 
more frequent and prematurity or low birth weight were 5.8% more frequent than among 
women without syphilis (Gomez et al., 2013).  
 
Untreated maternal syphilis results in congenital infection of newborns. Half of infants born 
with congenital syphilis die within their first year of life (WHO, 2007b) and 492 000 infants 
in Sub-Saharan Africa die annually from congenital syphilis (Schmid, 2004). Diagnosis of 
congenital syphilis is based both on a clinical evaluation and laboratory investigations 
(Saloojee et al., 2004a). Clinical suspicion of syphilis may lead to laboratory tests. However, 
clinical diagnosis is complicated because more than half of infants are asymptomatic at birth 
and signs such as prematurity, low birth weight, respiratory distress or fever,  are nonspecific 
to syphilis (Genc & Ledger, 2000) .   
 
Confirmation of a clinical suspicion requires combination of different tests such as IgM 
immunoblotting, PCR, lumbar puncture or bone radiograph. In poorly-resourced settings 
access to these tests are generally restricted or inexistent. The available tests such as VDRL 
and RPR are difficult to interpret because they should be compared with maternal serological 
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titres using the same test (Saloojee et al., 2004a). The main factor responsible for the 
continued incidence of congenital syphilis is the lack of adequate prenatal screening and 
treatment. 
 
In conclusion, many studies in sub-Saharan Africa have explored the effects of Syphilis on 
pregnancy outcomes. Few have examined the potential confounding effects on pregnancy 
outcome of factors such as human immunodeficiency virus (HIV) infection, and maternal 
malaria or anemia. 
 
 
2.4. Screening and treatment of syphilis in pregnancy 
The cornerstone for the control of maternal syphilis is the screening and treatment of women 
during pregnancy. Different interventions, such as mass treatment, and antenatal screening 
and treatment have been explored and evaluated. 
 
Mass treatment means that treatment is given to people without screening. A home-based 
antibiotic mass treatment in 15-59 year olds in an area in Uganda resulted in a significantly 
reduction of syphilis prevalence (Wawer et al., 1999). Targeted mass treatment also has an 
effect. Terris-Prestholt et al. showed that in high prevalence settings, mass treatment of all 
pregnant women presenting at ANC was relatively cheap and effective in the absence of 
screening supplies (Fern Terris-Prestholt et al., 2015).  
With screening supplies, antenatal syphilis screening could be implemented. Blencowe and 
colleagues argue that detection and appropriate, timely penicillin treatment are a highly 
effective intervention to reduce adverse syphilis related pregnancy outcomes (Blencowe, 
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Cousens, Kamb, Berman, & Lawn, 2011).  Examples of effective antenatal syphilis screening 
programs were documented for different settings including Bolivia (Garcia et al., 2007) , 
China (Cheng et al., 2007), Haiti (Schackman et al., 2007),  Kenya (Fleming et al., 2013; 
Jenniskens et al., 1995), Mongolia (Munkhuu, Liabsuetrakul, McNeil, & Janchiv, 2009), 
Mozambique (Stephen Gloyd et al., 2007; Osman, 2000), South Africa (Bronzan et al., 
2007a; Myer, 2003)  and Zambia (Bonawitz et al., 2015; Hira et al., 1990). With development 
of diagnostic tests, most of these programs involve decentralized interventions using point-of-
care testing and same-day treatment. A systematic review on interventions to improve 
screening for syphilis in pregnancy found that the effects on the uptake of testing for and 
treatment of antenatal syphilis were varied and the incidence of perinatal death and stillbirth 
was decreased by 50% (S. Hawkes, Matin, Broutet, & Low, 2011). .  
 
Although the advantages of introducing point of care test for syphilis in antenatal care are 
well documented, there is little evidence on how to address the structural issues within the 
health system (S. Hawkes et al., 2011). A better understanding on how the interventions work 
in a range of settings and contexts is needed in order to overcome bottlenecks at health 
system level.   
 
Most interventions for syphilis screening are implemented within antenatal services. Thus 
factors affecting attendance to ANC also affect syphilis screening for pregnant women. The 
barriers to the effectiveness of maternal syphilis screening and treatment are at policy, health 
provider, patient, and community levels. Many ANC programs in sub-Saharan countries do 
not provide syphilis testing, even if there is a national policy of testing. Gloyd et al. carried 
out a survey among 22 Ministries of Health in sub-Saharan Africa, complemented by data 
from published sources and key informants. This study found that over three-quarters of them 
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had national policies for syphilis screening in pregnancy. But of women in antenatal care, 
only 38% were estimated to be screened for syphilis. Cost of testing or treatment and the 
organization of services are the principal obstacles (S Gloyd et al., 2001).  
 
At facility and health provider levels, supplies, drugs, notification cards, and other 
consumables are often unavailable (Deperthes, Meheus, O’Reilly, & Broutet, 2004). Non 
prioritization of syphilis screening for the first antenatal visit, unawareness of the burden of 
congenital syphilis, difficulty to access to laboratory, especially at lower level facilities, are 
identified barriers (Schmid, 2004). Other factors such as the skills and motivation of 
healthcare workers are also contributing to the failure to screen women (Stephen Gloyd et al., 
2007; Watson-Jones et al., 2005).  
 
At the patient and community levels, Romoren and Rahman in Botswana show that uptake 
late in pregnancy delayed treatment and a high rate of seroconversion after testing were 
obstacles (Romoren & Rahman, 2006). Moreover Hawkes et al. argue that women who 
received the appropriate antenatal services in their two first trimesters were more likely to 
have a healthy infant, compared to women who were first seen in the third trimester (S. J. 
Hawkes et al., 2013). Communities may not perceive syphilis to be a problem because of its 
lack of visibility (Saloojee et al., 2004a). This influences the perception of the patient and 
his/her health-seeking behavior. 
 
The potential factors affecting syphilis screening at health provider and patient levels are 
summarized in the figure below.  
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Figure 3: Potential factors affecting syphilis screening and treatment at health provider and 
patient level 
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2.5. Economic studies on maternal syphilis 
 
The use of point of care tests such as immunochromatographic strip (ICS) tests for antenatal 
syphilis screening is highly cost-effective in sub-Saharan Africa (Kuznik, Lamorde, 
Nyabigambo, & Manabe, 2013). Screening and treatment of pregnant women for syphilis 
remain cost-effective even when the prevalence is low (Kahn et al., 2014; Schmid, 2004; F 
Terris-Prestholt et al., 2003). Studies used cost analysis or cost effectiveness approaches and 
cover one or more countries. 
 
Among studies in one country, Hira et al (1990) estimated the incremental cost effectiveness 
of a syphilis screening program that included health education and attempted to screen 
women twice during pregnancy in Zambia. The cost of each prenatal screening is US$0.60 
and of averting each adverse outcome US$12. It appears that they modeled the costs, rather 
than costing the actual project as implemented, and did not include any training or labour 
costs (Hira et al., 1990). A more recent  and comprehensive study found that among new 
ANC patients cost effectiveness improves dramatically if  those found positive are treated 
because additional treatment costs little but DALYs avoided are substantial (Larson et al., 
2014). 
Fonck et al (2001) assessed the performance, effectiveness, and costs of a decentralized 
antenatal syphilis screening program in Nairobi, Kenya after 6 years.  A cost analysis was 
conducted from the viewpoint of the payer. The total cost of the syphilis screening program 
for 1 year was US $30996. The total cost of testing and treatment was $18 429. The cost per 
case averted varies between US $95 and US $112. More detailed costs were presented, but 
neither the costs of initial staff training nor clinic staff salaries were included (Fonck et al., 
2001).  
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Terris-Prestholt et al. estimated the cost effectiveness of on-site antenatal syphilis screening 
and treatment in Mwanza, Tanzania and compared this intervention with other antenatal and 
child health interventions, specifically the prevention of mother to child transmission of HIV 
(PMTCT).  They found that syphilis screening is at least as cost effective as PMTCT and 
more cost effective than many widely implemented interventions (F Terris-Prestholt et al., 
2003). In the same site, Vickerman et al. estimates the relative cost-effectiveness of using 
these points of care tests in the Mwanza (Tanzania) syphilis screening intervention. Empirical 
cost and epidemiological data were used to model the potential benefit of using Point of care 
(POC) tests instead of RPR. The cost-effectiveness of using POC tests is mainly dependent 
on their cost and sensitivity for high titre active syphilis (HTAS) (Vickerman et al., 2006).  
 
Multi-countries studies show similar results.  Rydzak et al compared 3 approaches; screening 
with ICS, conventional screening and no screening from the societal perspective in sub-
Saharan Africa. Universal antenatal syphilis screening using rapid point of care tests is cost 
effective. But RPR was preferred when the ICS cost more than doubled or ICS test sensitivity 
fell below 88% (Rydzak & Goldie, 2008).    Kuznik et al. found that syphilis screening using 
ICS in 43 sub saharan countries was highly cost-effective, with each DALY prevented on 
average costing only US$11(Kuznik et al., 2013). A study of 10 antenatal syphilis screening 
and treatment approaches found that single rapid syphilis tests (RST) were the most cost 
effective follow by dual RST. But in case that the costs of dual RST were halved, the dual 
became more cost effective (Fern Terris-Prestholt et al., 2015).  
 
Cost effectiveness studies in Africa are concentrated in high prevalence countries such as 
Zambia, Kenya, or Tanzania. Studies on low prevalence countries such as West African 
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countries, used literature data and deplored the lack of field data (Kuznik et al., 2013). Thus 
data from these settings are needed for adding knowledge to the existing literature.    
 
 
2.6. Conceptual framework 
 
This section discusses the theories or models that have influenced the design of the research 
or data analysis and how they were adapted to the various phases of this research. 
  
Research including intervention studies for antenatal syphilis screening have tended to focus 
on understanding one or two domains within a program , such as the perspectives of the 
community or the providers (S. Hawkes, Miller, Reichenbach, Nayyar, & Buses, 2004). The 
Multilevel assessment (MLA) approach was developed by Hawkes et al.(S. Hawkes et al., 
2004) in order to understand the viewpoints and expectations of all major stakeholders as 
identified in section 2.4.  MLA is based on a number of existing methods for assessing needs 
in health programs. Undertaking MLA consists in identifying stakeholders, identifying 
interlinked perspectives, and analyzing these perspectives within the socioeconomic, cultural 
and political environment within which an intervention is designed to be delivered. MLA 
approach was adapted for the situational analysis that was conducted in phase 1.  
 
A complementary approach was also adopted for policy analysis of antenatal syphilis 
screening. This approach was based on the policy triangle framework developed by Walt and 
Gilson (Walt & Gilson, 1994). This framework has been used to analyze a large number of 
health issues, including antenatal syphilis control. The framework takes into account the 
program content, the actors involved, the processes contingent on developing and 
implementing change, as well as the context within which changes are introduced. In our 
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case, it was useful for examining factors that have affected implementation of the policy in 
practice, and circumstances that have influenced its outcomes. 
 
 
Many simultaneous activities are necessary to reduce syphilis because of the interactive 
behavioral and biologic dynamics of sexual spread. The approaches taken for syphilis, and 
the measures used, have been a model for other control programs such as tuberculosis, 
immunization, maternal and child health, and human immunodeficiency virus (HIV) (Cates et 
al., 1996). A syphilis control intervention is a complex intervention that requires exploring 
theory on complex interventions. 
 
A complex intervention is built up from a number of components, which may act both inde-
pendently and interdependently (MRC, 2008). Interventions widely used in the health 
services, in public health practice, and in areas of social policy could be considered as 
complex interventions. The theoretical framework used is grounded in the United Kingdom 
Medical Research Council (MRC) framework. In 2000, the UK MRC published a Framework 
in order to help researchers and research funders to recognize and adopt appropriate methods. 
This approach has been influential internationally. In 2008, the Council has revised and 
updated the guidance.  The MRC framework emphasizes a staged approach to establishing 
the feasibility of interventions before embarking on large-scale evaluations (May et al., 
2007). The revised approach comprises four major phases: development, feasibility, 
evaluation and implementation (see figure below). The process from development through to 
implementation of an intervention does not follow a linear sequence (Campbell et al., 2007). 
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Figure 4: Key elements from the development to the implementation of MRC framework 
 
 
 
Source: adapted from Craig et al., 2008 
 
Our process consisted in identifying the existing evidence in order to learn about and from 
similar interventions; then to develop a theoretical understanding of the intervention and 
incorporate insights from the theory into an explicit model of how the intervention might 
influence outcomes.  
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2.6.1.  Identification of components of intervention  
 
From the phase of identifying evidence from antenatal syphilis screening interventions, we 
identified key components that are screening, and treatment as highlighted in section 2.4.  
With advances in diagnostic tools, screening is very helpful in identifying individual with or 
without syphilis. The type of screening depends on the epidemiology of conditions, but 
targeted screening is generally more cost effectiveness than mass screening (D. G. Walker & 
Walker, 2002). In our case, targeted screening was selected for pregnant women according to 
the evidence on its effectiveness (Shahrook, Mori, Ochirbat, & Gomi, 2013).  
The literature also identifies different types of treatment. Selective or mass treatment are the 
two major interventions. Depending on the prevalence, one or the other intervention is 
adequate and effective. A mass treatment is useful to interrupt an ongoing syphilis epidemic. 
Community mass treatment could be also interesting, in the case of maternal syphilis, when 
partner notification is not effective. For this intervention, selective treatment for pregnant 
women was chosen as the target of the study was pregnant women in ANC services.  
 
In addition to these components, partner notification is also an important element for 
preventing re-infection of the patient and transmission of the STI to others. The partner 
notification process involves a series of interrelated activities. Strategies such as patient 
referral (in which the index patient informs the partner and refers him/her for care, provider 
referral (in which healthcare staff notifies the partner) and contact referral (in which the index 
patient notifies the partner with the understanding that health care staff will contact the 
partner when s/he has not visited the clinic by a certain date) have been developed with the 
aim to reach and treat partners. Through a comprehensive literature review, Alam et al. found 
that counseling of index STI patients and patient delivered partner medication were 
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somewhat effective in Africa (Alam, Chamot, Vermund, Streatfield, & Kristensen, 2010). For 
this intervention, the national partner notification strategy was followed, consisting of patient 
referral. 
 
Theoretically antenatal syphilis screening using point of care test should improve the 
coverage rate of screened women and enable to promptly treat pregnant women with positive 
result.  
 
Quality control is also one of essential elements of an intervention using rapid test for 
syphilis (Ratnam, 2005; Schmid, 2004).  A guideline for syphilis rapid testing was elaborated 
and adapted by some implementers. Quality control measures are important for ensuring that 
results delivered to clients are both accurate and reliable (Elizabeth Glaser Foundation, 2011). 
A quality control assesses whether a product provides sufficient internal quality control 
mechanisms and is compatible with external quality schemes (Lehe et al., 2012).  Two 
components are frequently implemented, internal and external quality control. For our 
research , we adopted definition from study implemented in Zambia and Uganda (Elizabeth 
Glaser Foundation, 2011). This study defined internal control as assessment of the ability of 
the test to distinguish between samples that are known to be positive or negative, and the 
external one as assessment of the ability of health workers to use the test as described by 
manufacturers in their guidelines. 
 
The involvement of stakeholders in the design of an intervention is important for its smooth 
implementation. The design of the intervention with its components was discussed during a 
workshop with district managers and health workers before its implementation. 
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2.6.2.  Implementation and evaluation of intervention 
The feasibility or pilot stage is an essential step in the development and testing of an 
intervention, prior to a large-scale evaluation. In summary, it is an opportunity to check 
whether the intervention that one is proposing to deliver, can be delivered. After the 
development stage in this study, the feasibility of the model was tested.  
 
For the evaluation stage, the MRC approach was complemented by the Normalization 
Process Model which is a conceptual tool intended to assist in understanding the factors that 
affect implementation processes in clinical trials and other evaluations of complex 
interventions like this intervention (May et al., 2007). This approach focuses on the 
workability and integration of the components of the intervention in practice. Our study was 
focused on the factors which facilitated or hindered the full implementation of the 
intervention. Moreover we explored the likelihood that point of care test for syphilis will 
become routinely incorporated in practice through four factors identified by the 
Normalization Process Model. These factors are interactional workability, relational 
integration, skill-set workability, and contextual integration (May et al., 2007) . Each of 
factors has two dimensions (See table below). 
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Table 1: Factors and dimensions of the normalization process model (NPM) 
 
Factors Dimensions 
Interactional workability  
The interactional workability construct seeks to 
examine whether the complex intervention 
promotes ease and efficiency of interaction 
between people and practice. The model 
proposes that the new intervention is more 
likely to be normalized if the intervention 
maintains or enhances existing norms and 
social relations. 
Congruence 
Congruence requires shared expectations of 
normal conduct and purpose of the clinical 
encounter. 
 
Disposal of work 
This requires an investigation into the level 
of agreement about the meaning and 
consequences of the work and of 
expectations about its goals. 
Relational workability  
The relational workability construct 
investigates the extent to which the complex 
intervention can be integrated with existing 
knowledge, practices and relationships. The 
model proposes that normalization is more 
likely if the intervention maintains or improves 
accountability and confidence within existing 
professional networks. 
Accountability 
Accountability requires agreement about 
the validity and expertise of knowledge and 
role divisions underpinning the work. 
 
Confidence 
Confidence requires agreement on the 
credibility and utility of the knowledge and 
expertise, and the criteria by which it is 
evaluated. 
Skills-set workability 
Skills-set workability is concerned with how 
the current division of labour is affected by the 
intervention, the capacity of participants to 
deploy the required tasks and how the quality 
of the work is monitored. The model proposes 
that normalization is more likely if the 
intervention has a good fit with an actual or 
realizable division of labour. 
Allocation  
Allocation requires agreement on the 
formal and informal rules about the 
assignment of tasks, beliefs about 
ownership and appraisal of skills, rewards 
linked to roles and how work is monitored. 
 
Performance  
Performance involves the ability of the 
organization and people to deploy the 
intervention as planned and includes 
agreement about the tasks, boundaries, 
responsibility and autonomy of 
participants. 
Contextual integration 
Contextual integration focuses on how the 
organization uses its capacity and resources in 
the normalization of the complex intervention. 
Execution  
Execution refers to the organizational 
factors influencing practical 
implementation and monitoring of the 
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The model proposes that the complex 
intervention is more likely to be normalized if 
the organization is able to be responsive and 
flexible in executing the work. 
intervention. This includes decisions about 
distributing responsibility, power and 
resources and linkages to organizational 
structures. 
 
Realization  
Realization is made possible by agreement 
about the value of the intervention, policies 
about procurement, delivery of personnel 
and equipment and mechanisms for 
modifying organizational objectives 
 
Source: (Leon, Lewin, & Mathews, 2013) 
 
Costs are also important elements in feasibility of intervention.  
Undertaking an analysis of costs depend largely on the purpose of the study. In the review in 
section 2.5, several studies found that introducing the point of care test for syphilis is cost 
effective even in low prevalence settings (Kuznik et al., 2013; Fern Terris-Prestholt et al., 
2015; WHO/TDR, 2006), so we did not consider it necessary to do a formal cost-
effectiveness analysis in this setting.  What could be of more interest for decision makers 
such as senior ministry of health or ministry of finance officials, managers or head of districts 
is to know the cost for replication, scaling up, or sustainability. For this a cost analysis (rather 
than a cost effectiveness analysis) could be conducted. Cost analysis is not an economic 
evaluation because it does not compare the ratio of costs and effects of at least two 
alternatives. However it is a key component of economic evaluation (D. Walker, 2001). In a 
costing exercise, it is important to clearly state the purpose of the work because it is helpful 
for establishing the boundaries of costs to be included or excluded (Fern Terris-Prestholt, 
Santos, Sweeney, & Kumaranayake, 2011). For instance costs for replication will include 
both on-going and start-up costs whereas start-up cost could be excluded in case of 
examining efficiency of an intervention. In our case, sustainability of the intervention in the 
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selected facilities was examined instead of costs for scaling up or replication of the 
intervention which required more funds from the health district. 
 
The overall conceptual framework of our research is summarized in the figure below. This 
figure was adapted from Craig et al. (Craig et al., 2008) who presented the revised MRC  
guidance.  
 Figure 5: The conceptual framework of the research 
 
 
Source: adapted from Craig et al. 2008 
 
In conclusion, this chapter provides a clear understanding of the issues related to maternal 
syphilis and the factors that affect uptake of screening. Finally, based on literature a 
conceptual framework was developed for conducting the research. 
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CHAPTER 3: Methods 
3.1. Research setting 
 
3.1.1.  Burkina Faso context 
 
Burkina Faso is a landlocked country located in the heart of West Africa. It has around 17 
million inhabitants. Its population is very young, 65% of population being less than 25 years 
old (Institut National de la Statistique et de la Démographie (INSD), 2008).  The urban 
population represents about 26.5%. Burkina Faso has achieved regular economic growth over 
the last decade - 6% per year between 2000 and 2013. The majority of the population (90%) 
is engaged in subsistence agriculture. There are few natural resources and a weak industrial 
base. Cotton and gold are key exports (CIA, 2014).  In 2013, 43.9% of populations were 
living under the poverty line. Households contributed to 31.7% of total health expenditures, 
mainly through out of pocket payment (DGISS, 2015).  
  
The public healthcare system is organized into three levels that provide primary, secondary 
and tertiary care. The first level is the health district level with two layers: 
 Health and Social Promotion Centers (CSPS).  These are the lowest level of the health 
system and provide primary health care. There were 1,643 CSPS in 2014. 
 Medical Centers with Surgical Units (CMA) or district hospital. These are reference 
facilities for the districts. There were 47 CMAs in 2014. 
The second level in the health structure is the regional hospital (CHR). The CMAs refer up to 
the CHRs. There were 9 CHRs since 2012. 
The third level includes the teaching hospitals. This is the highest referral level and provides 
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specialized care. In 2013, there were 3 teaching hospitals. 
In addition to these public facilities, Burkina Faso had 407 private facilities in 2014. 
Traditional medicine is widely available and is recognized by the law no. 23/94/ADP of 
19/05/94 covering the public health code (DGISS, 2013). 
 
Focused ANC is the national norm in Burkina Faso (see figure 5 below). A minimal number 
of 4 visits are required for each pregnant woman. The rate of first antenatal care attendance 
(ANC 1) has increased modestly in the last decade from 81.9% in 2004 to 84.8% in 2014. 
However less than 30% of women attended in the first trimester. The proportion of pregnant 
women who attend four ANC visits is also weak (35% in 2014) (DGISS, 2015). Syphilis 
screening is strongly recommended for premarital tests and during pregnancy (see figure 5 
below). 
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Figure 6: Guideline for conducting focused antenatal care in a primary health facility 
 
 
 
As for other STIs, a syndromic management is mainly used by health workers for syphilis 
screening. Syndromic management of sexually transmitted infections is a recommendation of 
WHO that “is based on the identification of a group of symptoms and easily recognized signs 
associated with infection with well-defined pathogens” (WHO, 2007a). The recommended 
treatment at national level is benzathine penicillin G, 2.4 million (BBP) units intramuscularly 
as a single dose in addition to polyvidone- iodine for ulceration treatment. For those who are 
sensitive to BBP, the protocol is erythromycin 500mg 1 tablet, 4 times per day during 14 days 
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in addition to polyvidone-iodine for ulceration treatment (Ministère de la santé du Burkina 
Faso, 2010) . 
 
3.1.2 The study site:  Kaya HDSS 
 
The intervention was nested in the Kaya Health and Demographic Surveillance System (Kaya 
HDSS), which was launched in 2007 by the Health Sciences Research Institute (IRSS). Kaya 
HDSS is located in the Kaya health district that is situated in the North Central region of 
Burkina Faso, 100 Km from Ouagadougou the capital city. Syphilis prevalence in the district 
of Kaya is among the highest (3
rd
 in 2011) in the country. Kaya HDSS covers 7  urban areas 
and 18 villages of the health district (figure 7).  
 
Subsistence farming and livestock breeding are the two main occupations. Handicrafts  also 
contribute to the local economy. Traditional artisanal gold mining has developed rapidly 
since 2013 and there are some sites in Kaya HDSS area. 
 
The landscape is semi-arid. The climate is tropical, with two seasons, a long dry season and a 
short rainy one. Within Kaya HDSS, dirt roads and bush paths provide means of access to the 
villages. These roads present a challenge for users especially during the rainy season when 
there are floods.  
 
By the end of 2011, 64 480 inhabitants living in 10 587 households were being followed. The 
population is very young 55.5% are under 20 years of age. The Mossi are the predominant 
ethnic group and Islam is the main religion (78.9%). The majority of the population of the 
HDSS (53.3%) has not attended school. The main causes of death are malaria (20%), diarrhea 
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(12.4%), and renal failure (7.5%) (Kouanda et al., 2013).  
Kaya HDSS covered seven public primary health facilities that offer ANC, one faith-based 
health center and one regional hospital. The faith-based facility and the hospital do not offer 
ANC but their laboratories offer the venereal diseases research laboratory (VDRL) test and 
Treponame pallidum hoemagglutination assay (TPHA). In 2012, a pharmacy began offering 
a rapid test for syphilis but due to low demand they stopped selling the test.  
The seven public primary health facilities, four urban and three rural, were selected for the 
intervention. All facilities have a maternity unit, dispensary and drug shop. Health staff in a 
rural facility are from 2 to 3 whereas urban facilities have on average more than 7. In Kaya, a 
primary health facility is staffed by cadres as nurse, midwife, auxiliary midwife and itinerant 
health officer. It is led by a state registered nurse. Nurses and midwives have formal training 
that includes syndromic STI case management.  
 
 Figure 7: Map of Kaya HDSS 
 
Source: IGB, IRSS investigations 
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3.2. Study design 
 
The study used a mixed-method design. Both quantitative and qualitative methods were 
collected. According to Leech and Ownuegbuzie (2009) this study could be classified as 
partially mixed concurrent dominant status design because the quantitative and qualitative 
portions of the study were collected simultaneously and qualitative portion had the greater 
emphasis (Leech & Onwuegbuzie, 2009).   A major component of this study was a feasibility 
study. Before introducing a new intervention, one of the recommendations in the MRC 
framework (MRC, 2008) is to conduct a feasibility or pilot study.  The term pilot study is 
sometimes used synonymously with feasibility study – this was the case in the research 
reported here. Our feasibility study was carried out in order to guide decision makers on a 
feasible approach to adopt for maternal syphilis screening and treatment. Decision makers 
want to understand why they have to make a choice, and then why they should choose a 
certain option. A feasibility study is an important tool for making the right decisions; it is a 
preliminary investigation into the potential benefits associated with undertaking a specific 
activity or project. Thabane et al. argue that pilot studies can be very informative but often, 
the emphasis is wrongly placed on statistical significance, not on feasibility - which is the 
main focus of the pilot study (Thabane et al., 2010).    
3.3. Sampling 
 
All 7 primary health facilities which offer ANC services in Kaya HDSS were selected for the 
intervention. Among these facilities, 4 were located in semi urban and 3 in rural areas. 
Sampling was performed for each phase and study. Details on sampling are provided in each 
paper (Chapters 4-7). Respondents included the staff of the health centres, key informants 
from the health district and Ministry of Health, and pregnant women attending first antenatal 
visit (ANC 1).  
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3.4. Study description  
 
The study comprises three phases; the first to assess the performance of the current ANC 
program in detecting maternal syphilis, the second to develop an intervention strategy and 
introduce the new on-site test for syphilis in the package of antenatal services, and the third 
phase to assess the acceptability and explore the effects of introducing the on-site test in the 
package of antenatal services on the organization and staff at the primary health facility and 
to identify facilitators and barriers to integration of the test into routine ANC.   
The phases are summarized in the figure 8 below. 
 
Figure 8: Schematic representation of the research process 
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3.4.1.  Phase 1: Situational analysis 
 
Most studies have tended to focus on understanding one or two domains within a program, 
such as the perspectives of the community or the providers (S. Hawkes et al., 2004). In order 
to understand the viewpoints and expectations of all major stakeholders, a comprehensive 
approach was adopted.  Thus phase 1 included a situation analysis that explored health 
system and client perspectives.   
  
Data were gathered through a desk review and stakeholder appraisal. 
Desk review 
Desk review was conducted in order to gather evidence on syphilis control programs as well 
as disease prevalence and any previous studies in local settings that have not been identified 
through the database searches conducted in preparing this proposal. An exhaustive review of 
existing documentation, literature, reports and data relating to the key subjects of the study 
was carried out. This consisted in a review of maternal and newborn national guidelines and 
national monitoring and evaluation reports at the ministry of health, a review of thesis and 
other relevant research reports and published literature at local libraries (Institut de recherche 
pour le développement (IRD), school of nurse (Ecole Nationale de Santé Publique), faculty 
of medicine (Unité de recherche et de formation en science de la santé de l’université de 
Ouagadougou)). 
 
Stakeholder appraisal 
Participants were purposively selected to capture a range of perspectives across different 
actors with different roles and responsibilities. These are described below. 
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 Key informant interview 
Interviews were conducted with managers of key national programs relevant to the AIDS, 
STIs, and maternal and child health programs, laboratory staff, head of the district, district 
pharmacist, and staff responsible for monitoring. In addition, interviews were conducted with 
traditional healers in order to explore their perceptions and practices of STI management. 
The interview explored the STI management policy, in particular maternal syphilis; identify 
the barriers and constraints which affect the effective delivery of STI services and 
particularly maternal syphilis screening, supervision, monitoring, the perceptions of rapid 
diagnostic test (RDT), and patients. An interview guide was designed and adapted for each 
profile of respondent (see appendix).  
 
 Individual interviews with pregnant women 
Interviews were conducted with pregnant women (N = 35) in order to assess knowledge and 
perceptions of syphilis. A guide was developed and explored experiences of ANC, 
satisfaction with ANC, perceptions of syphilis, knowledge about existing tests, and 
perceptions of additional test. All the interviews were conducted in Mooré , a local language. 
 
 Health facility survey 
The health facility survey documented the current program performance of providing routine 
syphilis screening to antenatal care (ANC) clients at each health facility.  
 The facility assessment was conducted through a comprehensive inventory in terms of 
infrastructure, equipment and supplies. The assessment was conducted in the 7 facilities. 
Interviews with providers were conducted to obtain information on their knowledge, attitudes 
and practices on STI and syphilis, maternal syphilis management including diagnosis and 
treatment and their perception on content of ANC package. All providers (N = 17) who are 
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involved in ANC in each facility were interviewed. 
A time motion study and structured observation were performed to obtain data on workload, 
resources used and interaction between patient and health workers during ANC consultation. 
ANC consultation was observed in each facility during one day. A sheet (see in appendix) for 
observation was developed. Profile of health provider, materials and consumables, duration 
for each activity were reported on the sheet for each consultation. Researcher (PhD student) 
sat in the consultation room and noted all the information. 
 
Data collection and analysis  
Each potential participant was contacted by the researcher to invite them to the interview. 
The researcher was trained two research assistants for interviews with women. After 
providing information about the study and gaining consent from the participant, the interview 
was held in a convenient place. Interviews were recorded and transcribed in French. 
Interviews with traditional healers and pregnant women were recorded in local language 
(Mooré) then transcribed directly in French. Data collection was conducted from August to 
October 2012 in Kaya and Ouagadougou for decision makers at national level. In total 75 
interviews were conducted. Following the principles of thematic analysis (Braun & Clarke, 
2006), a thematic framework was developed based on the research question, the guide and 
familiarization with the first transcripts, and then applied to each transcript using the 
qualitative software package NVivo (QSR International).  Data analysis was conducted by 
the researcher. 
The researcher conducted facility assessment, interviews with health workers and time 
motion study.  Data were collected the day of ANC in the facility. Data were entered with 
Epidata then analyzed with SPSS.  Descriptive and univariate analysis were conducted.  
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3.4.2.  Phase II: Implementation  
 
The process for implementation is presented in Chapter 6. In that manuscript, a summary of 
each of the main stages is presented. The implementation occurred between November 2011 
and August 2014. Before the implementation of the intervention, a workshop was organized 
where researchers shared the findings of this evaluation, the situation analysis, and the core 
components of the intervention, with health workers who are involved in ANC in the selected 
facilities and district managers. This participatory workshop informed the design of the 
intervention and the implementation process. 
The intervention was implemented in five steps:  
 Selection of rapid syphilis test  
The test was selected among registered tests in Burkina Faso.  The selected test respects the 
followed criteria:  sensitivity between 85 and 95% and specificity of 95% at least, a detailed 
notice in French, simple to use, and use of whole blood. Finally determine syphilis TP was 
selected regarding the criteria. The results were published (Yaya Bocoum, Ouédraogo, 
Tarnagda, Kiba, Tiendrebeogo, Simon Bationo, et al., 2015) and are presented in Chapter 5.  
 Training of human resources 
 The health professionals of the primary health care level were trained on how to perform the 
test and on the management of maternal syphilis. All health workers at the ANC services 
received an on-site one-day training (see figure 8). Manuals and technical guides on syphilis 
testing during ANC were given. More details are presented in results chapter 6. 
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Figure 9: During onsite training in a rural health facility 
 
 
 
 Provision of rapid test and package for treatment  
The selected facilities received syphilis test and kits for syphilis treatment.  
The medicines for the kit were bought at the national central depot for essential medicines 
(CAMEG (Central d’achats des médicaments essentiels génériques)) and put in bags by the 
research team (see figure 9).  The tests and all the materials were bought with representative 
distributor of Alere firm in Burkina Faso.  Funds for the procurement were obtained through 
the scholarships received by the PhD student, notably ADDRF and TDR grant.  The initial 
provision of rapid tests and ancillary supplies occurred on the same day, after the training. 
Thereafter, supplies were ordered by the research team and distributed to facilities by the 
health system’s district management team.  
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Figure 10: Kit for syphilis treatment 
 
 
 
 Enrolment and screening of women 
The intervention targeted pregnant woman aged 18 and over at first ANC visit. Women aged 
less than 18 years and not at their first ANC were excluded from the study. Participants under 
18 years are not eligible because they are minors.  For minors’ participation, it would be 
necessary to obtain the permission of the parent or the legal tutor. For this, health worker 
should go to the house of the woman because most of them are not accompanied by the legal 
tutor (father or husband) for ANC. That mean the research would need to cover their 
transportation costs. We decided to limit the participation to women aged 18 and over. 
 Every eligible woman was offered the test when she was in the consultation room. If she 
agreed she signed consent and received the test. The decision to offer treatment was based on 
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test results. The treatment of positive pregnant women, who are not allergic to penicillin, is 
benzathine penicillin G, 2.4 million units intramuscularly as a single dose in accordance with 
Burkina Faso guidelines. Women who have an allergy to penicillin receive alternative 
treatment following the national guideline of erythromycin 500mg 1 tablet x 4 per day during 
14 days + Polyvidone iodine.  The treatment is available at the primary health facility because 
it is on the national list of generic medicines. Negative pregnant woman received counseling 
on STI prevention.  
In Burkina Faso partner notification is on a voluntary basis.  In the case of STI, the health 
worker gives advice to positive patient to inform his or her partner.  The health worker is not 
allowed to contact partner without the agreement of the patient. For our study, the national 
legal framework was followed. This implied that pregnant women who tested positive for 
syphilis were free to inform her partner or not.  
 
 Quality control and supervision 
Every 20
th
 negative and all positive women screened by rapid test were to have blood 
collected by venipuncture and sent to the laboratory of the regional hospital of Kaya, where 
RPR and TPHA were performed for the quality control. Transport of blood samples from the 
health facility to the laboratory was conducted by a health worker with an ice box. Transport 
costs were reimbursed. Supplies such as syringes, cryotubes were provided to health facilities 
and reagents (RPR and TPHA) and other supplies were provided to the laboratory. Regularly 
research team collected data from the laboratory staff. 
For supervision, each health facility was visited once a month. A detailed checklist was 
elaborated for supervision. A separate register book for screened women was kept in each 
health facility. During supervisory visits, difficulties were discussed and patient register 
books were checked. 
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The conceptual model outlined in the figure  below summarizes the components of the 
intervention. 
 
Figure 11: Conceptual model of the intervention 
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3.4.3.  Phase III: Evaluation 
 
The evaluation consisted in identification of the potential effects of the intervention, the 
facilitators or barriers to implementation and estimating additional costs due to the 
intervention. Different methods were used. 
For identifying potential effects of the intervention, at health facility a review of registers was 
undertaken. In each facility registers for rapid syphilis test were compiled. Data extracted 
from registers allowed estimating: 
• Proportion of pregnant women who received a syphilis test 
• Proportion of pregnant women being tested syphilis positive 
• Proportion of pregnant women being tested syphilis positive and treated 
Gestational date and demographic characteristics were also collected through register. 
Interviews with health workers (N =12) and district managers (N = 2) were conducted. 
Through these interviews perceptions of health workers on the intervention, potential effects, 
facilitators and barriers to implementation were explored.  
 
A time motion study was conducted before and after the intervention in order to collect 
information on workload and time consumed. For this study, observation was held during 
ANC at health facility and all activities, resources used and time were recorded. Results from 
time motion were used for assessing the effect of the intervention on the length of ANC and 
costing health workers efforts. The details of this method are explained further in Chapter 7. 
 
The additional costs of introducing rapid syphilis test were estimated from a provider’s 
perspective. An incremental cost analysis looks at the cost of adding or implementing the 
additional intervention or program into existing services and does not estimate cost for 
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existing services (Fern Terris-Prestholt et al., 2011).  The choice of this costing approach is 
twofold, first to provide evidence on costs for sustainability of the intervention and second to 
estimate how much the provider or decision maker should bear if they want to offer syphilis 
test for free to pregnant women coming for ANC visit. The costing approach was adapted 
from one used by Larson et al  for syphilis diagnosis and treatment in Zambia (Larson et al., 
2014). This costing approach is more adapted for estimating the cost per test using any 
technology. The details of the methodology used to estimate the incremental cost are 
discussed further in Chapter 7.  
 
3.5. Validity  
 
In research, different procedures can be used to enhance validity. In this study, key measures 
included drawing on validated approaches, and triangulation. Instrument and methods were 
based on previously published frameworks and approaches validated for African settings. 
Triangulation was used for improving validity of our research. Mucchielli reports 5 types of 
triangulation (Mucchielli, 2009). In our study 3 types were used: 
- Triangulation of methods: different methods were combined. The results from one 
method could be used as complementary of another one. Moreover different 
techniques such as in-depth interviews complemented by observations allowed 
corroborating results. 
- Triangulation with researchers: other researchers such as our supervisors and co 
authors of articles were helpful in better understanding and interpreting the results. 
This work integrated work experiences from different researchers with various 
profiles (epidemiologist, biologist, anthropologist, statistician, health economist, and 
clinician). 
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- Triangulation through dissemination: different disseminations were used.  Two 
workshops at district level allowed presenting results and discussing with local 
stakeholders.  The doctoral seminar of the School of Public Health at UWC offered an 
opportunity to present the results and discuss them with professors and PhD students 
from the school.  
 
3.6. Limitations 
 
Resource constraints limited this intervention to a pilot study which has several limitations. 
The aim of this feasibility study is mainly to inform decision makers about the conditions of 
implementation and costs for sustainability of the intervention. Some data on health outcomes 
were collected but these findings should be interpreted cautiously given that this is a   
feasibility study with a small size (MRC, 2008).  Moreover, the concept of feasibility may 
include dimensions such as legal, political, cultural, ethical and technical, which were not 
fully explored in this study.  
Data are representative for pregnant women who attended ANC services in the study area and 
not all pregnant women. Although not all pregnant women who attended to ANC, in Burkina 
Faso over 80% of women have at least one ANC visit (DGISS, 2015).  
This study enrolled women 18 years of age and older, as ethics procedures for informed 
consent or for assent to participate in research for youth under 18 are not yet commonly 
accepted in Burkina Faso, particularly in rural areas, and particularly for married women. 
This means that women under 18 who attend ANC were not included in the study, and that 
barriers specific to this age group may not have been taken into account. 
During observations, the presence of the researcher could introduce potential changes in the 
behaviors of the health workers (the Hawthorne effect) (Fernald, Coombs, DeAlleaume, 
 
 
 
 
48 
 
West, & Parnes, 2012). This was limited because the researcher who conducted the 
observations was not medical personnel and the participants were aware of her background. 
The cost outcomes for testing for antenatal syphilis screening are context-dependent.  In 
general, variations reflect differences in the epidemiology of the disease, treatment patterns 
and health system organization in urban and rural areas (Levin et al., 2007). Limitations due 
to the costing approach used were also highlighted. Using an incremental costing 
underestimated the general administrative nature borne by the health facility (particularly 
communications and office supplies).  Moreover it is difficult to generalize results from this 
costing study (Fern Terris-Prestholt et al., 2011). 
 
3.7. Ethical Concerns 
 
This research was approved by the Senate Research Committee of University of Western 
Cape, the National Ethics Committee for Health in Burkina Faso and the Ethics Committee 
Review of the WHO. In addition, the study team obtained permission to conduct the 
intervention and research from the District authorities. Consent was obtained from pregnant 
women who received the test by health worker. They gave a witnessed signature or thumb-
printed approval to participate. An information sheet explaining the purpose of the study, its 
potential benefits and risks was written by the researcher, in order for participants to 
understand what the study entailed prior to the signing of the consent form (see appendixes). 
The researcher in collaboration with the health workers took care to protect the 
confidentiality of the positive patients by following the national guideline regarding partner 
notification.  
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CHAPTER 4: Barriers to antenatal syphilis screening in Burkina 
Faso 
 
This chapter (Paper I- published) presents the results of the situational analysis which 
emanated from phase I. Paper I responds to the subsidiary research question concerning the 
operational performance of the current antenatal syphilis screening program.  
 
Paper I: Fadima Yaya Bocoum, Seni Kouanda, Christina Zarowsky, Barriers to antenatal 
syphilis screening in Burkina Faso, Pan Afr Med J. 2014; 17(Suppl 1): 12, 18 January 2014  
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 INTRODUCTION 
Despite several advances in treatment and management, syphilis remains a major public 
health problem. The World Health Organization (WHO) estimates that there are twelve 
million new cases of syphilis worldwide each year (World Health Organization (WHO), 
2001). Ninety percent of syphilis cases occur in low income countries (World Health 
Organization (WHO), 2001) and the prevalence ranges from less than 1% to 10%. African 
studies show prevalence during pregnancy of 2% in Mali (WHO, 2007b), 3% in Nigeria 
(Taiwo, Adesiji, & Adekanle, 2007), 5% in Botswana (Romoren & Rahman, 2006), and 7.3% 
in Tanzania (Swai et al., 2006). In Burkina Faso, Kirakoya-Samadoulougou et al found a low 
prevalence of syphilis during pregnancy at national level but with important regional 
variations (Kirakoya-Samadoulougou et al., 2011). For instance, in Kaya District the 
prevalence was 7.5 in 2009 whereas in Ouagadougou it was 1% (CMLS/Santé, 2010).  
 Syphilis in pregnancy poses major health risks for the mother and the fetus and also 
increases the risk for HIV transmission (D. G. Walker & Walker, 2004). The World Health 
Organization (WHO) estimates that two million pregnant women each year are infected with 
syphilis globally (WHO, 2007b). The risk of vertical transmission could be up to 80% in 
early latent syphilis (WHO, 2007b). Approximately 1.2 million pregnant women with 
syphilis transmit the infection to their newborn every year (Kamb et al., 2010). It is estimated 
that 492 000 infants in sub-Saharan Africa die annually from congenital syphilis (Schmid, 
2004) . In Tanzania, a clinic-based study found that a quarter of women with high-titer active 
syphilis infection had stillbirths compared with 1% among seronegative women (Watson-
Jones et al., 2002).  
 Maternal syphilis is detectable by serological screening and entirely treatable with penicillin. 
Therefore, screening and treatment for syphilis has been recommended as a routine part of 
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antenatal care (Control Centers for Disease, 2002; WHO, 2001). In Burkina Faso, syphilis 
screening is recommended for premarital tests and during pregnancy (Ministère de la santé du 
Burkina Faso, 2010). Unfortunately, antenatal syphilis screening is often poorly implemented 
in many sub-Saharan African countries (S Gloyd et al., 2001). Currently, only 30% of women 
with syphilis are screened and treated in developing countries (The Lancet, 2012). The 
influence of health systems issues on timely prenatal syphilis screening has been observed in 
several countries, including Bolivia, Kenya and South Africa (Deperthes et al., 2004). In 
West African countries such as Burkina Faso, barriers to syphilis screening are understudied.  
In this study, we sought to identify and understand barriers affecting health system 
performance for syphilis screening among pregnant women in Burkina Faso. Existing 
literature on syphilis screening among pregnant women suggests that antenatal care (ANC) is 
the cornerstone for the control of maternal syphilis. Thus, factors affecting attendance to 
ANC are likely to affect syphilis screening for pregnant women. We therefore explored 
various factors at policy, health provider, patient, and community levels that are likely to 
drive syphilis screening levels.  
 
METHODS 
Study design  
 We conducted a Multilevel Assessment (MLA) (S. Hawkes et al., 2004) comprising of 
qualitative interviews and observations, as well as a review of existing data. For the latter, we 
assessed health information systems records, policy documents, service provider guidelines, 
training manuals, monitoring and evaluation reports and other relevant research reports and 
published literature. These data enabled us to investigate how the syphilis screening policy 
was implemented at facility level, the available indicators of its health outcomes, and any 
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documented barriers to its implementation to date. The in-depth interviews were held with 
health providers, district managers, facility managers, traditional healers, pregnant women, 
community health workers, and representatives of national and international Non 
Governmental Organizations (NGOs) which work on maternal and child health issues to 
explore barriers and constraints which affect the effective delivery of maternal syphilis 
screening. During data collection, the first author also observed interactions between health 
workers and clients in selected health facilities.  
Study setting  
 The study was conducted in the Kaya health district, based in the central north region of 
Burkina Faso. Kaya district has 484 932 inhabitants, 40 primary health facilities and is a 
sentinel site for the national AIDS and STI control program. We conducted this research in 
Kaya District because of the high syphilis prevalence relative to the national average. Figure 
1 presents the trend of syphilis prevalence among pregnant women from 2004 to 2009 in 
Kaya district and nationally. The study was nested in the Kaya Health and Demographic 
Surveillance System (Kaya HDSS), which was launched in 2007 by the Health Sciences 
Research Institute (IRSS). Kaya HDSS covers seven semi-urban areas and 18 villages of the 
district with a population of 48,131 inhabitants. In 2011, there were seven public primary 
health facilities that offered ANC, one faith-based health center and one regional hospital. 
The faith-based facility and the hospital did not offer ANC but their laboratories offer the 
venereal diseases research laboratory (VDRL) test and Treponame pallidum 
hoemagglutination assay (TPHA). One pharmacy offered a rapid test for syphilis. The health 
facilities selected for the study were all located within Kaya HDSS area.  
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Figure 1 Trends in syphilis prevalence from 2004 to 2011 in Burkina Faso. Source: report 
CMLS/Santé, 2010, 2011 
 
 
Study population and sampling  
 The study population consisted of health providers, district managers, facility managers, 
traditional healers, pregnant women, community health workers, and NGO managers (Table 
1). The healthcare providers included doctors, midwives, nurses, laboratory personnel, and 
pharmacists. Participants were purposively selected to capture a range of perspectives across 
different actors with varying roles and responsibilities. In each health facility, five pregnant 
women were approached as they queued to receive antenatal services and informed about the 
study. For those who consented, the interview was held at the end of their visit. Although we 
initially planned to have focus group discussions (FGDs) with pregnant women, the number 
of women available for the FGDs was too small because data collection occurred during the 
rainy season.  
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Table 1 : Study Sample 
Group Number and position 
District managers - 1 pharmacist 
- 1 information systems specialist  
- 1 reproductive health specialist  
- Head of District 
- Head of regional laboratory 
Health workers - 2 lab technicians 
- 4 midwives 
- 6 auxiliary midwives 
Community health workers - 4 community care workers 
- 7 drug shop managers 
NGO and private  - 2 NGO managers 
- 1 midwife 
- 1 lab technician 
- 1 pharmacist 
Facility manager  - 7 (Primary health care center) 
Community - 35 pregnant women 
- 4 traditional healers  
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Data collection  
 Data were collected using interview guides. Guides  were adapted for each profile of 
respondent. The interview with pregnant women explored experiences of ANC, satisfaction 
with ANC, knowledge and perceptions of sexually transmitted infections (STIs) including 
syphilis, perceptions of existing point-of-care tests, opinion on the introduction of additional 
test. We sought to find out key informants’ perception of ANC, management of STI during 
pregnancy, knowledge and perceptions of syphilis, barriers and constraints which affect the 
effective delivery of maternal syphilis screening, organizational and managerial issues, 
experience with point-of-care tests, and introduction of a rapid diagnostic test (RDT) for 
syphilis screening.  
 Data tools were pre-tested and appropriate modifications made before the final data 
collection. Data collection was conducted by the first author and two research assistants who 
are familiar with qualitative studies and have a social sciences background. Research 
assistants were trained on the study objectives, data collection tools, and processes before 
embarking on field data collection. Interviews with health providers, district managers, 
facility managers, and NGO managers were conducted in French while those with pregnant 
women, traditional healers and community workers were conducted in Mooré the local 
language. Appointments were made with community health workers, traditional healers, 
health providers, district managers, facility managers and NGO managers. All interviews 
were recorded using a digital recorder and files downloaded to a laptop the same day. 
Transcription was done by two transcribers. Interviews in Mooré were translated into French 
and transcribed.  
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Data analysis  
 Interviews were transcribed into a text program and then uploaded on Nvivo software. An 
analytical grid of key themes was developed based on the list of possible barriers in our 
conceptual framework, the objectives of the research and familiarization with the first few 
transcripts. Additional themes that emerged during the process of re-reading of transcripts 
were coded. Thematic content analysis was employed to systematically analyze the content of 
each theme.  
 Ethical issues  
 Ethical clearance was obtained from the University of Western Cape, the National Ethics 
Committee for Health in Burkina Faso and the Ethics Committee Review of the WHO. In 
addition, the study team obtained permission to conduct the research from the District 
authorities. Written informed consent was obtained from all participants.  
 
RESULTS 
Although the guidelines on the management of STIs recommend syphilis screening for all 
pregnant women, we found no information on the proportion of pregnant women routinely 
tested for syphilis at district, regional and national level. Our study findings highlight 
considerable weaknesses within operational systems for syphilis screening. In tracking a 
woman's journey from antenatal care (ANC) through to laboratory, the study documented 
several barriers at health provider and community levels.  
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 Barriers at health provider level  
 The first barrier to routine syphilis screening among pregnant women was related to 
providers' perception that syphilis in pregnancy was not an important issue relative to other 
diseases. In addition, health workers also felt that syphilis prevalence was low because most 
women who undertook the test were seronegative. As one auxiliary midwife who had worked 
in an urban facility since 2009 stated, "I have never found a positive test, all were negative." 
Related to this, some health workers felt that syphilis was more prevalent in urban areas and 
thus, screening was more systematic in urban-based facilities. One district manager noted 
"For syphilis screening it is not really systematic and I know that in urban facilities health 
workers prescribe it to all women but at rural facilities it is not systematic." Overall, we 
noted an absence of interventions and information on maternal syphilis in the district.  
 The second barrier to routine syphilis screening among pregnant women was related to the 
availability of screening equipment, which was particularly a challenge for rural facilities. 
One facility manager in a rural-based facility noted that, "I do not systematically prescribe 
syphilis test because we have no laboratory here." A mapping of the facilities in the district 
indicated that three facilities (one public and two private) offered the syphilis test. All three 
facilities were urban-based. The public facility hosts the laboratory of the regional hospital 
and performs rapid plasma reagin (RPR) and Treponema pallidum particle agglutination 
assay (TPHA) tests. Between August 2011 and August 2012, this facility had performed 279 
RPR tests and 260 TPHA tests. Among the two private that offered screening, one was a 
pharmacy offering a point of care test, while the second was a faith based facility offering the 
RPR and TPHA test. At the private pharmacy, only four clients had requested a syphilis test 
between June 2011 and June 2012. At the faith based facility, 50 RPR tests and 10 TPHA 
tests were performed between August 2011 and August 2012.  
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 The third barrier was related to health workers' inability to communicate the need for 
syphilis screening to pregnant women. Health workers noted that it was difficult to convince 
women about the importance of screening for syphilis. This challenge was partly related to 
the need to collect multiple blood samples from women for an HIV test, as part of the 
PMTCT program, as well as for the syphilis test. According to one health worker, women did 
not understand the need for multiple blood tests: "when we do an HIV test, you get a blood 
sample. We said that they need to go to the laboratory and have another blood test to know if 
they have other diseases, they said no, it is the same blood you got here and tested it is not 
necessary to have another sample." Health workers acknowledged that they did not explain 
the importance of some of the examinations. For example, one manager in an urban-based 
facility noted that "Most of the time it is a lack of communication at our level, we do not tell 
to the women the importance of some exams, why this prescription..." The narratives from 
pregnant women corroborated this observation. One pregnant woman in a rural area stated 
"One day the health worker took blood from my left finger but I did not know if it is HIV test 
or not ...) I don't know because until now they have said nothing." The poor communication 
between health workers and pregnant woman may be related to the lack of routine training as 
the health workers stated that they had no specific training, except for a course on syphilis 
management during their professional training.  
 A fourth barrier was the fragmentation of services in a setting where geographic distance 
was already a barrier. Often women have to be referred to an external laboratory for the 
syphilis screening. According to health workers, many women live in rural areas and have to 
travel long distances to health facilities that offer screening services. One health worker 
commented, "we observe that most women are from villages around Kaya, they walk from 
their house to our facility and we ask them to do the test the day after. The distance from their 
house to the laboratory is same to our facility. Thus the majority do not go." We observed 
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that traveling from the nearest urban primary health facilities to the public laboratory would 
take about 1 hour by foot or 20 minutes by bicycle. Due to this situation, one urban health 
center had a lab technician who came to the facility to collect blood samples, but few women 
did the test.   
Barriers at community level  
 The cost of the syphilis test was reported to be a barrier for many women. At the public 
laboratory, RPR and TPHA cost the equivalent of USD 2-3. The point of care test cost more 
in the pharmacy (USD 3) compared with the faith based facility (USD 2). Although the cost 
of syphilis tests in the public sector is subsidized by the government, many women are not 
screened because of the cost of the test. One auxiliary nurse stated "There are women who 
keep the exam prescription until delivery because they said that they have no money for the 
exams."  
 Our findings also indicate that a pregnant woman's husband or partner plays a key role in the 
decision to be screened for syphilis. Due to exemption of fees, women do not carry a lot of 
money when they go for their ANC visit. When they receive a prescription for additional 
medical examinations, such as the syphilis test, they have to go back home and get money 
from their husband. Sometimes, women need approval from their husbands as illustrated by 
this quote from a midwife in an urban facility, "sometimes, until the delivery they (women) 
kept the prescription in their health card, when you ask them why, they explain that they gave 
it to the head of the family but he did nothing."  
 Findings also show that poor knowledge about syphilis was also a potential barrier to testing. 
For example, although many women could describe the symptoms of sexually transmitted 
infections (STIs) (itches, pimples, and vaginal discharge), many were unaware about syphilis 
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or the consequences of untreated syphilis for the mother and child.  
 Finally, perceptions about syphilis also affected screening rates. In particular, the stigma 
surrounding sexually transmitted diseases was noted as a barrier to screening particularly in 
certain settings like pharmacies. One facility manager noted "the pharmacy advertised and 
gave the prices but you know women, it is difficult for them to go to the pharmacy and do an 
exam related to sex. They prefer to go to the laboratory of the hospital if they have money 
because it is a public service."  
 DISCUSSION 
Syphilis screening is recommended for premarital tests and during pregnancy (Ministère de la 
santé du Burkina Faso, 2010). Although a policy that promotes syphilis screening in pregnant 
women exists in Burkina Faso, screening is very limited. Our findings identified several 
barriers to the uptake of syphilis screening among pregnant women in Burkina Faso.  
 Syphilis testing is largely dependent on the availability of adequate laboratory facilities 
(Tucker, Bu, et al., 2010). However, our results suggest that the fragmentation of services is 
key barrier to the uptake of syphilis screening. Health workers often have to refer women to 
external laboratories and many women, particularly those living in rural areas, have to travel 
long distances to access these laboratories. Other studies have also reported that long 
distances to screening facilities are associated with delay or failure to screen (Munkhuu, 
Liabsuetrakul, Chongsuvivatwong, Geater, & Janchiv, 2006; Yang et al., 2011). Our findings 
suggest the need to introduce a "one-stop" service point that including ANC, PMTCT and 
syphilis testing.  
 As highlighted in previous studies (Stephen Gloyd et al., 2007; Watson-Jones et al., 2005), 
we found that low motivation of healthcare workers to prescribe syphilis screening also 
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contributes to low screening. Although the need for continued antenatal screening for syphilis 
may be questionable in areas with low prevalence (Shakoor, 2004), health workers in the 
current study were not aware about the relatively high prevalence of syphilis in their district. 
Consequently, some health workers failed to prescribe the test. Trepka et al (Trepka, Bloom, 
Zhang, Kim, & Nobles, 2006) also found that a lack of provider awareness of the prevalence 
of syphilis was associated with inadequate provision of screening test in the United States. 
The absence of interventions to increase syphilis screening and the lack of information on 
maternal syphilis in the district shows also the low prioritization of the problem. Efforts to 
increase awareness about syphilis are therefore warranted in order to enhance syphilis 
screening levels.  
 The relatively high cost of screening, despite government subsidies, also prevents pregnant 
women from being screened for syphilis. The cost for testing was observed to range between 
$2 and $3 USD, a prohibitive cost in a country where 73% of population lives on less than $2 
a day (Worldbank, 2013) . The cost of screening is, therefore, a significant deterrent for many 
women particularly those who are financially dependent on their husband or partner. 
Women’s financial dependency means that pregnant women’s husbands or partners play a 
key role in the decision to be screened. Similar findings have been highlighted in previous 
studies (Adamu & Salihu, 2002; Simkhada, Teijlingen, Porter, & Simkhada, 2008) and 
underscore the need for male involvement in efforts to increase the uptake of syphilis 
screening among pregnant women.  
 Lack of knowledge about syphilis in the community was identified as a reason for not being 
screened. Most respondents at community level do not know the symptoms of syphilis nor its 
serious consequences for the unborn and born child. This misperception may be due to the 
lack of differentiation between STIs (L. Kleutsch, E. Rosser, H. Choi, J. Holley, 2009). Most 
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of STIs are recognized through symptoms and respondents do not realize that a STI could be 
asymptomatic. Community may also not perceive syphilis to be a problem because of its lack 
of visibility (Saloojee et al., 2004b). Low knowledge about syphilis might therefore pose a 
barrier to screening since pregnant women do not perceive the benefit of testing particularly 
for asymptomatic infections. As reported in a recent meta synthesis, many pregnant women 
did not feel the need to seek professional care when there is nothing wrong with their 
pregnancy (Finlayson & Downe, 2013). Efforts to enhance awareness of syphilis and other 
STIs are therefore recommended.  
 Our study findings should be interpreted in light of several limitations. First, because of the 
exploratory nature of the study, we relied on qualitative methods and therefore our findings 
cannot be generalized to the larger population. Second, community’s perceptions reflected 
mostly health services users. However, study findings highlight potential barriers to the 
uptake of syphilis screening. Further research using a more representative sample is 
warranted.  
 CONCLUSION 
Our study suggests that barriers such as distance to health facilities, cost of testing, and 
knowledge about syphilis among health workers and communities may limit screening levels 
and hinder the implementation of syphilis screening during pregnancy as recommended in 
national guidelines. Pregnant women often weigh the benefits of syphilis screening against 
the high direct and opportunity costs. Our results have several implications for efforts to 
improve screening levels. First, communication between health workers and clients needs to 
be improved in order to facilitate the acceptability of the test. Second, the introduction of 
point of care testing for syphilis during ANC may improve coverage of antenatal syphilis 
screening.  
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CHAPTER 5: Evaluation of the diagnostic performance 
and operational characteristics of four rapid 
immunochromatographic syphilis tests in Burkina Faso 
In this chapter, the study reports the results of a comparative analysis of potential candidates 
for point-of-care rapid diagnostic tests for syphilis which might be integrated into the ANC 
package in Burkina Faso. This paper (Paper II – published) thus reports on the first step 
towards implementation of the intervention and addresses objective 4. 
Paper II: Yaya Bocoum F, Ouédraogo HG, Tarnagda G, Kiba A, Tiendrebeogo, Simon 
Bationo F, Liestman B, Diagbouga, Serge Zarowsky, Christina Ouédraogo/Traoré R, 
Kouanda S: Evaluation of the diagnostic performance and operational characteristics of four 
rapid immunochromatographic syphilis tests in Burkina Faso. Afr  Health Sci 2015, 15.  
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INTRODUCTION 
Syphilis in pregnant women remains a major public health problem. The World Health 
Organization (WHO) estimates that 90% of syphilis cases occur in low-income countries 
(WHO, 2007b). The prevalence in developing countries ranges from less than 1% to 10%. In 
a recent review among studies in 1990-2011, prevalence estimates were 4.5% (3.9%-5.1%) in 
East and southern Africa and 3.5% (1.8%-5.2%)  in  West and Central Africa (Chico et al., 
2012). In Burkina Faso, prevalence in pregnant women is low, with notable regional 
variations (Kirakoya-Samadoulougou et al., 2011; Sombie et al., 2000). According to WHO 
estimates, each year, maternal syphilis is responsible for at least 50,000 spontaneous 
abortions or stillbirths and 500,000 premature births of babies infected with congenital 
syphilis or who have low birth weight (WHO, 2007b). However, rates of congenital syphilis 
are generally underestimated (Saloojee et al., 2004a). Congenital syphilis is an avoidable 
disease that prenatal testing and early treatment of infected pregnant women could eliminate 
(F Terris-Prestholt et al., 2003).  
In response to this situation, the scientific and technical consulting group of the WHO’s 
Department of Reproductive Health and Research adopted a strategy for the global 
elimination of congenital syphilis by 2015 (WHO, 2007b). Consequently, many countries 
have included syphilis testing as part of a minimum package of tests conducted during 
prenatal visits.  
    
Unfortunately syphilis diagnosis in peripheral clinics (CSPSs) in Burkina Faso is conducted 
using a syndromic approach, while the majority of syphilis cases are asymptomatic. In 
hospital laboratories (Medical Centers with Surgical Services (CMA), regional hospitals 
(CHR), national hospitals (CHU)), testing is conducted with a venereal diseases research 
laboratory (VDRL) test or with a Treponema pallidum hemagglutination assay (TPHA) . 
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Although these tests present certain advantages in that they allow for the differentiation 
between an old or treated syphilis infection and active syphilis, as well as an analysis of 
treatment adherence, their use requires qualified personnel, laboratory equipment, and a 
source of electricity, which limits their utility to peripheral clinics (CSPSs).  
 
Currently, there are several available specific, rapid syphilis tests that are simple to use and 
could be implemented in CSPSs. When compared to the diagnostic tests currently being used 
(VDRL and TPHA), rapid treponemic tests have several advantages, including the rapid 
availability of results (30 minutes) and the fact that their usage does not require electricity or 
highly qualified laboratory staff (WHO/TDR, 2006). Simultaneous point-of-care treponemal 
and non-treponemal are available with good performance (11) and are undergoing wide 
adoption for their benefits.  However, despite reports of diagnostic performance provided by 
the manufacturers of rapid syphilis tests, data on test effectiveness and operational 
characteristics in the field remain limited in West Africa and non-existent in Burkina Faso. 
Against that background, we conducted a study to evaluate the diagnostic laboratory 
performance and operational characteristics of four rapid tests for Treponema pallidum 
available in Burkina Faso.  The objectives of the study were;  to assess the sensitivity and 
specificity of four on site rapid tests in comparison with Treponema pallidum 
haemagglutination assay (TPHA) as a gold standard and to evaluate  the operational 
characteristics of the tests.  
 
METHODS  
Study populations 
We evaluated rapid syphilis tests commercially available in Burkina Faso using archived 
serum samples and TPHA as the gold standard. Rapid syphilis tests were defined as 
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Treponema pallidum tests (i) capable of giving a result within 30 minutes and (ii) that could 
be used at service delivery points without any need for special storage or transport 
(WHO/TDR, 2006).  Only rapid syphilis tests with market authorization in Burkina Faso 
(currently valid or in the process of renewing validity with the Ministry of Health) were 
considered. In total, four tests were selected. These were 1) Accu-Tell® Rapid Anti-TP 
(Treponema pallidum / Syphilis) (Accu Biotech Co Ltd, China), 2) AlereTM Determine
TM
 
Syphilis TP (Alere
TM 
Médical Co
 
Ltd, UK), 3) Syphilis Cypress Diagnostics (Cypress 
Diagnostics, Belgium), and 4) SD Bioline syphilis 3.0 (Standard Diagnostics INC, Korea). 
The characteristics of the tests according to the manufacturers are listed in Table 1.  
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Table 1 Characteristics of the tests according to the manufacturers.  
 
Characteristics 
Accu-Tell 
®
 
Rapid Anti-
TP 
Alere 
Determine™ 
Syphilis TP  
Cypress 
Diagnostics 
Syphilis Quick 
test Diagnostics 
SD Bioline 
Syphilis 3.0 test 
Manufacturer 
Accu Biotech 
Co Ltd 
Alere 
TM 
Medical Co
 
Ltd 
Cypress 
Diagnostics 
Standard 
Diagnostics INC 
Product code 
ABT-STD-
B17 
7D2443 
353 Syphilis 
Quick Test 
06FK11 
Lot used 
2011071312 
 
14448k100 
 
25094 
 
32052 
 
Type of 
antigen 
Immunochro
matographic 
TP 
Ag1, Ag2 
Immunochromato
graphic 
 
Ag Treponema 
pallidum 
Immunochromato
graphic 
Ag 17, 15 KDa 
Treponema 
pallidum 
Immunochromato
graphic 
Ag recombinant 
pale (17, 15 kDa) 
Specimen 
Serum or 
plasma  
Serum, plasma or 
whole blood 
Serum, plasma or 
whole blood 
Serum, plasma or 
whole blood 
Time needed 
for results 
15 minutes 
15 minutes 
24 hours 
maximum 
5–20 minutes 5–20 minutes 
Stable result 20 minutes 24 hours 20 minutes 20 minutes 
Storage 
conditions 
2–30°C 2–30°C 8–30°C 2–30°C 
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Blood samples were collected between November 2011 and June 2012 from blood donors at 
the Regional Blood Transfusion Center (CRTS) of Ouagadougou, Burkina Faso. A total of 
120 serum samples were considered for the evaluation. There were 60 samples positive for 
syphilis (50 samples were TPHA and VDRL positive: active syphilis, and 10 were TPHA 
positive and VDRL negative: previous or primary case of syphilis) and 60 samples negative 
for syphilis (50 samples were TPHA negative and VDRL negative, and 10 were TPHA 
negative and VDRL positive). The comparative analysis was conducted in the laboratory of 
the Institut de Recherche en Science de la Santé (IRSS) in Ouagadougou, Burkina Faso. 
 
For the evaluation of the operational characteristics, the study was conducted in a primary 
healthcare centre (CSPS) located in Ouagadougou the capital city of Burkina Faso. In total 
sixteen healthcare professionals (midwives, birth attendants, and auxiliary birth attendants) 
working in the maternity ward of an urban first-level healthcare were trained in the use of the 
four tests. Their seniority in the maternity ward was between 6 months and 18 years, although 
none had previously used a rapid syphilis test. However, they had used HIV and malaria 
rapid tests.  
 
Sample collection 
After obtaining the blood donor’s consent, approximately 10 mL of blood was taken from the 
blood collection bag, put in a dry BD Vacutainer® tube (Becton, Dickinson and Company; 
USA) without anticoagulant and kept at +4°C for approximately four hours while waiting for 
the results of the syphilis test.  
 
For the operational characteristics study, during the routine prenatal consultations, each 
healthcare worker used each rapid syphilis test on 5 pregnant women who consented to a 
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blood-draw by finger prick. A self-administered questionnaire was made available to the 
healthcare workers for the data collection. The operational characteristics were appreciated 
following: (i) the clarity of the manufacturers’ pamphlets, mainly the description of use, in 
terms of level of comprehension, (ii) the complexity of technique, (iii) the length of time 
required to complete the entire testing process, (iv) the time of apparition of line result, and 
(v) the interpretation of result.  For each criterion measures were defined. 
 
The clarity of the manufacturer’s pamphlets was appreciated regarding comprehension of the 
text if it was very clear, moderately clear or difficult to understand. 
The complexity of technique was looked if the technique for utilization (from blood 
collection to the availability of the result) was complex (very difficult), moderately complex 
(difficult) or very easy in comparison with other rapid tests they had already used such as 
HIV test.  
The length of time required for a test (from blood collection to the availability of the result) 
was compared to the duration of other rapid tests they had used following the modalities of 
long, equivalent or short duration.  
The time for apparition of line result was compared to what was written in the pamphlet of 
each test. Finally the ease in interpretation of the result, in terms of visibility and readability 
of line result, was compared to other used rapid tests following the modalities of very easy or 
moderately easy to interpret.  All these criteria were used to appreciate if a test has good 
operational characteristics or not. 
 
Laboratory methods 
After blood collection from blood donors, syphilis test was conducted by CRTS using the 
ARCHITECT Syphilis TP automated treponemal antibody test (Abbott Diagnostic, USA). 
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This is a two-step immunoassay for the qualitative detection of anti-TP antibodies in human 
serum or plasma. It uses chemiluminescent microparticle immunoassay (CMIA) technology 
with flexible dosage protocols called Chemiflex. The microparticles are covered with 
recombinant TP antigens (TpN15, TpN17, and TpN47). Once the syphilis status of the blood 
donor was determined by CRTS, we chose positive and negative samples for syphilis for our 
evaluation. At the end of the collection day, the samples were centrifuged at 3000 rpm for 10 
minutes and then submitted to combined VDRL/TPHA (BIOLABO SA, France) testing in 
the serologic laboratory of the Institut de Recherche en Sciences de la Santé (IRSS) to 
confirm the syphilis status. After confirmation, the serum was aliquoted in two cryotubes of 2 
mL, labeled, and stored at -20°C until beginning of the next stage of the evaluation. 
Hemolyzed samples were excluded. 
 
The evaluation of the rapid syphilis tests performance was conducted at the laboratory of 
IRSS in July 2012 using the stock of serum samples from CRTS. The evaluation followed the 
manufacturers’ instructions and used good laboratory practices.  First the frozen serum 
samples were brought to ambient temperature before use. Then each test was used in series. 
To avoid the comparison of results between tests during the laboratory analysis, each rapid 
test was used on all samples before moving to the next test. There was a blind interpretation 
of test results, independent of the results of the reference test (TPHA). TPHA (BIOLABO 
SA, http://www.biolabo.fr/pdfs/noticesFR/Syphilis) was used as the gold standard (reference 
test). It is an indirect hemagglutination assay (IHA) for the identification of Treponema 
pallidum antibodies circulating in human plasma and regularly used for the diagnosis of 
syphilis in a laboratory. 
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3.7.1. Statistical data analysis 
For each test, the laboratory evaluation results were compared to the reference test (TPHA) 
and categorized as true positive, false positive, true negative, or false negative. The data were 
entered with Epidata and analyzed using SPSS version 15 and R version 2-12.1. The 
performance characteristics, such as sensitivity, specificity, positive predictive value (PPV) 
and negative predictive value (NPV), were calculated.   
 
Ethical issues 
 The research protocol received the approval of the Health Research Ethics Committee 
(CERS), Ministry of Health, Burkina Faso.   
 
RESULTS  
Performance of diagnostic tests  
A total of 120 samples were tested for the evaluation of the performance.  The sensitivity of 
the tests was compared to the gold standard used (TPHA). Analysis of the sensitivity of the 
tests showed that Alere Determine
TM
 syphilis TP had the best sensitivity (93%) among the 
four selected rapid tests. Then  in second position, Cypress syphilis and SD Bioline Syphilis 
3.0 with 90%followed. Accu-Tell 
®
 Rapid Anti-TP had the lowest sensitivity (78%). In terms 
of specificity, Alere Determine
TM
 syphilis TP, Accu-Tell 
®
 Rapid Anti-TP and SD Bioline 
Syphilis 3.0 had the same result (98%), while Cypress syphilis had a specificity of 95% 
(Table 2).  
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Table 2 Results of the diagnostic performances of rapid syphilis tests.  
 
 
Accu-Tell 
®
 
Rapid Anti-TP 
(Accu Biotech 
Co Ltd) 
Alere 
Determine™ 
Syphilis TP 
(Alere
TM 
Médical Co
 
Ltd) 
Cypress 
Diagnostics 
Syphilis Quick 
test (Cypress 
Diagnostics) 
SD Bioline 
Syphilis 3.0 test 
(Standard 
Diagnostics INC) 
Sensitivity 
(95% CI) 78% (66 - 87) 93% (84-97) 90% (79-95) 90% (80-95) 
Specificity 
(95% CI) 98% (91-100) 98% (91-100) 95% (86-98) 98% (91-100) 
     
     
CI =  confidence interval 
 
 
Operational characteristics of the four tests according to healthcare professionals  
The results of the evaluation of the operational characteristics of the four tests by 16 
healthcare professionals are summarized in Table 4. The pamphlet of the test  was clearly 
comprehensible by 12 of the 16 respondents for Accu-Tell 
®
 Rapid Anti-TP, by 11 
respondents for SD Bioline syphilis 3.0, by 9 respondents for Cypress Diagnostics Syphilis 
Quick test, and by 7 respondents for Alere Determine
TM
 syphilis TP.  
As a whole, the healthcare professionals judged the technique for utilization of the tests to be 
very easy. Indeed, of the 16 healthcare professionals who participated in the evaluation, 15 
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found Cypress Diagnostics Syphilis Quick test and SD Bioline Syphilis 3.0 to be very easy to 
use, while 14 said the same for Accu-Tell 
®
 Rapid Anti-TP and Alere Determine
TM
 syphilis 
TP. 
 
Overall, the time needed to obtain results was determined to be similar to other tests already 
used for HIV and malaria. Specifically, 10 respondents found Alere Determine
TM
 syphilis TP 
and Cypress Diagnostics Syphilis Quick test to be similar to the previously used tests, and 
approximately 50% found this for Accu-Tell 
®
 Rapid Anti-TP (9/16) and SD Bioline syphilis 
3.0 (8/16).  
 
For the majority of respondents, the time required to obtain results matched the time 
indicated by the manufacturer for Accu-Tell 
®
 Rapid Anti-TP, Cypress Diagnostics Syphilis 
Quick test and SD Bioline syphilis 3.0 (Table 4).  
The interpretation of results was found to be very easy by 14 of 16 respondents for Accu-Tell 
®
 Rapid Anti-TP and SD Bioline syphilis 3.0 and by 12 of 16 respondents for Alere 
Determine
TM
 syphilis TP. As for Cypress Diagnostics Syphilis Quick test, only 9 of 16 found 
the results to be easy to interpret. 
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Table 3 Operational characteristics of syphilis diagnostic tests.  
 
   Characteristics evaluated 
Accu-Tell 
®
 
Rapid Anti-
TP 
Alere 
Determine
™ Syphilis 
TP 
(Alere
TM 
Médical Co
 
Ltd) 
Cypress 
Diagnostics 
Syphilis 
Quick test 
SD Bioline 
Syphilis 3.0 
test  
(Standard 
Diagnostics 
INC) 
Clarity of the test pamphlet  (n=16) (n=16) (n=16) (n=16) 
            Difficult to understand                                            2 2 1 1 
             Moderately clear 2 7 6 4 
                Very clear 12 7 9 11 
    
  Complexity of technique (n=16) (n=16) (n=16) (n=16) 
Complex 1 0 0 0 
              Moderately complex 1 2 1 1 
Very easy 14 14 15 15 
Time needed for performing  (n=16) (n=16) (n=16) (n=16) 
Long 0 4 0 0 
Equivalent 9 10 10 8 
Short 7 2 6 8 
 
Time need for results  
 
(n=16) 
 
(n=16) 
 
(n=16) 
 
(n=16) 
Time indicated in pamphlet 15 14 15 15 
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Time indicated plus 5 minutes 1 2 1 1 
 
Ease of result interpretation 
 
(n=16) 
 
(n=16) 
 
(n=16) 
 
(n=16) 
Moderately easy 2 4 7 2 
Very easy 14 12 9 14 
 
The realization of the tests requires the use of equipment not provided in the kit. Specific and 
non-specific equipment are needed. Specific equipment, such as capillary tubes with EDTA 
for Alere Determine™ Syphilis TP and pipettes for Cypress Diagnostics Syphilis Quick test 
and SD Bioline syphilis 3.0 Accu-Tell
® 
are needed. Rapid Anti-TP does not require specific 
equipment. Non-specific equipment, including alcohol swabs and lancets, was required for 
the four tests. (Table 4) 
 
Table 4 Equipment required but not available in kits 
 
 
Accu-Tell 
®
 
Rapid Anti-
TP 
Alere 
Determine™ 
Syphilis TP 
(Alere
TM 
Medical Co
 
Ltd) 
Cypress 
Diagnostics 
Syphilis 
Quick test 
SD Bioline 
Syphilis 3.0 test  
(Standard 
Diagnostics 
INC) 
Specific 
consumable  
Capillary tube 
with EDTA Pipette Pipette 
Non-specific 
consumable 
Alcohol 
swab 
Alcohol swab Alcohol swab Alcohol swab 
Lancet Lancet Lancet Lancet 
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DISCUSSION 
This is the first evaluation of the performance and the characteristics of commercially 
available rapid diagnostic syphilis tests for Burkina Faso, and it allows the identification of 
the test that is best adapted to the context of the country. To our knowledge, two of the tests, 
Cypress Diagnostics Syphilis Quick test and Accu-Tell 
®
 Rapid Anti-TP, were for the first 
time compared to other rapid tests for syphilis in West Africa. 
 
All the tests used an immunochromatographic detection of anti-Treponema pallidum 
antibodies. These tests used one or more of several similar recombinant Treponema pallidum 
antigens, although their diagnostic performances in our study were different. With a 
sensitivity of 93%, Alere Determine
TM
 Syphilis was the most sensitive of the four rapid 
syphilis tests. It was followed by SD Bioline Syphilis 3.0 and Cypress Diagnostics Syphilis 
Quick test (Se = 90%), with Accu-Tell 
®
 Rapid Anti-TP being the least sensitive (Se =78%). 
In general, the four tests demonstrated a good diagnostic specificity for syphilis (95–98%). 
Taking into account the two diagnostic criteria of sensitivity and specificity, our study 
showed that Alere Determine
TM
 Syphilis was the best of the four evaluated tests (Se = 93%, 
Sp = 98%) followed by SD Bioline Syphilis 3.0 (Se = 90%, Sp = 98%). The good diagnostic 
performance of these rapid tests compared to other tests has been reported in the literature (D 
Mabey et al., 2006; Montoya et al., 2006; Nessa et al., 2008; Tucker, Bu, et al., 2010) . 
However, few data exist regarding the performances of Cypress Diagnostics Syphilis Quick 
test and Accu-Tell 
®
 Rapid Anti-TP. 
 
The performance of the tests was different than what was indicated in the manufacturers’ 
pamphlets. Our results showed lower values than those reported for Cypress Diagnostics 
Syphilis Quick test (99.3% and 99.5%), Alere Determine
TM
 syphilis TP (100% with serum), 
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and SD Bioline syphilis 3.0  (99.3% and 99.5%). The pamphlet for Accu-Tell 
®
 Rapid Anti-TP 
did not give any indication of performance. These data, which are crucial in the choice of 
diagnostic tests, are unavailable in the current published literature. This result calls into 
question the criteria used for obtaining market authorization from the Ministry of Health to 
sell rapid tests in Burkina Faso. Additionally, this result emphasizes the need to evaluate 
available tests on the local market to properly inform policy decision makers.   
 
The performances of Cypress Diagnostics Syphilis Quick test, Alere Determine
TM
 syphilis TP, 
and SD Bioline syphilis in this study were in accordance with the threshold set by the WHO 
(WHO/TDR, 2006), which recommends a minimum sensitivity of 85% and a minimum 
specificity of 95%. The low sensitivity of Accu-Tell 
®
 Rapid Anti-TP (78%) when compared 
to the WHO threshold shows that this test is inappropriate for syphilis testing in Burkina 
Faso.  
 
The sensitivities found for Alere Determine
TM
 syphilis TP and SD Bioline syphilis 3.0 are 
below those found by Herring et al. (Herring et al., 2006b) using stored serum samples in 
Gambia (100%), Tanzania (96% and 94%), and South Africa (96% and 94%). However, their 
specificities are higher than those found by Herring et al. and Mabey et al. (D Mabey et al., 
2006) and similar to the results obtained in China. This variation in performance could be 
explained not only by ambient storage conditions and use of the different tests but also by the 
use of fluorescent treponemal antibody, absorbed (FTA-ABS) as reference test and the type 
of specimen used. This study, whose objective was to evaluate rapid syphilis tests 
commercially available in Burkina Faso, used tests bought or received by intermediaries of 
local distributors. A direct order of rapid tests from the manufacturer would have permitted 
the traceability of the tests evaluated.   
 
 
 
 
78 
 
Regarding the evaluation of operational characteristics, no test was found to be easier to use 
than any other. We found all four tests to have very good operational characteristics. In fact, 
the majority of respondents found that the results were very easy to interpret, and the time 
required to use the tests was similar to that of existing tests for HIV and malaria. These 
results are corroborated by Herring et al. for Alere Determine
TM
 syphilis TP and SD Bioline 
syphilis 3.0. Other studies have also shown rapid diagnostic syphilis tests to be easy to use 
(Sabidó, 2009) but this criterion is not the most important in choosing a diagnostic test. 
Although perceived favorably by the healthcare professionals, the four test kits were missing 
equipment. This equipment, such as alcohol swabs, lancets, pipettes, and capillary tubes, is 
necessary to use the tests in the field. We recommend that the distributors include them in the 
kits to ensure correct use of the tests.  
 
Of the four tests, three can be performed using whole blood. Studies have documented the 
performance of Alere Determine
TM
 syphilis TP in both the laboratory as well as in real-world 
situations (D Mabey et al., 2006). Given its simplicity and its good performance in our study, 
which is in agreement with data collected in previous studies by other research teams, Alere 
Determine
TM
 syphilis TP seems the best adapted to syphilis testing in Burkina Faso.  
 
While our study presented the laboratory performance of these tests when used with serum  
samples, their performance with whole blood will be different (Siedner, Zapitz, Ishida, De La 
Roca, & Klausner, 2004). In addition, providing diagnostic tests to CSPSs would allow for 
the collection of more information on the effects of storage conditions on test performance 
when used in rural settings. Moreover, we did not evaluate the effects that additional 
infections, such as HIV or malaria, could have on the performance of these tests in real-world 
situations with whole blood. 
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CONCLUSION 
Rapid syphilis tests in limited-resource countries can help diagnose syphilis in CSPSs that, 
until now, have used a syndromic approach to STI diagnosis. Our study allowed us first to 
confirm the good performance of three of four rapid syphilis tests in Burkina Faso. 
Additionally, it allowed us to identify Alere Determine
TM
 Syphilis TP as the test that is best 
adapted to Burkina Faso. More research on the feasibility and acceptability of these rapid 
syphilis tests in first-level healthcare centers should allow for the effective implementation of 
the recommendation for systematic testing of pregnant women. 
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CHAPTER 6: Introducing an onsite antenatal syphilis 
screening in Burkina Faso: implementation and evaluation 
of a feasibility intervention tailored to a local context 
 
 
Chapter 6 (Paper III- submitted) presents the process of development and implementation of 
the intervention and its outcomes notably the identification of the facilitators and barriers to 
the implementation of an antenatal syphilis screening at primary health facilities in Burkina 
Faso. Thus it responds to the subsidiary question about the facilitators and barriers to 
introduce the rapid syphilis tests in the package of antenatal care services. This chapter 
presents results of phase II and III that address objectives 4 to 7. 
 
Paper III: - Fadima Yaya Bocoum, Grissoum Tarnagda, Fabrice Bationo, Justin R. Savadogo, 
Sarata Nacro,  Séni Kouanda, Christina Zarowsky  
Introducing onsite antenatal syphilis screening in Burkina Faso: implementation and 
evaluation of a feasibility intervention tailored to a local context,  
Under review in BMC Health Services Research (manuscript ID: BHSR-D-15-00765) 
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Background  
Syphilis in pregnancy poses major health risks for the mother and the fetus (Genc & Ledger, 
2000) and also increases the risk of HIV transmission (D. G. Walker & Walker, 2004). The 
World Health Organization (WHO) estimates that two million pregnant women each year are 
infected with syphilis globally (WHO, 2007b). The risk of vertical transmission could be up 
to 80% in early latent syphilis (WHO, 2007b). Approximately 1.2 million pregnant women 
with syphilis transmit the infection to their newborn every year (Kamb et al., 2010). Each 
year, maternal syphilis is responsible for at least 50,000 spontaneous abortions or stillbirths 
and 500,000 premature births of babies infected with congenital syphilis or who have low 
birth weight (WHO, 2007b). In Burkina Faso, prevalence in pregnant women was 1.9% , with 
notable regional variations (PSSLS-IST, 2013). In 2011 in Kaya the prevalence was 4.3%  
whereas in Ouagadougou it was 2.1% (PSSLS-IST, 2013). 
 
Maternal syphilis is detectable by serological screening and is entirely treatable with 
penicillin. Consequently, screening and treatment for syphilis has been recommended as a 
routine part of antenatal care in many countries (Control Centers for Disease, 2002; WHO, 
2001). Unfortunately, antenatal syphilis screening is often poorly implemented in many sub-
Saharan African countries (S Gloyd et al., 2001). The influence of health systems issues on 
prenatal syphilis screening has been documented in several countries, such as Bolivia, Kenya 
and South Africa (Deperthes et al., 2004). Yaya Bocoum et al. have documented constraints 
related to syphilis screening at primary health care facilities (CSPS) in Burkina Faso (Yaya 
Bocoum, Kouanda, & Zarowsky, 2014).  
 
Syphilis screening in primary health care facilities during ANC in Burkina Faso is conducted 
using a syndromic approach, but the majority of syphilis cases are asymptomatic. Testing is 
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available at the hospital laboratories and conducted with a venereal diseases research 
laboratory (VDRL) test or with a Treponema pallidum hemagglutination assay (TPHA) 
which require qualified personnel, laboratory equipment, and a source of electricity, which 
limits their utility for primary health care facilities.  
 
Currently, there are several available specific, rapid syphilis tests that are simple to use and 
could be implemented at primary health care settings (WHO/TDR, 2006). These rapid tests 
for syphilis screening are available in Burkina Faso, and four of them have had their 
performance and operational characteristics assessed (Yaya Bocoum, Ouédraogo, Tarnagda, 
Kiba, Tiendrebeogo, et al., 2015) . Unfortunately they are not widely adopted for ANC 
services.  
 
Interventions to improve the outcomes of antenatal syphilis screening have been implemented 
in low and middle income countries where most congenital syphilis cases occur (Shahrook et 
al., 2013) . Although the advantages of introducing point of care testing for syphilis in 
antenatal care are well documented, there is little evidence on how to address the structural 
issues within the health system (S. Hawkes et al., 2011). A better understanding on how the 
interventions work in a range of settings and contexts is needed in order to overcome 
bottlenecks at health system level.   When implementing any intervention, how – indeed 
whether – it works depends on elements of context such as socioeconomic background, 
health system structure and dynamics, and other factors (Campbell et al., 2007).   It is with a 
view to better understanding the relationships between implementation and context that we 
developed and implemented an intervention focused on the integration of a rapid test for 
syphilis screening in the ANC services in primary health care facilities in Burkina Faso.  
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Revised UK Medical Research Council guidance on evaluating complex interventions(Craig 
et al., 2008)  recommends describing the intervention and context and reporting on all stages 
of the process including feasibility evaluations. 
The objectives of this study were to develop and describe the experience of a pilot integration 
of a rapid test for syphilis screening and its operational implementation into routine antenatal 
services in order to draw lessons for scaling up maternal syphilis screening in Burkina Faso.. 
This manuscript reports on the experience of implementing antenatal syphilis screening with 
a point of care test, the identification of barriers and facilitators to integrating this 
intervention into routine ANC in rural Burkina Faso. Finally its reports on the likelihood that 
point of care test for syphilis will become routinely incorporated in practice.  
 
Study site – Kaya HDSS 
The intervention was nested in the Kaya Health and Demographic Surveillance System (Kaya 
HDSS), located in the Kaya health district in the North Central region of Burkina Faso, 100 
Km from Ouagadougou, the capital city.  It covers seven urban areas and 18 villages of the 
health district. By the end of 2011, 64 480 inhabitants living in 10 587 households were being 
followed. The population is very young as 55.5% are under 20 years of age. The Mossi are 
the predominant ethnic group and Islam is the main religion (78.9%). The majority of the 
population of the HDSS (53.3%) has not attended school. Subsistence farming and livestock 
breeding are the two main occupations. Artisanal mining is also significant. Within Kaya 
HDSS, dirt roads and bush paths provide means of access to the villages. These roads present 
a challenge for users especially during the rainy season when there are floods (Kouanda et al., 
2013). 
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Health facilities 
Within Kaya HDSS, there are seven public primary health facilities that offer ANC, one 
faith-based health center and one regional hospital. The faith-based facility and the hospital 
do not offer ANC but their laboratories offer VDRL and TPHA tests for syphilis. In 2012, a 
pharmacy began offering a rapid test for syphilis but due to low demand they stopped selling 
the test.  
 
All seven public primary health facilities, four urban and three rural, were selected for the 
intervention. All facilities have a maternity, dispensary and drug shop. There are 2 to 3 health 
workers staffing a rural facility compared to an average of 7 in urban facilities. Primary 
health care facilities are led by a state registered nurse and staffed by cadres including nurse, 
midwife, auxiliary midwife and outreach health workers. Nurses and midwives have formal 
training that includes syndromic STI case management.  
 
The drugs for STI are standardized kits that are subsidized by the national committee for HIV 
and STI control. Every year kits are ordered by the national committee for HIV and STI 
control and supplied to the district for each facility. Frequently, drugs from these kits are 
expired or out of stock depending on the facility.  
 
Syndromic STI case management and reference for laboratory test were used for syphilis 
screening in these facilities until the time of the intervention.  
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Methods 
Design of the intervention 
 The main strategy of the intervention was the development and implementation of a 
decentralized model of syphilis screening among pregnant women. The components of this 
intervention included: (1) providing onsite training of health workers involved in ANC, (2) 
providing supplies and drugs to health facilities for diagnosis and treatment (3) implementing 
a quality control system, (4) and supervision and monitoring. Before the implementation a 
preparatory phase of formative research was undertaken. 
 
Preparatory phase 
A situation analysis and evaluation of health worker and community perspectives on syphilis 
screening was the first stage of this project (Yaya Bocoum et al., 2014) .  An evaluation of 
the performance of four available onsite rapid syphilis tests in Burkina Faso was also 
conducted in order to select the test. The results of this evaluation are reported elsewhere 
(Yaya Bocoum, Ouédraogo, Tarnagda, Kiba, Tiendrebeogo, Simon Bationo, et al., 2015). 
The selected point of care test for syphilis was Alere TM  Determine TM Syphilis TP 
(AlereTM Medical Co Ltd, UK). Before the implementation, the head of the health district 
received information on the objectives and procedures of the intervention.  
 
A workshop was organized with health workers from each of the selected facilities. 
Participants were staff who regularly performed antenatal care. During the workshop, the 
importance of decentralizing antenatal syphilis screening, case management of syphilis 
positive cases, including treatment, counseling and the components of the intervention and a 
manual were presented. The treatment of positive pregnant women, who were not penicillin 
sensitive, was benzathine penicillin G, 2.4 million units intramuscularly immediately as a 
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single dose in accordance with Burkina Faso Ministry of Health (MOH) guidelines. In the 
national guideline the alternative treatment to penicillin is erythromycin 500mg 1 tablet 4 
times per day during 14 days in addition to Polyvidone – iodine for ulceration. 
 
Discussions about the eligibility criteria for women who would receive the test, the design of 
the intervention and the program manual were held during the workshop. The booklet-format 
manual was elaborated by the research team and included general information on syphilis, 
how to use of rapid diagnostic test (RDT) for syphilis, the purpose of the study, criteria for 
eligible women, obtaining consent, instructions for filling registers, and quality control.  
 
There was no additional health educational campaign beside the routine health education 
organized by the facility or nongovernmental organization in the district. 
 
Conceptual framework 
We adapted and applied the Normalization Process Model (NPM) proposed by May et 
al(May et al., 2007). NPM focuses on the workability and integration of the components of an 
intervention in everyday health care practice and identifies conditions that need to be 
addressed in order to facilitate health intervention integration into routine care. It assists 
process evaluation in two ways.  First, it allows identification and description of factors that 
have been shown to be important in promoting or inhibiting the implementation of 
interventions.  Second, it provides a basis for assessing the likelihood that an intervention will 
become routinely incorporated in practice. We sought to identify barriers and facilitators for 
the introduction of a rapid test for syphilis screening among pregnant women and to 
understand the conditions under which such an intervention could become routinely 
incorporated in the antenatal care package.  
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Data collection 
Data were collected through qualitative and quantitative methods. 
Interviews were conducted among health workers  (n= 12) who used the point of care test for 
syphilis and district managers (n=2). We sought to explore health workers’ opinions on 
organizational and managerial issues and  their experience with point-of-care test for syphilis. 
Non-participant observations were conducted during ANC visits. The aim was to observe 
how ANC was offered and how RDT was used. A researcher sat in the consultation room 
during ANC from the time a woman entered until the end of her consultation. Observations 
(n= 14 ANC 1  observed) included listening and asking questions as they arose out of 
observations in order to gain insight into what was observed. 
 
Data analysis 
Interviews were transcribed into a text program and then uploaded on Nvivo software. An 
analytical grid of key themes was developed based on the interview guide, the objectives of 
the research and familiarization with the first few transcripts.  
Ethical considerations 
This research was approved by the University of Western Cape, the National Ethics 
Committee for Health in Burkina Faso and the Ethics Committee Review of the WHO. In 
addition, the study team obtained permission to conduct the intervention and research from 
the District authorities. Consent was obtained from pregnant women who received the test by 
a health worker. They gave a witnessed signature or thumb-printed approval to participate. 
The consent process included an explanation of the study, its objectives, potential benefits 
and risks, confidentiality, and the voluntary nature of participation including the right to 
withdraw at any time. 
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   Implementing and evaluating the intervention 
Organizational issues  
Seven health facilities participated in the intervention. Data were compiled from 6 facilities 
because one facility did not complete the record tools. The intervention was implemented in 
the maternity unit over 4 months in 4 facilities, 2 months and 1 month in 2 facilities. For 
these latter facilities, stock outs and lack of communication among staff were the main 
difficulties. The intervention was integrated into the existing package of antenatal care 
services at primary healthcare level of the district, using the available staff. Syphilis test was 
performed during ANC. In many cases, it was delivered at the same time as the HIV test. The 
health worker pricked a woman’s finger once for a blood sample for both syphilis and HIV 
tests. In a few cases health workers pricked twice.  There was no change in the organization 
of the health facilities and patient flow. The main complaint was the filling of the register for 
syphilis test. Health workers reported that there were many procedures and items to complete. 
In addition, some health workers highlighted an increase in the length of antenatal 
consultation. From our observations the difference in time between before and after the 
intervention was approximately 3 minutes. 
 
Training  
A one day on-site practical training was organized in each selected facility. The training was 
held in the maternity unit with all the staff available the day of the training. It covered the use 
of an onsite rapid syphilis test, filling of register book, case management of test-positive 
syphilis cases and quality control. After training, a simple manual, in French, was given to 
ensure standardization in screening and treatment for all trainees. In total 18 health workers 
such as midwife, auxiliary midwife and nurse received the training across 7 facilities.  A 
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pharmacist working for IRSS laboratory and the lead researcher travelled to selected facilities 
to provide the training. 
 
Health staff found the training interesting and useful mainly because it was a refreshment of 
their knowledge.  They also appreciated the onsite session because this avoided absence of 
staff and benefited all staff simultaneously, although due to turn over of health workers, some 
did not receive training. Nonetheless, some of the staff who did not receive training 
performed the test. 
 
Provision of supplies and drugs 
The initial provision of rapid tests and ancillary supplies occurred on the same day, after the 
training. Thereafter, supplies were ordered by the research team and distributed to facilities 
by the health system’s district management team. The ancillary supplies comprised cotton 
wool, lancets, gloves, capillary tubes with EDTA, buffer and alcohol.  
 
In addition to the kits provided by the national committee for HIV and STI control, the 
research team provided kits that comprised benzathine penicillin, erythromycin and 
polyvidone- iodine. Each facility received 7 kits. 
 
Case management and partner notification  
All eligible women were offered the syphilis test in the consultation room. Women at their 
first antenatal visit during the intervention period were eligible for the test. The decision to 
offer treatment was based on the point of care test result. Kits were available for treatment.  
All women diagnosed with syphilis were treated free of charge.  
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Women with syphilis were advised by the health worker to inform their partner or to invite 
them for a visit at the health facility without any letter or card of invitation. All health 
workers declared that partners did not respond to the invitation. 
 
Quality control 
All the seven facilities were involved in the quality control tests which were performed by the 
laboratory of the regional hospital located in Kaya. Supplies such as syringes, cryotubes were 
provided to health facilities and reagents (RPR and TPHA) and other supplies were provided 
to the laboratory.  
 
Every 20
th
 negative and all positive rapid tests were to be followed immediately by 
venipuncture with blood samples sent to the laboratory. RPR and TPHA were the gold 
standard for the diagnosis of syphilis. Transport of blood samples from the health facility to 
the laboratory was conducted by health worker. Transport expenditure was reimbursed. 
 
In sum, only 4 facilities sent at least one sample to the laboratory of the regional hospital for 
control. In total 12 samples were sent. Among these samples 8 were positive and 4 negative. 
According to the laboratory record, 10 samples were appropriate for analyzing, the others 
were hemolyzed. There was no discordance between the rapid test results and TPHA one. 
The small number of samples sent for validation is due to misunderstanding of health workers 
about the 20
th
 negative sample (some health workers misinterpreted the guidance as the 20th 
patient) and the system of reimbursement of transport costs.   
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Supervision and monitoring 
For supervision, each health facility was visited once a month. A detailed checklist was 
elaborated for supervision. A separate register book for screened women was kept in each 
health facility. Records included the essential information as serial registration number, 
patient name, sociodemographic information, result of test, reasons for partner notification or 
non-notification. Supervision was perceived as important but not sufficient in some cases 
where staff did not follow the guidelines of the intervention despite many reminders. 
Supervision was also useful for supplies provision such as tests and treatment kits. In addition 
to visits to facilities, the team had monthly phone contact with the head of the maternity unit, 
with additional calls if there was any difficulty such as filling in the register, criteria for 
quality control or other issues. During supervisory visits, difficulties were discussed and 
patient register books were checked. 
 
Effectiveness 
Of 812 pregnant women who came for their first visit 39% were screened during the period 
(table 1). Rural facilities had higher coverage (66.8%) than the urban ones (25.6%). Among 
these screened women, 5.7% were positive. 
 
Table 1: Percentage of pregnant women screened through the intervention 
 
 
Expected  
   
Screened            % 
CSPS rural 1 119 97 81.5 
CSPS rural 2 63 40 63.5 
CSPS urban 1 76 40 52.6 
CSPS rural 3 83 40 48.2 
CSPS urban 2 124 39 31.5 
CSPS urban 3 347 61 17.6 
Total  812 317 39.0 
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Barriers and facilitators 
Interviews with health workers allowed collecting information on barriers and facilitators to 
introducing this new procedure into routine care.  
 
Barriers 
The perceived barriers were lack of training of all staff, workload, and lack of motivation. 
Regarding lack of training for all staff as a barrier to introducing syphilis test, an auxiliary 
midwife in urban facility declared that “ You have to train everybody, because we work 
together. It could happen that the person who received the training is absent. You are here 
and would like to work but you have to call the person to ask what to do. If you are with a 
pregnant woman, she will wonder if you know your work.” The lack of training prevents 
health workers from performing new tasks. Moreover health workers without training will 
not be able to address questions raised by women during consultation. 
 
Health workers found that the increase in workload is a barrier as illustrated by a midwife in 
charge of maternity unit in urban health facility “People find that the workload is high with 
PMTCT here, malaria RDT there, with the filling of registers mainly with addition of PBF 
(Performance Base Financing), people find that the workload is too high.” In fact the main 
complaint was the filling of the register for syphilis test. Staff felt that they already have 
many registers (4) and there was no need to add another. In addition, some health workers 
highlighted an increase in the length of antenatal consultation. 
 
Another reported barrier was frequent stock-outs of consumables, which is also a source of 
demotivation. Consumables such as gloves and chase buffer were frequently claimed by 
health workers to be unavailable. The availability of chase buffer was crucial for the 
 
 
 
 
93 
 
continuity of the activity in the health facility. Gloves were also important but when there 
was no free stock health workers said that pregnant women are required to buy them at the 
pharmaceutical store of the facility. It becomes a barrier when woman does not have enough 
money to purchase gloves. Stock-outs of consumables were a common reason that health 
workers offered for not screening women. 
Lack of supervision influences motivation of health workers to perform task. One nurse in 
charge of a rural facility declared: “ if we start something without monitoring, at some point, 
staff will wonder if people who initiate the activity are interested in it. Thus there will be a 
demotivation for that activity”.    
 
Facilitators 
All health workers found that offering the rapid test was a satisfying experience for them. 
Among facilitators, health workers cited political environment, ease of use and acceptability 
to pregnant women. 
 
In terms of political environment, syphilis screening is officially part of the package of ANC 
in the guideline for ANC in Burkina Faso. In addition, there are new policies or reforms such 
as performance based financing (PBF) in which offering the full package of ANC is 
important. This is a good opportunity for implementation of syphilis screening as a routine 
activity as illustrated by this auxiliary midwife in rural facility “With PBF, syphilis is part of 
[indicators that count in the evaluation]. If we get it (syphilis test), it will help us, we will 
gain points.” 
 
All health workers agreed that the rapid test was easy to use due to the similarity with the 
HIV testing. The comment of a midwife in an urban facility illustrated the ease of use: “We 
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did not face difficulties in performing testing as we did it for PMTCT, it is the same thing, we 
tick and collect blood, so it is the same thing. There was no difficulty because we received 
training for PMTCT.” In addition, some health workers declared that they received support 
from other colleagues who received training.  
 
Acceptability to women is important to the success of an activity. There was a good 
acceptability of the test and the health workers recorded few refusals from women. Health 
workers were reported that women agree to testing because they would like to know more 
about their health status and protect their fetus. Moreover a nurse in charge of rural facility 
argued that “HIV screening is already performed, women know that there are different tests 
at CSPS level. Thus, asking a woman to do syphilis test will not be a problem. They are used 
to the different tests we deliver here, mainly HIV, it is a routine.” In other word, pregnant 
women have got used to point of care tests like urine, HIV or malaria test and this is a 
favorable factor for introducing a new test in the package of ANC. 
 
Discussion 
The study demonstrated that it is operationally feasible and acceptable to staff to integrate a 
point of care test including rapid on-site syphilis testing and prompt treatment of syphilis 
cases at primary healthcare level in Kaya health district, Burkina Faso. It also highlighted 
implementation challenges and barriers to routine implementation that need to be addressed 
prior to rolling out the intervention.  
 
In developing countries, one of the gaps in syphilis control in pregnant women is the access 
to syphilis testing at peripheral facilities. To address this challenge, a pilot model with a point 
of care test was designed and tested in Burkina Faso. This pilot model included different 
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components including onsite training, quality control and supervision.  Decentralized models 
integrating a point of care for syphilis in ANC were designed and experimented in Low and 
Middle Income Countries (LMIC). These models were mostly implemented in Asia 
(Munkhuu, Liabsuetrakul, McNeil, et al., 2009; Tucker, Hawkes, et al., 2010), Latina 
America (P. J. García et al., 2013; S. G. García et al., 2007) and eastern and southern Africa 
(Bonawitz et al., 2015; Bronzan et al., 2007b; Elizabeth Glaser Foundation, 2011; Fleming et 
al., 2013; Watson-Jones et al., 2005). Few were implemented in West Africa (Dassah et al., 
2015). Each model was adapted to the contextual health system and was feasible. This 
underlines the importance of contextual specificities in the implementation of health 
interventions and pilot studies.  
 
In terms of training, onsite training was chosen instead of the usual off-site approaches. Off –
site training has known limitations like absence of staff during training, small numbers of 
beneficiaries and that often it is the head of the facility and not front line workers who are 
targeted.  Onsite training was chosen to limit absence of the staff from their facility and to 
offer a chance for all staff at maternity units to be trained to  avoid the situation , common 
with off-site training as seen with HIV services, that staff who did not receive the training 
could use this to justify the non use of the rapid diagnostic test (Yaya Bocoum, Kouanda, 
Kouyaté, Hounton, & Adam, 2013) . Nonetheless some health workers complained about not 
having received training. Most of these were absent during the training session or had been 
newly appointed at the facility. It is important, in case of scale –up of the intervention, to plan 
refresher training and to explicitly include mechanisms for trained staff to train new or 
untrained staff. Those who performed the test without training reported that it was due to the 
similarity with HIV testing. 
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Case management of positive pregnant women was not reported to be a problem for health 
workers. The main challenge was partner notification. In most of the cases, the patients’ 
husbands did not come to the facility as reported in many studies (Alam et al., 2010). This is 
one of the limits of patient driven notification and may be particularly challenging in 
patriarchal societies where polygamy is common, such as Burkina Faso. Further research 
might study constraints to partner notification in such contexts and develop a workable and 
acceptable partner notification model (McNutt & Coles, 2007).  
 
With respect to the definition of integration of services understood as “the organization and 
management of health services so that people get the care they need, when they need it, in 
ways that are user friendly,..” (World Health Organisation, 2008), integration of syphilis 
services was observed at ANC units in this study as a “one stop shop”. Rapid syphilis testing 
and treatment were delivered during ANC within the examination room. At the staff 
organization level, there was no specific additional mechanism put in place. Unfortunately, 
there were missed opportunities as not all the women who were eligible received test. Missed 
opportunities could be explained by insufficiently clear instructions, lack of financial 
incentives in a context where some health workers have come to expect financial incentives 
for adding new tasks (Israr, 2005; Ridde, 2010), increase in duration of consultation and high 
number of patients or workload as found by Zongo et al (Zongo, Ridde, & Haddad, 2013) in a 
study on utilization of RDT for malaria conducted in primary health care facilities in Burkina 
Faso.   
 
The quality control was a challenging component because in the routine system the 
relationship between health workers at primary health facilities and lab personnel is limited to 
referral for laboratory tests that are not available at primary health facility. These cadres do 
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not really collaborate except during HIV serosurveillance surveys where health workers at 
health facility send blood samples. The laboratory does not conduct any routine supervision 
to validate rapid diagnostic tests that are delivered at the peripheral level. For the 
implementation of the quality control during our study, health workers received 
reimbursement for their transport depending on the distance. In two facilities where there 
were delays in reimbursement, the activity was stopped. This finding underlines that the issue 
of health workers’ motivation in quality control needs to be properly addressed. In addition 
there is a need to implement a rigorous quality control, with regular supervision from 
laboratory personnel, in order to improve utilization of rapid diagnostic tests as a whole. The 
use of a rapid diagnostic test at level like primary health facility by non-lab personnel is a 
form of task shifting and needs supervision from lab personnel.   
 
Most studies that documented syphilis screening programs did not pay particular attention to 
the workability and integration of the syphilis testing in ANC services. Our research 
identified facilitators and barriers that need to be addressed in order to facilitate integration of 
rapid test for syphilis into routine ANC services.  
At the health worker level, respondents agreed that the rapid test for syphilis is easy to use 
because it is similar to HIV testing and is therefore compatible with their daily activities in 
ANC. The barriers to the full integration of the test are availability of consumables, filling of 
forms and lack of supervision. These factors - especially stock-outs of consumables - 
influence health workers’ motivation to deliver the service. Due to lack of supplies, staff 
frustration was underlined in HIV services at peripheral facilities in Burkina Faso (Yaya 
Bocoum et al., 2013). Regular supply and supervision could help in maintaining motivation 
to deliver testing.  
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At the patient level, acceptability of testing is reported to be high. According to health 
workers, this high acceptability is due to their knowledge of existing testing such as HIV or 
malaria. The few refusals come from women who need prior agreement from their husband. 
However, the high acceptability hides constraints that oblige women to accept any service 
such as tests from health workers. From our observational survey of ANC, the interaction 
between health workers and pregnant women was unidirectional as Pembe et al. found 
(Pembe et al., 2010) . The health worker talks and the pregnant woman nods or answers to 
questions. In such a frame, a pregnant woman does not have an opportunity to refuse any 
offer from health workers. This situation is corroborated by findings from  Malawi where 
rural Malawians perceive routine testing for HIV at antenatal clinics as compulsory to receive 
antenatal care (Angotti, Dionne, & Gaydosh, 2011). Moreover they found that constraining 
choice is likely when clients are women, rural and relatively uneducated compared to health 
personnel, as is the case in our study site.  Although the situation helps staff in gaining high 
rate of acceptability of HIV testing and other services, the rights of clients may not be not 
fully respected.  
 
Through the lens of the four factors of the Normalization Process Model (NPM), assessment 
of the likelihood that point of care test for syphilis will become routinely incorporated in 
practice was explored. These factors are interactional workability, relational integration, skill-
set workability, and contextual integration. 
 
In terms of interactional workability, the point-of care test for syphilis is both an opportunity 
to address a service gap and an opportunity to improve the standard of antenatal care.  Health 
workers were aware that the current antenatal services did not provide optimal access to 
syphilis testing. This awareness could strengthen the willingness of health workers to 
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consider its implementation. So, there is congruence with operational needs (difficult access 
to syphilis test) and antenatal care practice.     
 
Regarding relational integration, the dimension of confidence was explored. Health workers 
are confident in the reliability of the test and the utility of the test.  Health workers did not 
show any reticence regarding the reliability of the results. The results from quality control 
reinforce the confidence in those results. Their perceptions of the reliability could be 
influenced by similarity with HIV test. From our knowledge, health workers had a good 
perception of the reliability of HIV except in some cases of indeterminate results. While 
reliability could be a promoting factor, the utility of the syphilis test could be also considered 
as such.  However this could be threatened by the low prevalence. Where the prevalence is 
low the utility for routine test could be questioned and reduce the willingness of health 
workers to systematically test all the patients. 
 
Skill-set workability could be considered as a promoting factor in relation to the capacities of 
the health workers to perform the test and there being no change required in the division of 
labour. The challenge posed by the intervention was the increase in workload due to filling 
the register and the increased perceived duration of consultation. The existing routine ANC 
register and ANC card do not allow for filling in information on syphilis testing. This would 
need to be addressed as filling in separate syphilis registers is a significant disincentive. The 
perceived extension of ANC consultation time could be addressed by sharing the results of 
observation survey (only 3 minutes additional time) and drawing attention to possible 
improvement of ANC service quality. Supervision of the work by both district managers and 
laboratory personnel could also mitigate the effects of the challenge.     
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Contextual integration is favorable at international and national levels. At the international 
level, the global initiative for the elimination of congenital syphilis, launched by WHO 
(WHO, 2007b), emphasized screening and treatment of pregnant women and their partners as 
a key component. At national level, policy and management of maternal care guidelines 
emphasize the importance of diagnosing and treating pregnant women for reproductive tract 
infections (RTIs). Moreover implementation of performance based financing with indicators 
concerning antenatal syphilis screening is a promoting factor.  It could be argued that these 
initiatives provided a receptive international and local context for introducing point of care 
testing for syphilis in ANC services. Integration of point of care tests using available staff 
could contribute towards embedding this in to routine practice. The main challenge was the 
provision of supplies. Supply chains in Burkina Faso are known to have difficulties that often 
lead to stock out of consumables.   
 
In summary the study identified a number of facilitators to potential normalization including 
congruence with professional practice, confidence in the reliability and utility, capacities for 
performing the test and no change at organizational level.   
 
One of the limits of the study is that there was no baseline data on the percentage of women 
who had their syphilis test at the laboratory. Available data do not allow linking women and 
health facilities. Thus comparison between before and after coverage was not possible. But 
we assumed that the coverage was increased as found in other studies (Munkhuu, 
Liabsuetrakul, Chongsuvivatwong, McNeil, & Janchiv, 2009) . Another limitation is that we 
were not able to show impact as our main focus was feasibility.  
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Conclusion 
In conclusion, point of care test for syphilis could be integrated in ANC at primary health 
facility in Burkina Faso. Nonetheless, barriers need to be addressed before scaling up. These 
barriers relate to staff motivation, which is negatively influenced by practical considerations 
such as stock-outs and the chore of filling in registers, inadequate supervision, and by some 
aspects perceived as unfair regarding training and incentives. Through the lens of NPM, 
point-of care test for syphilis is likely to be acceptable by health workers as routine service 
and incorporated as a normal practice, and may strengthen the quality of overall ANC 
services. 
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CHAPTER 7: Incremental costs of adding rapid syphilis 
test in  to existing antenatal services at primary healthcare 
level in Burkina Faso 
 
Chapter 7 (paper IV- submitted) answers questions about the costs for adding rapid 
diagnostic test for syphilis in antenatal care services.  Paper IV emanated from phase III of 
the research.  
Paper  IV:  Fadima Yaya Bocoum , Christina Zarowsky ,  Seni Kouanda ; Incremental costs 
of adding rapid syphilis test to existing antenatal services at the primary healthcare level in 
Burkina Faso. Under review in BMC Health Services Research (manuscript ID: BHSR-D-15-
00773) 
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Introduction 
Syphilis is a serious source of adverse pregnancy outcomes for both mother and infant (Di 
Mario et al., 2007; David Mabey & Peeling, 2011)  and can also facilitate HIV acquisition 
and transmission (Mwapasa et al., 2006; Reynolds et al., 2006) . Approximately 1.36 million 
pregnant women globally were estimated to have probable active syphilis (Newman et al., 
2013).   According to WHO estimates, each year, maternal syphilis is responsible for at least 
50,000 spontaneous abortions or stillbirths and 500,000 premature births of babies infected 
with congenital syphilis or who have low birth weight(WHO, 2007b). However, rates of 
congenital syphilis are generally underestimated (Saloojee et al., 2004a). Congenital syphilis 
is an avoidable disease that prenatal testing and early treatment of infected pregnant women 
could eliminate(F Terris-Prestholt et al., 2003). Screening and treatment of pregnant women 
for syphilis remain cost-effective even when the prevalence is low (Kahn et al., 2014; 
Schmid, 2004; F Terris-Prestholt et al., 2003). Kuznik et al. found that screening  in 43 sub 
Saharan countries was highly cost-effective, with each DALY prevented on average costing 
only US$11(Kuznik et al., 2013). Despite its potential benefits, antenatal syphilis screening is 
often poorly implemented in many sub-Saharan African countries (S Gloyd et al., 2001). In 
many low resource settings, the traditional lab based diagnostic and syndromic approach have 
still ran with a low coverage due to number of barriers (Deperthes et al., 2004; The Lancet, 
2012; Yaya Bocoum et al., 2014) .  
 
Currently point of care syphilis tests that are simple to use and with high accuracy compared 
to lab based diagnostic are available (Guinard et al., 2013; D Mabey et al., 2006; Tucker, Bu, 
et al., 2010). In Burkina Faso, these point-of-care tests are available but they have not been 
used by health workers at health facilities (Yaya Bocoum, Ouédraogo, Tarnagda, Kiba, 
Tiendrebeogo, Simon Bationo, et al., 2015). An intervention research project was 
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implemented on antenatal syphilis screening and treatment using a point of care test at 
peripheral health facilities. It included training of health workers, provision of supplies and 
drugs, supervision and offering testing and treatment for free to pregnant women coming for 
first ANC visit. This intervention has permitted pregnant women to receive syphilis testing as 
recommended by national ANC guidelines.  
 
At the end of an intervention, issues such as the costs for replication, scaling-up or 
sustainability are usually raised by decision makers or program managers. An incremental 
cost analysis is required to answer such questions. An incremental cost analysis looks at the 
cost of adding or implementing the additional intervention or program to existing services 
and does not estimate cost for existing services (Fern Terris-Prestholt et al., 2011).  The 
choice of this costing study is twofold, first to give evidence on costs for sustainability of the 
intervention and second to estimate how much the provider or decision maker should bear if 
they want to offer syphilis test for free to pregnant women coming for ANC visit. Moreover 
our study will contribute to fill the knowledge gap in low syphilis prevalence countries where 
lack of costing studies has deplored (Kuznik et al., 2013).  This paper reports on an 
incremental cost analysis of the antenatal syphilis screening intervention we implemented in 
rural Burkina Faso. 
 
Methods 
Type of study 
A cost analysis study in the frame of a pre post implementation intervention group with no 
comparison group was conducted.   
 
Study settings 
The intervention was nested in the Kaya Health and Demographic Surveillance System (Kaya 
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HDSS), located in the Kaya health district in the North Central region of Burkina Faso, 100 
Km from Ouagadougou, the capital city.   
Within Kaya HDSS, there were seven public primary health facilities that offered ANC, one 
faith-based health center and one regional hospital. The faith-based facility and the hospital 
did not offer ANC but their laboratories offered the venereal diseases research laboratory 
(VDRL) test and Treponame pallidum hoemagglutination assay (TPHA). tests for syphilis. 
All seven public primary health facilities, four urban and three rural, were selected for the 
intervention. All facilities have a maternity, dispensary and drug shop. There were 2 to 3 
health workers staffing a rural facility compared to an average of 7 in urban facilities. 
Primary health care facilities were led by a state registered nurse and staffed by cadres 
including nurse, midwife, auxiliary midwife and outreach health workers. The drugs for STI 
were standardized kits that were subsidized by the national committee for HIV and STI 
control. Every year, kits were ordered by the national committee for HIV and STI control and 
supplied to the district for each facility. Frequently, drugs from these kits were expired or out 
of stock depending on the facility.  
 
Unit costs for unscreened and screened woman  
The costs for unscreened and screened woman were calculated from a government 
perspective at health facility level. The calculation of the cost depends on many pieces of 
information. We adapted the costing approaches developed by Larson et al  for estimating 
cost of diagnosis and treatment of syphilis in Zambia (Larson et al., 2014) and cost of point-
of-care testing (Larson et al., 2012).  
  The focus of this study was the cost of syphilis testing and treatment, as an additional 
service at public health facilities that already exist. Thus fixed cost such as costs of buildings 
and equipment (weigh scale, metric, blood pressure monitor, obstetrical stethoscope, tape 
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measure, table, and chair, etc.) were not relevant for the analysis. 
Costs of daily startup were not relevant regarding the type of test which did not use resource 
for startup. Costs of quality control were not collected during the intervention.  Costs for 
electricity and water were excluded because in majority of rural health facilities they used 
solar system for electricity and borehole water. 
Of the components used in the approach of Larson et al, we selected 4 major inputs; (1) cost 
of test, (2) materials costs, (3) staff time and (4) salary cost.  
In sum the unit costs for unscreened woman (before introducing of the rapid syphilis test) 
included: 
- Material costs used for first ANC visit   
- Salary cost estimated from staff mean time.  
Material costs used for first ANC visit included gloves, cotton wool, alcohol, urine test, 
lancet, HIV test, chase buffer.  
During ANC visit, multiple activities took place. One or more health workers could be 
involved in these activities and spent time with pregnant women. We conducted a non 
participant observation of time related activities which consisted of observation of each ANC 
consultation and recording of every activity, its duration and resources used.  
Using a chronometer, time was recorded in minutes and seconds. For this study only time 
spent for first antenatal visit was used because syphilis test was performed only during this 
visit.  
Using health worker time per ANC, staff costs per ANC were estimated. The full cost of 
salary and benefits was used for estimate.  While there were potentially 260 working days in 
a year, the majority of employees in Burkina Faso worked less than this, due to national 
holidays, annual leave, and sick leave. Finally health workers worked on average 216 days 
per year. Using previous calculations, salary per day was estimated. Then with official 8 
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working hours, the salary per working hour was estimated.   
The unit costs for screened woman (after introducing the rapid syphilis test) included: 
- Material costs used for first ANC visit ;  
- The rapid syphilis test cost; 
- Materials cost for rapid syphilis test (chase buffer); 
- Salary cost estimated from staff time used for conducting an ANC visit in addition to 
syphilis screening. 
The rapid syphilis test and its materials (chase buffer) prices were drawn from the invoice of 
the company that supplied syphilis test during the intervention. Materials cost of lancet, 
alcohol, cotton wool and gloves were not added because health worker pricked a woman’s 
finger once for a blood sample for both syphilis and HIV tests. Health workers completed 
rapid syphilis test during ANC visit. Thus after the implementation of the intervention, a non 
participant observation study was conducted following the same method described above. 
Salary cost was estimated following the method described above. 
 
Unit costs for treatment  
The recommended treatment at national level was benzathine benzyl penicillin (BBP) G, 2.4 
million units intramuscularly as a single dose and for women who are allergic, the protocol is 
erythromycin 500mg 1 tablet, 4 times per day during 14 days. In each kit for treatment there 
was polyvidone- iodine for ulceration treatment. Cost was estimated for each treatment. 
The unit costs for treatment with benzathine benzyl penicillin (BBP) G, 2.4 million included: 
- The dose  of BBP; 
- Materials used for the injection (water, lidocaine or xylocaine, polyvidone-iodine, 
alcohol, cotton wool, syringe); 
- Salary cost for staff time for the injection.  
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The unit costs for treatment with erythromycin included: 
- Number of tablet of erythromycin. 
The dose of BBP, materials for the injection, tablet of erythromycin prices were from the 
official list of consumables and essential medicines in public health facilities in Burkina Faso 
in 2014. For salary cost, we followed the same method as described above. However, during 
observation we did not meet enough pregnant women who tested positive (1 case). Thus we 
added an additional 5 minutes of time to prepare and complete one injection of penicillin as 
per Larson et al. (Larson et al., 2014). 
Sampling  
Data collection was held in primary health care facilities in the maternity unit. From 7 
facilities that received the intervention, 4 facilities, 2 rural and 2 semi-urban, were selected 
and observed before and after the implementation of the intervention. For the purpose of this 
study, only prenatal services were analyzed. 
Observations were conducted by a non medical researcher during one day scheduled for 
antenatal visits before and after the intervention. All consenting pregnant women coming for 
antenatal visit were observed the day of the survey. The researcher sat in the consultation 
room and reported all the information on a sheet during each antenatal consultation. 
 
Data collection and analysis 
Surveys were conducted before and after the implementation of the intervention respectively 
in 2012 and 2013. Data for staff time and materials were collected from observations of 
provider contacts with pregnant women. 
Prices used in this analysis were from the official list of consumables and essential medicines 
in public health facilities in Burkina Faso in 2014 and the invoice from the company 
providing syphilis test during the intervention.  Salary and benefits of health worker were 
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from the 2012 official salary grid and 2014 official benefits of public services. The salaries 
from 2012 grid were depreciated with gross domestic product (GDP) deflator for 2014 year 
(source: WDI, july 2015).  
For analysis, only first antenatal visit observations were selected regardless the gestation 
time. Excel sheets were used for data entry and calculations. The information from each input 
were combined into final table that estimated the cost of unscreened , screened, screened and 
treated woman. Statistical means and standard deviation were calculated. Mean time for 
unscreened and screened woman was used for estimating salary cost for each type of health 
worker. For estimating salary cost we multiplied health worker salary per working hour by 
mean time for each activity (no test, testing, and BBP injection). Cost driver was also 
determined for each activity.  Finally, costs were collected in CFA franc (XOF) and 
converted to US dollars (USD) using the average exchange rate for 2014 (494 CFA = 1USD) 
(OANDA, 2014).  
 
 
Ethical considerations 
This research was approved by the University of Western Cape, the National Ethics 
Committee for Health in Burkina Faso and the Ethics Committee Review of the WHO. In 
addition, the study team obtained permission from the District authorities before conducting 
the study. Written informed consents were obtained from pregnant women and health 
workers for observation during ANC. For pregnant women, they gave a witnessed signature 
or thumb-printed approval to participate. The consent process included an explanation of the 
study, its objectives, potential benefits and risks.   
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Results 
Material costs per ANC 
During observation, for each ANC, materials used were noted.  For ANC 1, these materials 
include urine test, lancet and chase buffer for HIV test, cotton, alcohol, and 3 gloves. The 
total materials costs for ANC 1 without rapid syphilis test were 2.03 USD. HIV test was the 
cost driver which accounted for 80% of the total costs (table 1). When rapid syphilis test was 
added in ANC 1, the total materials costs were 3.90 USD (table 1). The main drivers costs 
were rapid syphilis test (45%) and HIV test (42%). 
 
Table 1: Material costs per unscreened and screened woman  
Item 
Unit 
per 
woman 
Cost 
per 
unit 
in 
2014 
XOF 
Cost 
per 
woman 
in 2014 
XOF 
Cost 
per 
woman 
in 2014 
USD 
Urine test 1 29.4 29.4 0.06 
 Lancet 1 10.2 10.2 0.02 
Cotton 1 15.0 15.0 0.03 
Chase buffer 1 50.5 50.5 0.10 
HIV test 1 808.4 808.4 1.64 
alcohol 1 6.5 6.5 0.01 
Gloves 3 26.9 80.6 0.16 
Material cost per unscreened 
woman 
    1000.7 2.03 
          
rapid syphilis test 1 875 875 1.77 
chase buffer 1 50.5 50.5 0.10 
Material cost per test     925.5 1.87 
Material cost per screened woman       3.90 
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Cost of treatment 
As outlined in table 2 the cost for treatment with BBP (1.11 USD) is lower than costs for 
treatment with erythromycin (4.47 USD). The driver cost in BBP treatment was lidocaine. 
Table 2: Material cost per pregnant woman for syphilis treatment 
Item 
Unit 
per 
woman 
Cost 
per 
unit in 
2014 
XOF 
Cost 
per 
woman 
in 2014 
XOF 
Cost 
per 
woman 
in 2014 
USD 
Water for injection 2 34.4 68.8 0.14 
Benzathine Benzyl penicillin  2.4 MU 1 128.59 128.59 0.26 
Syringe 1 36.6 36.6 0.07 
Alcohol 1 6.54 6.54 0.01 
Cotton wool 1 14.99 14.99 0.03 
Lidocaine 1 294.6 294.6 0.60 
Erythromycin 500mg  60 36.79 2207.4 4.47 
 Polyvidone iodine 
           
1  962.84 962.84 1.95 
Cost of treatment with BBP     550.12 1.11 
Cost of treatment with 
erythromycin     2207.4 4.47 
 
Staff time 
After observation, we found that health workers spend more time with pregnant woman when 
performing rapid syphilis test. As outlined in table 3, the average time for unscreened woman 
was 11 minutes and 14 minutes for screened woman.  
 
Salary costs depend on cadre and location of health facility. Table 3 shows salary cost 
according to cadre and location. Salary in semi urban area varied from 0.93 to 0.53 USD and 
0.77 to 0.48 USD in rural area.  Salary costs for nurse and midwife in semi urban area are the 
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higher one and salary cost for auxiliary midwife in rural area is the lowest one. From 
observations, in semi urban facility 2 profiles of health workers were involved in ANC that 
included midwife and/ or auxiliary midwife.  In rural facility there was auxiliary midwife or 
nurse. 
Table 3 : Salary cost per activity  
 Unit 
Auxiliary 
midwife 
(semi urban) 
Staff nurse/ 
midwife (semi 
urban) 
Auxiliary 
midwife 
(rural) 
Staff 
nurse/ 
midwife 
(rural) 
Salary (including all 
benefits according to 
government policy) 
USD/m
onth 218.38 383.58 199.41 317.21 
Salary per working hour 
salary/h
our 
working 1.52 2.66 1.38 2.20 
Staff time per unscreened 
woman (mean time) minute 11:28 11:28 11:28 11:28 
Staff time per screened 
woman (mean time) minute 14:01 14:01 14:01 14:01 
Additional time for 
treatment with BBP 
injection minute 05:00 05:00 05:00 05:00 
Salary cost per 
unscreened woman USD 0.27 0.48 0.25 0.40 
Salary cost per screened 
woman USD 0.35 0.61 0.32 0.51 
Salary cost per BBP 
injection USD 0.12 0.21 0.11 0.18 
 
 
 
Full cost per pregnant woman attending ANC 1 
Table 4 shows the full cost per pregnant woman attending ANC 1 before and after adding 
rapid syphilis test in ANC services.  
The average cost for unscreened pregnant woman was 2.38USD (±0.11) and the average cost 
for screened pregnant woman was 4.35 USD (±0.14). Cost difference between unscreened 
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and screened woman was 1.97 USD. The main cost driver in screening was syphilis material 
costs. Syphilis device test accounted for 39% to 42% of the total costs and HIV device test 
accounted for 36% to 38%.   
The average cost for screened and treated pregnant woman was 5.61 USD with BBP only and 
8.81 USD for erythromycin treatment (table 4). Regarding cost difference between treatment 
with and without polyvidone iodine (used for ulcers), cost for polyvidone iodine  increased 
the cost for screened and treated woman for about 22% to 36%.  Costs varied also by health 
facility location and profile of health worker.  The cost of personnel accounted for 11% to 
19% of the total costs for unscreened woman and 8% to 13% for screened woman. 
This cost was higher in semi urban facilities than in rural ones because of the number of 
health workers (on average 2 at semi urban facility) involved in ANC. For rural facilities 
where there was one health worker, either auxiliary midwife or nurse, the cost was higher 
with a nurse. In semi urban facility, the cost was higher when ANC was performed by 2 
midwives.  
 
Table 4: Cost analysis of antenatal syphilis screening according to health worker profile 
and location 
 Unit 
Auxiliary 
midwife 
(semi 
urban) 
Staff nurse/ 
midwife 
(semi 
urban) 
Auxiliary 
midwife 
(rural) 
Staff 
nurse/ 
midwife 
(rural) 
Mean 
cost SD 
Total cost per 
unscreened woman USD 2.30 2.51 2.27 2.42 2.38 0.11 
Total cost per 
screened woman USD 4.25 4.51 4.22 4.41 4.35 0.14 
Total cost per 
treated with BBP 
injection USD 1.23 1.33 1.22 1.29 1.27 0.05 
Total cost per 
treated with 
erythromycin USD 4.47 4.47 4.47 4.47 4.47 0.00 
Total cost per USD 5.48 5.84 5.44 5.70 5.61 0.19 
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screened and 
treated (BBP) 
woman 
Total cost per 
screened and 
treated 
(erythromycin) 
woman USD 8.72 8.98 8.69 8.87 8.81 0.14 
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Discussion 
In the national guideline for ANC 1 in Burkina Faso, screening for syphilis is recommended. 
However, syphilis testing is only available at laboratories, to which access is limited (Yaya 
Bocoum et al., 2014).  Our intervention introduced a point of care test for syphilis in 7 health 
facilities in Kaya HDSS. The purpose of the study was to evaluate the incremental cost of 
integrating rapid syphilis test in ANC services. 
 
We first estimate the cost of ANC 1 visit before the introducing of rapid syphilis test. The 
mean cost was 2.38 USD of which 2.03 USD was for material (mainly HIV test) and 0.35 
USD for health worker time. For ANC 1 with syphilis test the mean cost was 4.35 USD and 
material cost was 3.90 USD and 0.45 USD for health worker time. The incremental costs for 
adding syphilis test was 1.97 USD. Syphilis screening increased cost for ANC by about 83% 
on average.  When comparing syphilis material costs with HIV material costs, the difference 
is not high (0.13USD) on the local market. The policy-relevant difference is that HIV 
material costs are currently covered by donors, whereas there is currently no donor offering 
to cover the costs of implementing syphilis screening as recommended in the national and 
international guidelines for ANC.  
 In Zambia, the cost to test one patient for syphilis was estimated at 3.10 USD (Larson et al., 
2014) that is less than our findings.  The difference in these results could be explained by the 
price of the test. In fact the test kit cost needed for syphilis testing (1.15USD) was less than 
our estimate (1.77 USD).   The price depends heavily on the type of the test, the freight 
charges and taxes that vary from country to country.  The cost for materials would be 
significantly lower if a less expensive test was used, or if the government subsidized prices of 
these devices, or if donors take it in charge as they do for HIV tests.  
The incremental cost for adding rapid syphilis test in ANC represented 4% of per capita 
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healthcare spending in Burkina Faso and less than 1% of GDP per capita (717 USD in 2014).   
For defining a highly cost-effective intervention, a commonly accepted threshold of an 
Incremental Cost-Effectiveness Ratio (ICER) less than one times per capita gross national 
income was used (Marseille, Larson, Kazi, Kahn, & Rosen, 2015). 
Other relevant findings are related to location of the facility and the staff availability and 
profile. At semi urban or urban facilities, the staff number is higher than rural facilities. In 
semi-urban and urban facilities ANC is generally conducted by two health workers, which 
explains the high staff costs.  In contrast, in rural areas, generally ANC is provided by one 
health worker.  Profiles also differ. In urban and semi urban facilities; a midwife and 
auxiliary midwife provide ANC whereas in rural facilities, an auxiliary midwife, nurse or 
itinerant health worker provided this service. However, staff such as itinerant health workers 
do not receive training for performing tasks related to maternal health, making it difficult to 
follow the national service delivery guidelines.  
 
The interaction time between clients and providers was short. The mean duration was 13 
minutes without syphilis test and 16 minutes with. This is lower than found in Tanzania by 
Pembe et al. (Pembe et al., 2010). Even if this reduces the cost of health worker time, the 
issue of quality of service delivery is raised when the estimated time for good quality focused 
ANC is 46 minutes, about half of which should be dedicated to counseling (von Both, Flessa, 
Makuwani, Mpembeni, & Jahn, 2006) . The interaction time also raised the issue of time for 
reading the results of HIV and syphilis tests. The required time for reading the results is 15 
minutes. During observations all the health workers read the results before the adequate time. 
In sum, this study raises some questions about the quality of service delivery. 
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In terms of treatment, the costs vary between penicillin treatment and erythromycin 
treatment. Treatment with BBP was inexpensive in comparison with erythromycin treatment.  
Most of the women screened and treated during the intervention were not allergic to BBP 
thus BBP could be adopted as the main treatment as far as the risk of serious adverse 
reactions appears very low and does not outweigh its benefits (Galvao et al., 2013). During 
observations and discussions with health workers, they stressed that none of the women who 
were positive, had ulceration. That suggests the polyvidone- iodine was not useful as a 
significant component of the syphilis treatment kit. This questioned the reason to add this 
drug in the kit for syphilis when Grosskurt et al. argued that most ulcers are not due to 
syphilis or chancroid (Grosskurth, Gray, Hayes, Mabey, & Wawer, 2000). This could be 
explained by the fact that the kit is not specific to syphilis treatment but for any STI known 
with genital ulcers as symptom – yet the costs are attributed to the syphilis testing component 
of the program. We also found that health workers routinely use lidocaine to reduce injection 
pain, in line with their training but not accounted for in national policy . In the treatment kits 
(BBP) provided by the ministry of health, there was no lidocaine and supplies for injection 
(syringe and water for injection). These supplies had to be purchased by women who usually 
did not bring enough money for their ANC visit. Thus we recommend that the ministry of 
health could take it in charge, knowing that test-positive women requiring a painful 
benzathine penicillin injection are not many.     
 
This study has some limitations. One of the limitations is the possible bias due to observation 
(Hawthorne effect). To mitigate this effect, the researcher who conducted observations was 
non medical personnel and health workers were informed. Thus they could act as usual and 
they seemed at their ease during the observation. 
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Another limitation is the components of the costs. We did not estimate the cost of quality 
control for positive case and  training. These are components which need to be taken into 
account to maintain quality of services. Further studies could explore these costs.  
 
A key limitation is that study addresses incremental cost for introducing rapid syphilis test in 
one particular area located in a high prevalence health district of Burkina Faso. The results 
from the study could not be extrapolated to the country. But the costing approach can be used 
for reassessing costs and performing cost effectiveness studies in other settings. Nonetheless 
the results could be used for budgeting related activities at the district level. 
 
Conclusion 
Our analysis suggests that integrating point of care testing for syphilis in ANC services is 
feasible at an incremental cost with variations. This incremental cost is modest in comparison 
with HIV test and the benefits to mothers, infants, and averted health costs from syphilis 
screening.  
 The variation in costs reflects differences in treatment patterns and the complexity of 
healthcare delivery systems in semi urban and rural areas with varying human resources 
capacities.  In terms of priorities for sustainability, commodity management is key. With 
adequate supplies of tests, penicillin and other related supplies, health workers could perform 
their activities.  
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CHAPTER 8: Discussion, conclusions and 
recommendations 
 
The main aim of the research presented in this thesis is to provide evidence about the 
feasibility and costs of introducing an on-site test for maternal syphilis into the package of 
antenatal care services in Burkina Faso. This evidence provides policy makers with 
information to take decisions that could improve practical responses for maternal and 
newborn health. 
 
The thesis started by providing insight into the current practices of syphilis screening at 
antenatal services at primary health facilities. Then an appropriate onsite syphilis test adapted 
for peripheral facilities was determined among others available in Burkina Faso. The 
remainder of the thesis focused on the feasibility, effects and costs of the intervention on the 
health workers’ work and the organization of services. In this chapter, conclusions and 
recommendations are distilled from these findings.   
 
8.1. Discussion and contributions of this thesis 
-  
8.1.1. Situational analysis of current antenatal syphilis program 
 
Antenatal syphilis screening is often poorly implemented in sub-Saharan countries (S Gloyd 
et al., 2001) , so it is important to first identify and understand barriers affecting health 
system implementation of syphilis screening among pregnant women in Burkina Faso. 
Chapter 4 explored barriers to antenatal syphilis screening in Kaya health district where 
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antenatal syphilis prevalence is high. Qualitative methods were used including in-depth 
interviews and observations in the Kaya health district. Participants were purposively selected 
to capture a range of perspectives across different actors with different roles and 
responsibilities.  
 
In response to objective 1, (examining health workers’ perspectives on strategies for 
managing antenatal syphilis screening) our findings suggest that antenatal syphilis screening 
is not a priority for health workers at ANC services. First, there is no indicator for monitoring 
progress of antenatal syphilis screening at district or national level that shows any political 
commitment. Second, health workers perceived that syphilis in pregnancy is not an important 
issue because most women who undertook the test were negative. Thus they do not perceive 
the burden of antenatal syphilis highlighted by statistics of sentinel surveillance.  
 
The analysis of the operational performance of the current antenatal syphilis screening 
(objective 2) was challenging because we found no information on the proportion of pregnant 
women routinely tested for syphilis at district, regional and national level. However, 
organization of antenatal syphilis screening could be described and weaknesses were 
highlighted. The main weakness is the fragmentation of services because antenatal syphilis 
screening is through laboratory based tests. Laboratories are located in urban areas whereas 
majority of population live in rural areas. Health workers have to refer women to laboratories 
and many women, particularly those living in rural areas, have to travel long distances to 
access these laboratories. In other words, distance to laboratory is associated with delay or 
failure to screen. In rural areas health workers do not prescribe the test. This perspective was 
confirmed at district level. Overall the analysis of the current antenatal syphilis screening 
shows considerable weaknesses that contribute to low performance. Specific objective 3 (to 
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explore women’s perceptions and costs related to syphilis screening) was also explored in 
chapter 4. Lack of knowledge about syphilis in the community was identified as a reason for 
not being screened. Most respondents from the community such as pregnant women, 
traditional healers and community health workers did not know the symptoms of syphilis nor 
its serious consequences for the unborn and born child. Thus they do not perceive the benefit 
of testing particularly for asymptomatic infections. ANC and related services such as PMTCT 
for HIV, and urine test are free for women in Burkina Faso.  Although antenatal syphilis 
screening is part of essential screening in the national policy and management of maternal 
care guidelines, its cost is not subsidized as others.  The cost for syphilis test was observed to 
range between $2 and $3 USD, a prohibitive cost in a country where 73% of population lives 
on less than $2 a day.  
 
All these factors contributed to lower syphilis test uptake among pregnant women. Our 
results highlight the weaknesses of the antenatal syphilis screening at both provider and 
community levels. In contrast, many other studies mainly look at one of these levels (Dassah 
et al., 2015; Deperthes et al., 2004; Fonck et al., 2001; Gharoro & Abedi, 2000; Hira et al., 
1990) . The use of MLA was also an original contribution of this study to the literature on 
control of maternal syphilis in LMICs. The Multilevel Assessment (MLA) framework 
proposed by Hawke et al. allowed taking into account the perspectives of all key stakeholders 
as well as the contextual factors.  
 
Together, these findings on the operational performance and barriers to uptake and 
integration of syphilis testing suggest that there is a need for improving current antenatal 
syphilis screening strategy. The overall situation  presented in Paper I and reported in 
stakeholder dissemination workshops may stimulate decision makers’ interest into finding 
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interventions that can help ensure the full implementation of the integrated ANC package 
described in policy guidelines but weakly implemented in practice. This situational analysis 
led to the design and implementation of an intervention that introduced a point of care 
syphilis test at primary health facilities.  
 
Different stages were followed for the implementation of the intervention. Chapters 5 and 6 
present these steps.   
 
8.1.2.  Assessment of point of care diagnostic test for syphilis 
 
The first step was the selection of a point of care test through the evaluation of four point of 
care syphilis test. The objectives of the study were (i) to assess the sensitivity and specificity 
of four point-of care tests in comparison with Treponema pallidum haemagglutination assay 
(TPHA) as a gold standard and (ii) to evaluate the operational characteristics of those tests 
among health workers in a maternity unit.  Our study found that Alere DetermineTM Syphilis 
was the most sensitive of the four rapid syphilis tests evaluated. It was followed by SD 
Bioline Syphilis 3.0, Cypress Diagnostics Syphilis Quick test and Accu-Tell ® Rapid Anti-
TP, which was the least sensitive. The four tests demonstrated a good diagnostic specificity 
for syphilis (95–98%), and healthcare workers found them easy to use. Among the four tests, 
there are two for which no data was available in the international literature in terms of 
comparison with other tests. Our findings contributed new knowledge on the performance of 
the range of existing syphilis tests. Furthermore results provide practical evidence for 
decision makers when they are ready to select point of care test for syphilis for its integration 
in the health system as they did for HIV tests.   Further research on point of care tests could 
explore the cross reactivity with other infectious diseases such as HIV or malaria.  
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Undertaking this assessment in the context of an operational intervention study highlighted 
that more than sensitivity and specificity are important in the choice of a test. Beyond 
technical issues, operational issues need to be assessed in order to know how it is likely to 
work in real settings, and the preferences of health workers must also be considered. In sum, 
regulatory authorities should supplement technical evaluations with an operational 
component (Palamountain et al., 2012). 
 
8.1.3. Participatory process for intervention design and implementation 
 
After selection of the test, a participatory approach with health workers of the study facilities 
was put in place in order to design the intervention. During a workshop, the different 
components of the intervention were presented and discussed with health workers and district 
managers. The objective was to agree on the model of the intervention and how to integrate 
its activities in the health system. The model was graphically represented in chapter 3.  
The model was designed based on the existing infrastructure and resources of the health 
system and experiences of the participants because there was no formal framework for 
incorporating point-of-care in existing health system. Chapter 6 describes the different stages 
for designing and implementation of the intervention.    Alongside the implementation phase 
of the intervention, various actors were involved. At the research team level, a 
multidisciplinary team was required that comprised biologists, pharmacists and social 
scientists. The implementation of a complex intervention required several competencies that 
are complementary alongside the intervention. In the field, the participatory approach was 
crucial at district and health facility level for the success of the intervention.  
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8.1.4. Feasibility of introducing point of care diagnostic for syphilis 
 
In Kaya Health and Demographic Surveillance System (Kaya HDSS), all 7 primary health 
care facilities that offered ANC services were selected for intervention. Onsite training, 
provision of supplies and medicines, quality control and supervision were implemented in 
2013. Facilities provided onsite rapid syphilis testing with immediate treatment for positive 
cases at ANC services.  
 
The point of care test for syphilis was integrated into the existing package of antenatal care 
services at primary healthcare level of the district, using the available staff. It was delivered 
at the same time as HIV testing and other ANC services. The study showed that it is feasible 
to introduce point of care testing in ANC services at primary health facilities. But there are 
barriers that need to be overcome for the smooth implementation of the intervention.  
 
The framework of Normalization Process Model (NPM) proposed by May et al. was adapted 
in order to identify factors that are barriers or facilitators (objective 7) for the introduction of 
rapid test for syphilis screening among pregnant women. Moreover, NPM allowed assessing 
the likelihood that point of care test for syphilis will become routinely incorporated in 
practice. Using NPM for assessing the likelihood of antenatal syphilis screening was the 
originality of this study. To our knowledge, it was the first time that NPM was used as a 
conceptual framework for such intervention. In the context of an abundance of trials that are 
more focused on clinical effectiveness rather than workability in real settings, NPM could be 
useful.    
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8.1.5. Barriers to integration of point-of-care test for syphilis to ANC services 
 
The major reported barriers to the full integration of the test are stock out of consumables, 
filling of forms and lack of supervision. The main effect reported by health workers was the 
workload due to filling of registers and the duration of the consultation that was extended by 
about 3 minutes (objective 6).  
 
Turnover and lack of communication between staff are also barriers that could explain why 
some women did not receive tests during the intervention. The lack of training evoked by 
newly appointed health workers and no or little information given by health workers who 
were aware of the intervention to other staff are the key points raised here. Other reasons 
highlighted by Zongo et al for not using malaria rapid diagnostic tests in Burkina Faso could 
be considered such as lack of financial motivation, the increase in duration of consultation 
and high number of patients or workload (Zongo et al., 2013) .  
 
Even if the intervention is feasible, its implementation at a large scale could face barriers as 
highlighted by the experience of adding HIV tasks to routine care. From our HIV experience, 
we learnt that the way that a new task or intervention is introduced, is important.  If it is 
introduced as a vertical program, particularly with separate additional funding, health 
workers could perceive it as a “project” in the sense of the so called “project mentality” 
described by Israr ((Israr, 2005). In the study reported here, there was a disconnect between 
the reported and observed acceptability and operational feasibility of incorporating point of 
care syphilis testing into ANC, and the low rate of actually testing eligible women. This 
disconnect and the comments reported regarding the need for 100% coverage in training 
suggest that “project mentality” may be a relevant concept here.  “Project mentality” among 
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health workers, according to Israr, arises from direct incentives (perdiems) being paid to 
health workers who attend training or initial workshops, to motivate them to perform the 
tasks. This then leads to a situation where other staff cannot be motivated to perform the task 
even if they received onsite training (without perdiem) through their colleagues. 
Consequently only health workers who receive perdiems will perform tasks, as these tasks are 
perceived as being additional to and not part of the normal responsibilities. This situation is 
one of the manifestations of the “acute perdiemitis” described by Ridde as one of the most 
prevalent illnesses that undermine African public health projects (Ridde, 2010). Of course, 
discussions of “project mentality” and “acute perdiemitis” must also take into consideration 
the actual salaries and living and working conditions of African health workers.  It is 
important for decision makers to take these barriers into account before scaling up 
implementation. 
 
8.1.6.  Facilitators to integration of point-of-care test for syphilis to ANC services 
 
At the health worker level, respondents reported that the rapid test for syphilis is easy to use 
because it is similar to HIV testing. At the patient level, acceptability of testing is perceived 
by health workers (and observed during our study) to be high due to their knowledge of 
existing testing such as for HIV or malaria. At the staff organization level, there was no 
particular organization that needs to be put in place for integration of syphilis testing in ANC 
(objective 6). The study identified a number of facilitators to potential normalization 
including congruence with professional practice, confidence in the reliability and utility, 
capacities for performing the test and no change at organizational level.  In sum, the point-of 
care test for syphilis is likely to be acceptable by health workers as a routine service and 
incorporated as a normal practice, if identified barriers are overcome.   
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8.1.7.  Need for a functioning partner notification approach 
 
One of the important issues that this study raises is partner notification especially for positive 
women. In most of the ANC visits reported and observed  here, husbands did not accompany 
the women to the facility, in line with what has been reported in many studies (Alam et al., 
2010; Dassah et al., 2015).These positive women may be at risk of re-infection because their 
partner could also have been positive.  Reported barriers to partner notification are stigma 
associated with STIs, fear of violence and matrimonial conflict and fear of rejection (Alam et 
al., 2010; Díaz-Olavarrieta et al., 2007). These barriers are more strongly perceived in a 
context of polygamy where spouses are in “competition” for one man.  Further research 
might study constraints to partner notification and develop a workable and acceptable partner 
notification model (McNutt & Coles, 2007). 
 
8.1.8. Incremental costs for providing point of care test for syphilis during ANC 
 
Introducing rapid syphilis testing in ANC services generates additional costs for the 
“provider” (government or the facility) in a scenario of sustainability of the intervention and 
free treatment for women. Chapter 7 addressed the focus of the objective 8, which  was to 
estimate the incremental cost of the provision of the on-site test of syphilis for antenatal care 
services. The purpose of this study was to estimate the incremental costs of adding rapid 
syphilis test into first visit ANC from a provider’s perspective and identify the main cost 
drivers.   
 
The main cost driver in screening is the material costs. There are cost variations due to health 
facility location and profile of health worker. Adding point of care test for syphilis in ANC 
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services is feasible at a modest incremental cost, comparable to the cost of HIV testing. 
 
 Most costing studies for syphilis tests have been conducted in high prevalence countries in 
Africa. There are few studies in low prevalence countries where Kuznik et al. deplored the 
lack of field data (Kuznik et al., 2013). This study contributed to fill this gap. Further 
research could explore cost for quality control or scaling up of the intervention.  
 
The interaction time between clients and providers was, lower than what was observed in 
other studies but also lower than recommended for a focused ANC. The time motion study 
put in light weakness in the quality of testing performed by health workers at primary health 
facilities. This implies that the quality of ANC is also affected.  That means there is a need to 
explore health workers practices in maternal care and assess barriers to the full 
implementation of a comprehensive focused ANC package.  
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8.2. Conclusions: contributions of this study to knowledge, 
policy and practice 
Overall, the thesis contributes to knowledge about implementation of interventions related to 
maternal syphilis.  The contribution is at different levels.  
 
At the district level, although the district has one of the highest prevalence in the country, to 
our knowledge, there has been no study on maternal syphilis. Our study could contribute 
directly to the elaboration of an action plan by the district manager. Moreover, the costing 
analysis will contribute to budgeting.  
 
At the national level, the literature, as presented in the section of literature review, is more 
focused on epidemiologic aspects thus this thesis contributes to filling the knowledge gap in 
terms of practical responses for controlling maternal syphilis. In addition, most health 
interventions are context specific. Examples from one country cannot simply be copied to 
another one. In that sense, the study offers evidence to national decision makers for evidence 
based and contextually appropriate decisions, as well as modeling an approach to developing 
and testing contextually relevant interventions.   
 
This study adopted a participatory approach that involved district managers, health workers 
and researchers. This reinforces collaboration between these stakeholders but also offers an 
opportunity to researchers to present their results to local actors who are able to take action.  
 
At the international level, there is an important literature on syphilis especially on 
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interventions for maternal syphilis screening and treatment but studies from countries like 
Burkina Faso in Africa are few and they do not take a comprehensive, contextualized 
approach to both the technical and operational aspects of implementation in real-world 
settings. This thesis could motivate other research in similar contexts and could serve as a 
reference.   
 
8.3.   Recommendations 
 
Even though this was a pilot study, some tentative recommendations for decision makers can 
be made from the findings in the thesis: 
- The situational analysis showed that there are barriers to access to antenatal syphilis 
screening. This suggests that an intervention that introduces point of care test for 
syphilis at antenatal care services is an appropriate response (especially with a dual 
HIV/syphilis test which is the most advanced technology that was not available during 
my study) and could serve as an entry point for improving ANC quality and more 
widely strengthen the health system.  
- In addition to an intervention at health facility level, community based interventions 
that increase awareness of STI and health needs among the populations are needed to 
stimulate health care demand. 
- In designing intervention, it is important to consider both the reported views of 
stakeholders for a successful implementation. 
- The study identified a number of specific implementation challenges that should be 
addressed prior to scale-up of such an intervention (including clearer instructions to 
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staff to ensure testing of all eligible women and quality control of appropriate 
numbers of positive and negative tests), in addition to barriers that require 
interventions at the policy level (such as perdiems, registers, supervision, and quality 
control as discussed below) 
- Quality control system for rapid diagnostic tests is essential for ensuring that results 
delivering to clients are accurate and reliable. A quality control strategy is a key 
component that should be put in place for any rapid diagnostic test such as malaria, 
HIV or syphilis. 
- The study found that most positive women had no symptoms such as genital ulcers 
that need using Polyvidone- iodine, thus there is a need for revision of treatment 
regimens but also strategies for STI screening during pregnancy. 
- This study has demonstrated that rapid syphilis test could be introduced into ANC 
services. Further studies are required to develop comprehensive packages with other 
tests and cares that will strengthen the primary health care system. 
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Guide for health workers  
 
INTRODUCTION: 
[Information and consent] 
 
 
Perception on ANC 
 
1. Explain what is the content of ANC in your facility?  
2. Do you have priority in ANC activities?  
3. What difficulties are you face during ANC?  
 
Management of STI 
 
4. How do you screen STI during ANC?  
5. What kind of STI do you find among pregnant women?  
6. How do you manage medical follow up of pregnant women with a STI?  
7. How a patient with STI is considered in the community?  
 
Management of syphilis 
 
8. How do you screen syphilis during ANC?  
9. What are means of transmission of syphilis?  
10. What do you consider signs and symptoms of syphilis?  
11. What are the different phases of syphilis?  
12. What means of prevention against syphilis do you know?   
13. What are the causes and effects of syphilis?   
14. Do you systematically prescribe VDRL test during ANC to pregnant women?  Why?  
15. What kind of difficulties are you face with this prescription?  
16. Explain how do you manage a pregnant woman suffer from syphilis? 
 
Experience with RDT 
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17. Describe your experience with RDT for malaria, HIV and others?  
18. How these tests were introduced in your daily practice?  
19. How do you appreciate the process of introducing of these tests?  
20. What are the effects of these tests in your daily practice?  
21. What type of difficulties are you facing in the use of these tests?  
22. What effects do you observe on patients, utilization of services?  
23. What kind of collaboration do you have with lab technicians?  
24. How do you appreciate this collaboration?  
25. What do you think about task shifting from tests lab to point of care test using by less 
qualified staff?  
26. What category of health workers have to be involved in the use of RDT ?   
 
Introduction of RDT for syphilis screening  
27. What do you think about the introduction of a new RDT for syphilis screening in 
Burkina Faso ?  
28. What could be the barriers to the introduction of a new RDT ?   
29. What are the opportunities/ factors in favor to the introduction of a new point of care 
test In Burkina Faso ?   
30. What are your suggestions for the availability of the  new point of care test  to 
pregnant women ?  
31. What suggestions do you have for gaining adhesion of pregnant women to this test?   
32. What are the important steps in the introduction of new point of care test in health 
system?  
33. Who will be the main actors to involve in the process of introduction of a new point of 
care test in Burkina Faso?  
34. What kind of information would you need about a new point of care test?   
35. What kind of information would you think people in your community need about a 
new point of care test?   
36. What could be your contribution in the introduction of a new point of care test in your 
community?   
37. Do you have any suggestions about the introduction of a new point of care test?   
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Appendix 2 : Interview Guide for policy 
makers 
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Guide for policy makers 
INTRODUCTION: 
[Information and consent] 
 Context 
1. What do you think about the prevalence of STI and syphilis in Burkina Faso/ kaya 
district?   
2. Do you think that there are other health priorities than syphilis ? 
3. What strategies were implemented in order to control STI and syphilis for pregnant 
women in Burkina Faso ?   
 
4. How do you appreciate the implementation of  syphilis screening for pregnant 
women ?   
 
Implementation 
5. Who are donors involve in the funding of syphilis screening in Burkina Faso? 
6. What type of research program do you know in Burkina Faso?  
7. Who are people involve in maternal syphilis screening?   
8. Who are people involve in the supply of reagents, and medicines?  
 
9. What are the difficulties you are face in the implementation of the strategy? 
10. What requirements do you think need to be filling in order to optimize the strategy?  
 
Knowledge about RDT 
11. What are the type of point of care tests use in Burkina Faso?    
12. What do you think about point of care test?  
13. What are the advantages and the disadvantages of point of care test in Burkina Faso ?  
 
Introduction of RDT  
 
14. What do you think about the introduction of a new point of care test  for syphilis in 
burkina Faso ?  
15. What are the barriers  to the introduction of a new point of care test In Burkina Faso ?    
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16. What are the opportunities/ factors in favor to the introduction of a new point of care 
test In Burkina Faso ?    
17. What are your suggestions for the availability of the  new point of care test  to 
pregnant women ?    
 
18. What are the important steps in the introduction of new point of care test in health 
system?  
19. Who will be the main actors to involve in the process of introduction of a new point of 
care test in Burkina Faso ?  
20. What are the main requirements for the success of the process of introduction?   
21.  What would cause you to motivate in supporting the introduction of a new point of 
care test in Burkina Faso?    
22. What kind of support could you give to the success of the initiative?   
 
23. Do you have any suggestions about the introduction of a new point of care test in 
Burkina Faso?    
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Appendix 3 : Interview Guide for 
pregnant women 
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Guide for pregnant women 
 
INTRODUCTION: 
[Information and consent] 
 
Knowledge on STI and syphilis  
 
1. What types of STI do you know?  
2. What types of STI do you often find in your community?  
3. What do you consider signs and symptoms of STI and syphilis?  
4. What are the causes of STI and syphilis? How do STI and syphilis transmit?  
5. Who are more at risk for STI and syphilis?  
6. What are the effects of STI and syphilis on people who are infected?  
7. How do you do to prevent from getting STI and syphilis?  
8. When people suffer from STI or syphilis what does he/she do?  
9.  What kind of STI traditional healer could take care?  
10. How do traditional healers take in charge STI in your community?  
11. What are your appreciations on traditional healer’s work?  
12. What kind of STI could be care at health facility?  
13. How do health workers take in charge STI in your community? 
14. What are your appreciations on health worker’s work?  
 
Knowledge on TDR  
15. What do you think about point of care test?  
16. Based on your experience, what are the advantages of point of care test?  
17. Based on your experience, what are the disadvantages of point of care tests?  
 
Introduction TDR 
If a new point of care is available for syphilis screening  
18. What kind of information would you need about a new point of care test?   
19. What influences you to have access to the new point of care?  
20. What might keep you from getting new point of care test? 
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21. How much are you able to pay for this test? 
22. Who do you prefer to deliver you the test and the results of the test? 
23. What would be the best place for you to get the new point of care test?  
24. Which people will be at priority to access to the new point of care test?   
25. What other questions might people in your community have about a new point of care 
test?  
26. Do you have any suggestions about the introduction of a new point of care test?   
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Appendix 4 :  Sheet for observation 
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Observation sheet for ANC 
Sheet N° :  
Date :  
CSPS :   
Round :   
Total number of  health worker  :  
Profile of health worker :  
Time at beginning   :                                     time at end  :            
Type  of ANC 
(1,2,3,4),  
number 
and 
profile of 
health 
worker  
Activities Materials 
used 
Duration Observations 
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Appendix 5 : Ethical approvals  
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Appendix 6 : Informed consent form for 
individual interview 
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INFORMED CONSENT FORM FOR INDIVIDUAL INTERVIEW 
 
Principal Investigator : Seni KOUANDA 
Organization : Institut de recherche en science de la santé 
Sponsors: ADDRF/TDR/ LTG grant /IRSS 
 
Title: Feasibility of introducing onsite test for syphilis in the package of antenatal care at 
rural primary health care level in Burkina Faso 
 
This Informed Consent Form has two parts:  
• Information Sheet (to share information about the study with you)  
• Certificate of Consent (for signatures if you choose to participate)  
 
You will be given a copy of the full Informed Consent Form  
 
Part I: Information Sheet  
 
Introduction  
I am XXX, working for IRSS organization. I am doing a study on the disease syphilis which is very 
common in this district. I am going to give you information and invite you to be part of the research. If you 
have questions, you can ask them at anytime to me or to the principal investigator. 
 
Purpose of the research  
Syphilis is a sexual transmitted infection with a serious source of adverse pregnancy outcomes. If 
left untreated, maternal syphilis infection has significant medical, economic, and societal 
consequences. African Policy makers, programme managers and health professionals are faced 
with complex choices on how best to detect early maternal syphilis. The present study will assess 
the feasibility to integrate syphilis point-of-care diagnostic test in the package of antenatal care in 
order to guide decision makers on the best approach to adopt for maternal syphilis screening and 
treatment. We want to know more about local health practices, how you manage syphilis in your 
day to day practice with pregnant women because this knowledge might help us to learn how to 
better control syphilis in this community.  
 
Type of Research Intervention 
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This research will involve your participation in an interview that will take about 45 minutes.     
 
Participant Selection  
You have been identified as someone who can provide useful information for this study because 
we feel that your experience as a health provider can contribute much to our understanding and 
knowledge of local health practices.   
 
Voluntary Participation  
Your participation in this research is entirely voluntary. You may or may not decide to take part. 
It is your decision. The choice that you make will have no bearing on your job or on any work-
related evaluations or reports. You may change your mind later and stop participating even if you 
agreed earlier.  
 
Procedures  
During the interview, I will sit down with you in a comfortable place. If you do not wish to 
answer any of the questions during the interview, you may say so and the interviewer will move 
on to the next question. No one else but the interviewer will be present unless you would like 
someone else to be there. The information recorded is confidential, and no one else except the 
research team will access to the information documented during your interview. The entire 
interview will be tape-recorded, but no-one will be identified by name on the tape. The tapes will 
be destroyed when the study ends. Your name will not be recorded, and no name will appear in 
any presentations or reports. The information you give us will not in any way be used against you 
or your family.   
 
Duration  
The research takes place over one year in total. During that time, we will visit you two times for 
interviewing you at the situation analysis and the end of the intervention. Each interview will last 
for about 45 minutes.  
 
Risks  
The questions asked during interviews concerns mainly programme based information that is 
largely information in the public domain. These are questions which are commonly asked during 
regular in depth programme evaluations. Opinions will be asked regarding STI management 
policy, in particular maternal syphilis; identify the barriers and constraints which affect the 
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effective delivery of STI services and particularly maternal syphilis screening, supervision, 
monitoring, the perceptions of rapid diagnostic test (RDT), patients, and use of RDT.  
 
Benefits  
You will not benefit directly from this study. By sharing your views, you are giving your leaders 
information they need to make decisions about people’s health. 
 
Reimbursements 
You will not be provided any incentive to take part in the research.  
 
You can ask me any more questions about any part of the research study, if you wish to. Do you 
have any questions?   
 
Do you agree to take part in this study?   
 
Who to Contact 
If you wish to ask questions later, you may contact any of the following:  
Dr. Seni Kouanda, Principal Investigator, at 50 33 35 94.  
 
This research has been reviewed and approved by the Burkina Faso Comité d’éthique de 
recherche en santé (CNERS). This committee reviews research studies to help protect 
participants.  If you have any questions about your rights as a research participant you may 
contact: 
 
The chairman,  Comité national d'éthique pour la recherche en santé (CNERS), Ministère 
de la Santé, 03 BP 7009, Ouagadougou 03, Burkina Faso, phone number: 50 32 41 59. 
 
 
Part II: Certificate of Consent  
 
The study has been described to me in language that I understand and I freely and voluntarily 
agree to participate in this study. My questions about the study have been answered. I understand 
that my identity will not be disclosed and that I may withdraw from the study without giving a 
reason at any time and this will not negatively affect me in any way.  I promise to keep the 
information in this study confidential.   
 
 
 
 
166 
 
 
 
Print Name of Participant__________________     
Signature of Participant ___________________ 
Date ___________________________ 
 Day/month/year    
 
    
Statement by the researcher/person taking consent 
 
I confirm that the participant was given an opportunity to ask questions about the study, and all 
the questions asked by the participant have been answered correctly and to the best of my ability. 
I confirm that the individual has not been coerced into giving consent, and the consent has been 
given freely and voluntarily.  
   
 A copy of this ICF has been provided to the participant. 
Print Name of Researcher/person taking the consent________________________ 
    
Signature of Researcher /person taking the consent__________________________ 
Date ___________________________    
                 Day/month/year 
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Appendix 7 : Informed consent form for 
enrolled pregnant woman 
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[Name of Principle Investigator] 
 
 
 
 
 
INFORMED CONSENT FORM FOR PREGNANT WOMAN ENROLLED FOR TESTING 
 
Principal Investigator : Seni KOUANDA 
Organization : Institut de recherche en science de la santé 
Sponsor : ADDRF/TDR/ LTG grant /IRSS 
 
Title: Feasibility of introducing onsite test for syphilis in the package of antenatal care at 
rural primary health care level in Burkina Faso 
 
This Informed Consent Form has two parts:  
• Information Sheet (to share information about the study with you)  
• Certificate of Consent (for signatures if you choose to participate)  
 
You will be given a copy of the full Informed Consent Form  
 
 
PART I: Information Sheet 
 
Introduction  
I am XXX, working for IRSS organization. I am doing a study on the disease syphilis which is 
very common in this district. I am going to give you information and invite you to be part of the 
research. If you have questions, you can ask them at anytime to me or to the principal 
investigator. 
 
Purpose of the research  
Syphilis is a sexual transmitted infection with a serious source of adverse pregnancy outcomes 
like miscarriage and stillbirth. If left untreated, maternal syphilis infection can be transmitted to 
child during pregnancy and cause abnormal growth of child. Transmission most commonly takes 
place after 4 months of gestation. This is why it is important to have early detection of the 
infection. For the moment the detection is performed at laboratory. We would like to implement 
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an intervention in which a test will be possible in the health facility without a laboratory.  
 
Type of Research Intervention 
The present study will assess if it is possible to do early detection of maternal syphilis by 
providing an onsite test that give results in 20 minutes.  You will be asked to provide a sample of 
blood (1 tablespoon).  The blood will be taken with finger stick and you will get the results of the 
test within 20 minutes. If your result is positive, you will receive medicines. 
 
Participant selection 
We are inviting all pregnant women who attend clinic for first ANC and are unless 18 years old to 
participate in the research. 
 
Voluntary Participation 
Your participation in this research is entirely voluntary. It is your choice whether to participate or 
not. Whether you choose to participate or not, all the services you receive at this clinic will 
continue and nothing will change. If you choose not to participate in this research project, you 
will offer the care that is routinely offered in this health facility, and we will tell you more about it 
later. You may change your mind later and stop participating even if you agreed earlier. 
 
Procedures and Protocol 
You will be asked to provide a sample of blood (1 tablespoon).  The blood will be taken with 
finger stick and you will get the results of the test within 20 minutes. [If quality control: After 
completing your test, we would like to save any left-over blood for quality control. Your blood 
sample will be frozen and will be stored with a number assigned to it instead of your name.  The 
number will be linked to your name. The sample will be transported to a laboratory for testing. 
The results of this test will be told you.]. If your result is positive, you will receive the treatment 
of your condition according to national guidelines. This means that you will be given a single 
dose of benzathine penicillin G 2.4 million units intramuscularly. If you have allergy to penicillin 
you will be referred to the district hospital for an appropriate treatment. If your result is negative, 
you will receive advice on STI prevention. 
 
Duration  
The research takes place over one year in total. During that time, it will not be necessary for you 
 
 
 
 
170 
 
to come to the health facility. Your participation in this experiment will take approximately 20 
minutes for the blood draw and the waiting of the result.   
 
Side Effects 
This test cannot have some unwanted effects. But the treatment could give you allergy. If so we 
may stop the use of the drug and referred you to the district hospital. 
 
Risks 
The risks associated with this study are slight discomfort from the blood draw.  
 
Benefits  
You will not be paid to participate in this study. If the result of your test is positive, you will 
receive treatment for free. If your result is negative, you will receive advice on STI prevention. 
 
Reimbursements 
You will not be provided any incentive to take part in the research.  
 
Confidentiality 
The results of your sample will be used for research purposes only. We will keep the information 
about your result confidential. The information that we collect from this research project will be 
kept confidential. Information about you that will be collected during the research will be put 
away and no-one but the researchers will be able to see it. Any information about you will have a 
number on it instead of your name. Only the researchers will know what your number is and we 
will lock that information up with a lock and key.  
 
Alternatives to Participating 
If you do not wish to take part in the research, you will be provided with the care that is routinely 
offered in this health facility. 
 
You can ask me any more questions about any part of the research study, if you wish to. Do you 
have any questions?   
 
Do you agree to take part in this study?   
 
Who to Contact 
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If you wish to ask questions later, you may contact any of the following:  
Dr. Seni Kouanda, Principal Investigator, at 50 33 35 94.  
 
This research has been reviewed and approved by the Burkina Faso Comité d’éthique de 
recherche en santé (CNERS). This committee reviews research studies to help protect 
participants.  If you have any questions about your rights as a research participant you may 
contact: 
 
The chairman,  Comité national d'éthique pour la recherche en santé (CNERS), Ministère 
de la Santé, 03 BP 7009, Ouagadougou 03, Burkina Faso, phone number: 50 32 41 59. 
 
 
PART II: Certificate of Consent 
 
The study has been described to me in language that I understand and I freely and voluntarily 
agree to participate. My questions about the study have been answered. I understand that my 
identity will not be disclosed and that I may withdraw from the study without giving a reason 
at any time and this will not negatively affect me in any way.  I promise to keep the 
information in this study confidential. I consent to give my blood sample. 
 
Print Name of Participant__________________      
Signature of Participant ___________________ 
Date ___________________________ 
 Day/month/year    
     
If illiterate 
I have witnessed the accurate reading of the consent form to the potential participant, and the 
individual has had the opportunity to ask questions. I confirm that the individual has given 
consent freely.  
 
Print name of witness_____________________             AND         Thumb print of participant 
Signature of witness ______________________ 
Date ________________________ 
                Day/month/year 
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Statement by the researcher/person taking consent 
I confirm that the participant was given an opportunity to ask questions about the study, and 
all the questions asked by the participant have been answered correctly and to the best of my 
ability. I confirm that the individual has not been coerced into giving consent, and the consent 
has been given freely and voluntarily.  
   
 A copy of this ICF has been provided to the participant. 
 
Print Name of Researcher/person taking the consent________________________ 
    
Signature of Researcher /person taking the consent__________________________ 
Date ___________________________    
                 Day/month/year 
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Appendix 8: Supervision tools 
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BURKINA FASO 
CENTRE NATIONALE DE LA RECHERCHE SCIENTIFIQUE ET 
TECHNOLOGIQUE (CNRST) 
INSTITUT DE RECHERCHE EN SCIENCES DE LA SANTE 
 
 
 
03 BP7192 Ouagadougou 03, 
Tel : (00226 50) 363215 / 335684/ 333594 
Faisabilité et acceptabilité du dépistage de la syphilis en 
consultation prénatale par l’utilisation de test rapide au Burkina 
Faso 
 
FICHE DE SUPERVISION MEMSUELLE 
 
 
 
 
Supervision n°…………. 
Date  de la supervision…………………………………….. 
Nom du  Centre de santé (site) : ------------------------------------------------------------------------- 
 
 
 
 
 
 
175 
 
INFORMATIONS A RECEUILLIR 
Période supervisée:    
Nombre de CPN 1 vue au premier trimestre au cours de la période : 
Nombre total de femmes dépistées: 
Nombre de cas positif : 
Nombre de cas négatif : 
Nombre de cas indéterminé ou invalide : 
Nombre de cas traité : 
Nombre de partenaire traité : 
Nombre de tests en stock : 
Le stock disponible en médicaments (KIT UG) :  
 
Difficultés rencontrés : 
……………………………………………………………………………………
……………………………………………………………………………………
……………………………………………………………………………………
……………………………………………………………………………………
… 
Solutions proposées :  
……………………………………………………………………………………
……………………………………………………………………………………
… 
Les supervisés        les superviseurs 
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Appendix 9: Register for enrolled woman 
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BURKINA FASO 
CENTRE NATIONALE DE LA RECHERCHE SCIENTIFIQUE ET 
TECHNOLOGIQUE (CNRST) 
INSTITUT DE RECHERCHE EN SCIENCES DE LA SANTE 
 
 
 
03 BP7192 Ouagadougou 03, 
Tel : (00226 50) 363215 / 335684/ 333594 
Faisabilité et acceptabilité du dépistage de la syphilis en 
consultation prénatale par l’utilisation de test rapide au Burkina 
Faso 
 
REGISTRE DE SUIVI DES FEMMES ENCEINTES 
 
 
 
 
 
Date : /__/__/__/__/________/ 
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DEMANDE DE CONSENTEMENT 
PART II: déclaration de consentement éclairé 
J’ai été invitée à participer à l’étude sur le dépistage de la syphilis après avoir reçu toute les 
informations nécessaires pour m’éclairer sur les objectifs de l’étude. J’ai compris les 
informations qui m’ont été données et je décide de participer de façon libre et volontaire. Mes 
questions ont reçues des réponses et mon identité sera sauvegardée. J’ai compris que je peux 
me retirer à tout moment de l’étude sans raison et cela n’affectera en rien mon suivi. Je 
promets de respecter la confidentialité des informations sur l’étude que j’aurais en ma 
possession. Je marque mon accord pour participer à l’étude. Par conséquent, j’autorise l’agent 
de santé à me faire une prise de sang pour le test de dépistage. 
Nom de la Participante__________________      
Signature de la Participante ___________________ 
Date ___________________________ 
Si illettré 
J’ai été témoin que la fiche d’information et la déclaration de consentement éclair ont  
été lues à la participante et qu’une opportunité de poser des questions a été offerte à 
cette dernière. Je confirme que la participante a donné un consentement libre et 
volontaire.   
Nom du témoin_____________________             ET         empreinte de la participante 
Signature du témoin ______________________ 
Date ________________________ 
                 
Déclaration de la personne recueillant le consentement 
Je confirme que la participante a eu l’opportunité de poser toutes les questions 
concernant l’étude et que j’ai donné des réponses du mieux que j’ai pu. Je confirme que 
la participante a donnée un consentement libre et volontaire sans aucune pression.    
 Une copie du consentement a été remise à la participante. 
Nom de la personne recueillant le consentement________________________   
Signature de la personne recueillant le consentement __________________________ 
Date ___________________________    
         Non, je refuse de participer  /_/  
Pourquoi ?.....................................................................................................................................
...................................................................................................................................................... 
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Si Oui attribuer un numéro d’inclusion suivant  l’ordre séquentiel. 
NUMERO D’INCLUSION (Pour celle ayant donné leur consentement) : /__/__/__/ 
 
ENTRETIEN D’INCLUSION 
Date d’inclusion ou de CPN1______________________________ 
I. Données socio-démographiques de la patiente 
101.  CODE CPN DE LA FEMME : /___/___/___/___/___/___/___/___/    
102.  Age :  Date de naissance :        lieu de résidence : 
…………………………………… 
105.  Situation matrimoniale :    Marié (vie en couple monogame) :  /_/ 
 Marié (foyer polygame) :   /_/   Célibataire :    ./_/  Divorcée/séparée :  /_/     Veuves : 
/_/ 
106. Niveau d’instruction :    Non scolarisée:/_/    Primaire : /_/     Secondaire /_/     
Supérieur /_/ 
107.  Profession : 
………………………………………………………………………………………………… 
II. Historique de la grossesse et antécédent gynécologique 
201 :  Age de la grossesse /___/___/ mois.    H.U /___/___/ cm   nombre de geste :………… 
203.  Avez -vous déjà eu un avortement spontané ou provoqué :   Oui/_/   Non : /_/ 
204.  Parité : …………………   Nombre de naissances vivantes :…………Nombre 
d’enfants vivants……… 
III. DEPISTAGE DE LA SYPHILIS  
501. Test réalisé : Oui /_/  Non /_/      
502. Résultats du test de dépistage : 
a. Résultat du test initial: Positif : /_/ => Traiter et faire un prélèvement pour le contrôle de qualité                                  
Négatif : /_/ 
Invalide ou Douteux: /_/   =>  répéter le test sur place avec la permission de la patiente et reporter le résultat en 
bas. 
b. Résultat du test répété (2) : Positif : /_/ => Traiter et faire un prélèvement pour le contrôle de qualité 
Négatif : /_/    Invalide/Douteux : /_/=> faire un prélèvement pour le contrôle qualité ou référer au CHR 
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IV. CONSEIL POST-TEST ET ANNONCE DES RESULTATS A LA PATIENTE 
Quelque soit le résultat du test, rassurer la patiente avant de lui annoncer ses résultats.  
Poser la question : Nous vous avions dit que lorsque le test est positif, il sera souhaitable que vous 
informer votre (vos) partenaires sexuels pour qu’ils viennent se faire traiter. Acceptez-vous de 
l’informer et de le faire venir au centre médical la semaine prochaine pour le traitement ? 
 
Oui je vais l’informer :…………………………………. /_/   Oui, mais donner moi une invitation pour lui  : /_/
  
Non  : /_/ Pouvez vous nous donner la raison ? 
  
Absent du village : /_/                                           Je ne peux pas lui parler de cela :  /_/ 
Nous ne sommes plus ensemble :  /_/     Autres : /_/ Préciser…………………………………………. 
 
 
V. TRAITEMENT POUR LES PATIENTES POSITIVES AU TEST DE DEPISTAGE ET/OU PRESENTANT 
DES PLAIES SUR LES ORGANES GENITAUX 
601. Avez-vous déjà présenté des éruptions cutanées ou une allergie suite à l’administration 
d’un médicament (pénicilline surtout) ? 
Oui :       /_/ De quel médicament s’agit-il ?................................................... (Demander  
à voir son carnet de santé). Si suspicion d’allergie à la pénicilline, référer la femme au CMA 
pour prise en charge. 
Non :  /_/ Administrer le traitement a ou b ci-dessous selon le cas. 
602 : Traitement administré : 
a. Benzathine Benzyl Pénicilline  (BBP) 2,4MUI IM, 1 injection : …………………………………/_/ 
b. Ery 500 mg 1 cp x 4/j pdt 14j + Polyvidone Iodée solution 10% :.. /_/ 
NB :  a. Pour test de dépistage positif uniquement 
  b. Pour présence de plaie, ulcération génital +/- test positif. 
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Appendix 10: Manual for training  
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Dr Gautier Ouédraogo, pharmacien biologiste 
Dr Grissoum Tarnagda, pharmacien 
IRSS, 50 33 35 94  
 Faisabilité et acceptabilité du dépistage de la syphilis en consultation 
prénatale par l’utilisation de test rapide au Burkina Faso 
 MANUEL DE FORMATION DES AGENTS DE SANTE POUR LA REALISATION 
DES TESTS RAPIDES DE LA SYPHILIS 
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INRODUCTION 
_________________________________________________________________________ 
 
Ce manuel doit être soigneusement étudié et 
utilisé comme référence sur le terrain 
quand vous vous posez des questions 
concernant la façon de procéder pour 
effectuer toutes les tâches impliquées dans 
la procédure des tests. 
_____________________________________
___________________________ Avant de 
proposer le test à votre client, rassurez-vous 
que tout le matériel nécessaire pour votre 
travail est disponible. 
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CARACTÉRISTIQUES GÉNÉRALES 
 
Dans le cadre de cette enquête intitulé ‘’faisabilité et acceptabilité du dépistage de la 
syphilis en consultation prénatale par l’utilisation des tests rapide au Burkina Faso’’, 
des prélèvements de sang seront effectués auprès des femmes enceinte pour pratiquer le test 
de la syphilis. Ce manuel décrit les procédures que vous devez suivre pour harmoniser les 
pratiques, mais aussi assurer la qualité et la sécurité de votre travail sur le terrain. 
 
Contexte et justification  
La transmission de la syphilis demeure une source importante d’effets sur l’issue des 
grossesses et également un cofacteur important dans la transmission du VIH dans les pays en 
développement. Selon les estimations de l’OMS, la syphilis maternelle est chaque année 
responsable d’au moins 500 000 avortements spontanés ou mortinaissances, tout comme de la 
naissance de 500 000 enfants prématurés atteints de syphilis congénitale ou présentant une 
insuffisance pondérale à la naissance. Or, la charge que représente la syphilis congénitale est 
encore généralement sous-estimée. La syphilis congénitale est une maladie évitable que le 
dépistage prénatal et le traitement précoce des femmes enceintes infectées permettraient 
d’éliminer En réponse à cette situation, Le groupe consultatif scientifique et technique du 
Département OMS Santé et recherche génésiques (RHR) a approuvé une stratégie pour 
l’élimination mondiale de la syphilis congénitale d’ici 2015.   
Cette stratégie se base sur 4 piliers. L’un de ses piliers est d’assurer le dépistage et le 
traitement des femmes enceintes et de leurs partenaires. Ainsi de nombreux pays  ont inclus 
le dépistage de la syphilis dans un paquet minimum d’examens à effectuer lors des visites 
prénatales. Pour cela il est nécessaire que les tests diagnostiques soient accessibles aux 
populations les plus affectées.  
La technique de test de dépistage de la syphilis  dans cette enquête consiste à prélever par 
piqûre au bout du doigt des gouttes de sang et à le déposer dans une cassette de test rapide qui 
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vous donnera le résultat en 20 minutes.  
Les résultats de ces tests seront également remis sur place, et la femme sera prise en charge 
au service de santé  si le test est positif.  
 
 
 
 
1.1.1 But de l’étude 
Cette recherche a pour but de contribuer à l’élimination de la syphilis en fournissant des 
évidences scientifiques à l’intention des décideurs sur la faisabilité (pratique, acceptabilité, et 
coût) du dépistage de la syphilis par les tests rapides au niveau des structures périphériques 
de soins.  
 
1.1.2 Les sites de l’étude 
 
Les CSPS seront sélectionnés dans le district sanitaire de Kaya où l’Institut de Recherche en 
Sciences de la Santé (IRSS) a mis en place un site de surveillance démographique et de santé 
(KaDESS) depuis 2007. Le site couvre 20 CSPS dont 4 urbains situés dans la ville de Kaya.   
 
 
 
Généralités sur la maladie 
3.7.2. Aspects cliniques 
 Clinique  
[Dr Thomas Perpoint Hôpital de la Croix Rousse Service de Maladies Infectieuses, 
Lyon] 
Incubation # 3 semaines (10 à 90 j) 
• Primaire : 
– Chancre et adénopathies = complexe primaire 
– Chancre unique (2/3), indolore, base indurée…, cicatrisation spontanée en 3 à 5 semaines 
(1- 3 sem. Sous traitement) 
– Adénopathie satellite inguinale uni ou bilatérale unique ou multiple 
• Chancres génitaux, 
– Homme : sillon balano-préputial, méat, prépuce (phimosis), hampe 
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– Femme : grandes lèvres (géant), petites lèvres (nain), vagin (rare), col 
• Chancres extra-génitaux : lèvres, amygdales, anus 
 
        
 
 
                                                                                          
 
•Secondaire : (contagiosité +++) 
– Précoces : 
• Roséole (macule de 1 à 3 mm, tronc paumes et plantes… 
• Plaques muqueuses : érosions superficielles, contagion +++ 
• Alopécie 
– Tardives : 
Syphilis Congénitale 
Contamination in 
utero, 
2ème trimestre 
•Jetage nasal 
•Hépatosplénomégalie 
•Lésions 
cutanéomuqueuses et 
•osseuses 
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• Syphilides : papules squameuses, tronc, régions génitales, mains, pieds 
• polyAdp, AEG 
 
3.7.3. Aspects biologiques 
Principes pour l’interprétation de la sérologie de la syphilis 
1. Au stade primaire le diagnostic de certitude repose sur la recherche de TP  au microscope à 
fond noir (positif dans 30 à 50% des cas), pas de valeur au niveau buccal. 
2. Les 2 tests utilisés pour le diagnostic sont le TPHA et le VDRL 
3. Au tout début du chancre le TPHA et le VDRL peuvent être négatifs 
(3-7 premiers jours du chancre) 
1. Au stade de syphilis secondaire les 2 tests sont toujours positifs (exceptionnelles neg)  
2. Un VDRL positif isolé n’est pas synonyme de syphilis  
3. La surveillance sérologique après traitement repose sur le VDRL quantitatif 
4.  Aucun test actuel ne permet de différencier une syphilis d’une tréponématose non 
vénérienne 
5.  Interprétation des résultats avec la clinique (contact clinicien-biologiste) +++ 
 
Fausses sérologies de la syphilis, VDRL + isolé 
Causes infectieuses 
Bactériennes: lèpre, tuberculose, leptospirose, borréliose, scarlatine… 
Virales: varicelle, oreillons, MNI, hépatite, rougeole, VIH 
Parasitaires: trypanosomiase, paludisme 
Causes non infectieuses 
Grossesse, Toxicomanie IV, Hépatopathie chronique, Gammapathie monoclonale, Lupus 
Syndrome des anticardiolipides, Cancers… 
 
3.7.4. Aspects thérapeutiques 
Le traitement de la syphilis selon le protocole national de prise en charge des IST correspond 
à celui de l’ulcération génitale.  Il consiste à traiter, le chancre mou et l’herpès génital par 
l’un des Kits UG : 
 
 Kit UG1 : Benzathine Benzyl Penicilline 2,4 millions UI en IM unique + Polyvidone 
iodée solution à 10%  
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 Kit UG2 (si allergie, femme enceinte ou allaitante) 
Erythromycine 500 mg 1cp 4 fois par jour pendant 14 jours + Polyvidone iodée solution à 
10%  
 
 
 ORGANISATION DU TEST 
 
Pour pouvoir prélever les échantillons de sang,  chaque personnel de santé chargée de 
réaliser le test, aura reçu une formation spéciale pour le prélèvement du sang. Le 
consentement des femmes sera recueilli avant procéder au prélèvement. Les données 
socio-anthropométriques (âges, poids, situation matrimoniale), les données sur la 
grossesse en cour (âge de la grossesse, date probable d’accouchement), les antécédents 
gynéco-obstétricaux (nombre de grossesses vivantes, nombre de mortinaissances, nombre 
d’avortement spontanés,…) seront recueillis à l’inclusion. Après le recueil de ces données 
de base, une explication du déroulement du test sera donnée à la femme suivie d’une prise 
de sang capillaire (au bout du doigt) pour le dépistage rapide et instantané de la syphilis. 
Le test étant rapide et instantané (maximum 30 minutes), les résultats seront remis à la 
femme tout en prenant soins de lui en donner la signification et la conduite à tenir. En cas 
de positivité du test, un prélèvement sanguin veineux sera fait dans un tube sec sans 
anticoagulant avant l’administration du traitement et chez chaque 20 ième  cas 
négatif de chaque site  pour le contrôle de qualité ultérieure par le Laboratoire du 
CHR. 
Concernant le test auprès des femmes enceintes, les agents trouveront ci-dessous la liste 
des tâches principales qu’ils devront effectuer :  
 Identifier toutes les femmes qui sont éligibles pour le test ; 
 Obtenir le consentement éclairé de la femme enceinte et enregistrer les informations 
concernant la femme dans le registre de suivi des femmes. 
 Prélever un échantillon de sang capillaire pour chaque femme enceinte et effectuer le 
test de la syphilis en utilisant le test rapide  Syphilis. 
 Enregistrer le résultat du test sur la fiche de suivi de la femme; 
 Informer la femme du résultat de l’examen sur la syphilis; 
 Prescrire  le traitement pour les femmes ayant un test positif à la syphilis.  
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Dans les sections suivantes de ce document vous trouverez la description détaillée des 
procédures et les directives que vous devrez suivre pour mener à bien ces tâches. 
 
Formation des personnels de santé 
Votre formation pour apprendre à effectuer le test de la syphilis comprendra des cours 
théoriques et pratiques qui vous donneront la capacité nécessaire de pratiquer ce test sur le 
terrain. 
Durant la première phase de la formation, nous reverrons ensemble toutes les sections de ce 
manuel. Vous apprendrez comment choisir les femmes éligibles, comment enregistrer les 
informations concernant le test dans le registre ou comment procéder pour le prélèvement des 
échantillons, le test, etc. 
 
Durant la seconde phase de cette formation, nous organiserons des simulations pour les tests 
de la syphilis au cours desquels vous vous entraînerez à prélever les échantillons de sang 
parmi vos collègues en formation. 
 
Au cours de la session de formation, il vous faudra étudier soigneusement ce manuel, en 
prenant des notes et en écrivant les questions que vous vous posez. Posez toutes les questions 
que vous vous posez à n’importe quel moment ; cela vous permettra d’éviter de faire des 
erreurs sur le terrain. Vous pouvez apprendre beaucoup les uns des autres en posant des 
questions et en relevant les éventuelles difficultés que vous pourrez rencontrer.  
 
Supervision  
 
La formation est un processus continu.  L’observation et la supervision sur le terrain 
constituent une partie du processus de la formation et de la collecte des données.  Le 
coordinateur de l’enquête pour les tests biologiques jouera un rôle très important en 
continuant votre formation et en assurant la qualité des données de l’enquête. Il devra: 
 
 Contrôler la qualité de votre pratique des tests et la qualité de vos résultats  
 Aider à résoudre les problèmes que vous  pourriez rencontrer sur le terrain.  
Une équipe de supervision effectuera une fois par mois la tournée des centres de santé 
concernés par l’étude.  Chaque CSPS sera doté d’un code. 
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Contrôle de qualité 
Le contrôle de qualité des résultats des tests sera assuré par le laboratoire du CHR de Kaya. Il 
va s’inspirer du système de sérosurveillance pour le VIH. Le laboratoire sera chargé 
d’analyser les échantillons qui seront acheminés par les CSPS. Chaque 1/20  des cas négatifs 
et tous les cas positifs seront analysés pour confirmation. Un point focal sera désigné au sein 
du laboratoire du CHR de Kaya pour le suivi de l’étude. 
Les CSPS seront dotés de consommables (tubes et aiguilles de prélèvement sanguin, garrot) 
pour les prélèvements sanguins. Un prélèvement veineux sera effectué sur toute femme 
avec un résultat positif et sur chaque 20ème femme avec un résultat négatif. Les 
prélèvements seront conservés dans un tube sec au réfrigérateur à une température de 2 
à 4°C au niveau  du CSPS en attendant leur acheminement au laboratoire du CHR où 
ils seront centrifugés et testés. La collecte des échantillons dans les CSPS se fera deux 
fois par semaine (le Lundi et le Jeudi).  Chaque CSPS devra se charger de transporter 
les échantillons collectés au laboratoire du CHR les après midi entre 15h et 17h.  
Les CSPS recevront une prise en charge pour le transport des échantillons jusqu’au CHR en 
fonction du nombre de Km parcouru.  
Le CHR sera doté des réactifs et autres consommables pour effectuer les tests en laboratoire.  
 
 
MATÉRIEL ET ÉQUIPEMENT POUR EFFECTUER LES TESTS 
 
Dans cette section, vous trouverez une description détaillée des divers instruments et 
équipement que vous utiliserez pour effectuer les tests de la syphilis.  Des détails 
supplémentaires sont présentés dans le document concernant la description du déroulement 
de la procédure des tests. 
 
Matériel et équipement pour effectuer la piqûre au doigt  
 
Les gouttes de sang capillaire utilisées pour le test de la syphilis seront prélevées au doigt. 
L’équipement et le matériel suivants (Figure 12) seront utilisés pour effectuer la piqûre au 
doigt :  
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 Gants jetables en latex non poudrés : ils sont 
utilisés pour réduire le risque de 
contamination par le sang. Les gants doivent 
être portés par l’agent de santé et par 
quiconque qui participe à un prélèvement 
sanguin. 
 
 Tampons alcoolisés : ils sont utilisés pour 
nettoyer la peau avant d’effectuer la piqûre au 
doigt.  
 
 Compresses de gaze stérile ou simple coton : elles sont utilisées pour essuyer les 
premières gouttes de sang pour stimuler le flux sanguin. 
 
 Pansements adhésifs : Après le prélèvement sanguin, il faut appliquer un pansement 
sur l’endroit de la piqûre pour éviter qu’une infection ne se produise.  
 
 Lancettes (rétractables) : La lancette est un dispositif  d’incision automatique, jetable 
utilisé pour piquer le bout du doigt ou le talon. Elle est spécialement conçue pour 
s’adapter à la surface de la peau, réduisant ainsi l’indentation de la peau. En appuyant 
sur le déclencheur, on libère rapidement une lame chirurgicale qui se rétracte 
automatiquement.  L’angle de la lame est réglé de façon à ce que le débit sanguin soit 
au maximum et que le mouvement de la lame soit si rapide qu’il ne peut être vu.  
   
Le test : Matériel pour le test de la syphilis 
 
L’équipement suivant est utilisé pour le test de la syphilis: 
- Cassette du test syphilis unitaire (dans une pochette) 
- Flacon de réactif du test 
- Pipette ou micro tubes capillaire avec EDTA  
- Marqueur/crayon pour étiquetage   
 
 
Figure 12: Matériel  pour effectuer 
les piqûres au doigt  
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REMPLISSAGE DES QUESTIONNAIRES ET DES AUTRES DOCUMENTS 
POUR LES TESTS 
En tant que agents, vous êtes chargés d’enregistrer les informations qui seront utilisées pour 
suivre les résultats des tests.  
Cette section a pour objectif de passer en revue les tâches suivantes: 
 
 Identification des sujets éligibles ; 
 Obtention du consentement éclairé pour le test ;  
 Enregistrement les informations concernant les résultats des tests dans le cahier.  
Les activités spécifiques nécessaires à la réalisation de ces tâches sont décrites ci-dessous 
 
Identification des sujets éligibles 
 
Recrutement des femmes 
Les femmes enceintes seront recrutées avec leur consentement dans les formations sanitaires 
retenues dès leur première CPN et suivies durant toute leur grossesse. Le recrutement sera 
assuré par des agents de santé formés avec une expérience dans la prise en charge des 
grossesses au niveau périphérique. 
 
L’inclusion effective dans l’étude 
L’inclusion effective dans l’étude sera précédé par l’information de la femme des objectifs et 
du déroulement de l’intervention à l’issu de laquelle elle décidera librement de sa 
participation. 
 
Critères d’inclusion 
- Femme enceinte reçue en première consultation prénatal (toute femme en CPN 1) 
pour la grossesse en cours 
- Femme enceinte âgée d’au moins 18 ans 
- Femme acceptant de participer à l’étude 
 
Critères de non inclusion 
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- Femmes enceinte ayant déjà bénéficié d’une consultation prénatale pour la grossesse 
en cours car le test de la syphilis fait partie des examens prénataux obligatoires qui 
doit être prescrit dès la première consultation prénatale. 
- Femme enceinte âgée de moins de 18 ans  
- Femme refusant de participer à l’étude 
 
Obtention du consentement éclairé pour le test 
 
L’une des taches principales de l’agent sera d’expliquer l’objectif de ce test aux femmes 
éligibles, en vue d’obtenir leur consentement éclairé avant de commencer à effectuer les tests 
sanguins. Pour permettre aux femmes de fournir un consentement éclairé sur leur 
participation au test, des formulaires de consentement comportant des explications sur la 
nature des tests et une demande d’autorisation  seront administrés avant d’effectuer les 
prélèvements sanguins pour ces tests. Ces déclarations sont appelées des déclarations de 
consentement éclairé.  
 
Dans tous les cas, vous devez inscrire la réponse à la demande de consentement éclairé avant 
d’effectuer le prélèvement sanguin d’une femme. 
Vous devez signer la fiche de consentement pour attester que vous avez lu la déclaration aux 
femmes et que vous avez enregistré leur(s) réponse(s) de manière exacte.  
 
Les points suivants sont des points importants dont il faut se souvenir quand on cherche à 
obtenir le consentement éclairé pour effectuer les tests : 
 
1) Lire la déclaration de consentement à chaque personne telle qu’elle est 
exactement formulée dans la fiche. Quand vous recevez votre patiente et quand 
vous commencez à parler, vous pouvez discuter de manière informelle des points qui 
figurent dans la déclaration de consentement éclairé. Cependant, avant de commencer 
à effectuer le test d’un sujet, vous devez lire la déclaration de consentement telle 
qu’elle est exactement formulée dans le formulaire.  Si vous vous apercevez que la 
personne trouve la déclaration répétitive, expliquez-lui/elle que vous êtes tenu de lire 
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cette déclaration de manière formelle pour que les personnes bénéficient de toutes les 
informations appropriées.  
 
(2) Lisez clairement et de manière intelligible les déclarations de consentement 
éclairé.  Entraînez-vous à lire les déclarations de consentement éclairé pour être 
capable de les lire facilement sur un ton naturel. Éviter de les lire sur un ton 
monocorde ou en prenant un rythme trop rapide pour qu’elles puissent être comprises 
. 
(3) Ne jamais prélever le sang d’une femme sans au préalable avoir obtenu le 
consentement.  
 
(4) Ne jamais essayer d’obtenir un consentement par la force ou la coercition. 
Vaincre les craintes des personnes concernant le prélèvement sanguin exige du tact et 
de la patience. Prenez le temps de bien répondre aux questions et soucis des personnes 
qui sont hésitantes, afin de pouvoir obtenir leur consentement. Certains sujets peuvent 
souhaiter discuter des procédures avant d’autoriser les tests. Répondez patiemment à 
tous ceux qui posent des questions.   
 
  
Enregistrement des informations concernant les tests pour les femmes éligibles. 
  
Les résultats des tests seront enregistrés sur le cahier. Ce cahier mis à votre disposition est 
détenu par votre responsable de la maternité. 
 
Fournir les résultats du test de la syphilis   
 
Après avoir effectué le test, vous donnerez pour chaque femme ayant effectué le test les 
résultats. En donnant les résultats verbalement, expliquez brièvement ce que les résultats 
du test  du sujet signifient.  
Résultat négatif : Dites à la femme que le résultat est négatif, et que l’examen fait 
aujourd’hui n’a pas trouvé de germes de la syphilis dans son sang. Vous pouvez lui 
conseiller les rapports sexuels sans risque notamment la fidélité.  
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Résultat Positif : Dites à la femme que le test est positif à la syphilis, mais cela n’est pas 
grave parce qu’elle aura un traitement pour guérir et protéger son enfant. Il peut s’agir 
d’une infection ancienne, mais par mesure de précaution, nous allons lui administrer le 
traitement. Conseillez-lui des rapports sexuels protégés (port du préservatif) et expliquez-
lui l’intérêt de faire traiter son (ses) partenaire (s) sexuel (s). 
NB : Il n’est pas nécessaire de réaliser le test chez le partenaire. Un résultat 
négatif chez celui-ci pourrait entrainer des problèmes dans le couple. Pour ce 
faire, dites au partenaire que l’infection peut ne pas se manifester chez l’homme 
mais se manifester chez la femme. Un résultat positif au test utilisé ne veut pas 
dire que l’infection est en cours, cela peut être une infection ancienne, guérie, 
mais par mesure de précaution, surtout avec l’enfant à naitre, il sera mieux qu’il 
se fasse traiter. Expliquez-lui l’intérêt de se faire traiter et lui proposer 
l’administration du traitement. 
 
Résultat douteux/Invalide : Dites à la femme que le test n’a pas pu déterminer un résultat 
précis. Vous pouvez lui conseiller les rapports sexuels sans risque notamment la fidélité. 
 
 
PROCÉDURES GÉNÉRALES POUR PRÉLEVER DES GOUTTES DE SANG 
CAPILLAIRE 
 
Le prélèvement de la goutte de sang capillaire peut être effectué sur la surface palmaire 
de l’extrémité du doigt.  Les paragraphes suivants concernent la description détaillée des 
différentes étapes pour effectuer le prélèvement de gouttes de sang capillaire à partir du 
doigt.  
 
Étape 1 : Préparation générale 
 
a) Si possible, trouvez un endroit à l’intérieur pour être en privé. De même, il est souhaitable 
que l’endroit soit pourvu d’une table ou d’un autre « meuble » ayant une surface plate sur 
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Figure 2: Doigts à utiliser pour le prélèvement 
 
laquelle vous pourrez étaler vos fournitures. Un  lit ou un matelas doivent être disponibles 
au cas où un sujet viendrait à s’évanouir et devrait s’allonger.  
 
b) Passez en revue le matériel et  vérifiez le nombre de 
femmes éligibles. Après avoir établi le nombre de 
femmes à tester, sortez l’équipement approprié 
(Tableau 2).  Il vous faut tout le matériel à portée 
de mains avant de commencer à prélever les 
échantillons de sang.  
 
c) Lavez-vous soigneusement les mains avec de l’eau et 
du savon puis séchez-les ; mettez des gants avant de commencer à effectuer le 
prélèvement sanguin. 
 
d) Décrivez à la femme la procédure de prélèvement exacte et ce qu’elle  peut faire pour vous 
aider durant le prélèvement. 
e) Aussi,  faites preuve d’un calme rassurant quand vous commencez à prélever le sang.  
Rappelez-vous que pour diminuer l’anxiété des sujets, il est important de prendre un air 
amical et de faire en sorte d’établir un climat de confiance. 
 
Étape 2 : Sélection et préparation du lieu de ponction 
 
a) Le prélèvement sera généralement plus 
facile si vous vous asseyez du côté opposé à 
la main du sujet. Par exemple, si vous voulez 
prélever le sang de la main gauche, placez-
vous à la droite du sujet. 
 
b) Utilisez le troisième ou le quatrième 
doigt pour prélever le sang (Figure 2). 
N’utilisez pas un doigt avec une cicatrice, 
Tableau 2 : Équipement et fournitures nécessaires  
Pour la piqûre au doigt 
Lancettes rétractables  
Gants en caoutchouc 
Tampons alcoolisés 
Compresses de gaze stérile 
Pansement (Sparadrap) 
 
Pour le test de la syphilis 
Test rapide Alere Détermine syphilis  
Solution de migration (réactif) 
Pipette en plastique 
Marqueur/cryon pour étiqueter le test 
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une blessure ou une entaille, une infection, un œdème, une difformité, des boutons ou des 
callosités. N’utilisez pas un doigt auquel la femme porte une bague parce qu’elle peut 
gêner le flux du sang au bout du doigt. 
 
c) Si l’extrémité est froide, réchauffez la peau en la frottant à l’endroit où la ponction 
sera effectuée. Cela améliorera la circulation sanguine en diminuant la proportion de 
liquide du tissu et facilitera le prélèvement  de 
l’échantillon. 
 
d) Nettoyez la peau avec un tampon alcoolisé. Si la peau 
est très sale, prenez un nouveau tampon.  Laissez l’alcool 
sécher à l’air. Ne soufflez pas sur le lieu de ponction 
pour sécher l’alcool car des bactéries pourraient s’y 
incruster.  
 
e) Assurez-vous que la lancette est facilement à portée. Pour ce travail, vous utiliserez 
les lancettes dont la lame mesure 2,25 mm.  
 
Étape 3 : Piquer le doigt  
 
a) Retirez la protection blanche de l’ouverture de la lame en la tordant d’abord à 360o et 
ensuite en la tirant.  N’enlevez pas la protection de l’ouverture de l’aiguille sans la 
tordre au préalable, cela pourrait empêcher l’aiguille de percer la peau.   
 
b) Assurez-vous que le doigt se trouve en dessous du cœur du sujet pour augmenter le 
flux du sang vers le doigt. En décrivant un mouvement circulaire avec le pouce, appuyez 
doucement sur le doigt à partir de la jointure supérieure vers le bout. Cela stimule la 
circulation sanguine vers le lieu de ponction.  
 
 
 
 
Figure 3 : Nettoyer le doigt 
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Figure 5 : Essuyer la première goutte de 
sang   
c) Quand votre pouce atteint le bout du doigt, maintenez une pression légère. Placez la 
lancette perpendiculairement à l’empreinte digitale sur la surface palmaire au bout du 
doigt, soit au centre ou légèrement sur le côté. Évitez l’extrémité du doigt ou les 
côtés extérieurs à l’empreinte digitale parce qu’il y a un risque d’atteindre l’os sous-
jacent. .    
 
d) Utilisez la lancette pour piquer la peau en plaçant la 
surface de  l’ouverture de la lame contre le lieu de 
ponction et appuyez sur le déclencheur (Figure 4). Le 
bout de la lame s’éjecte à travers l’ouverture, causant 
une micro-incision dans la peau et se rétracte 
immédiatement dans le dispositif. Lorsque vous piquez 
la peau, vous coupez ainsi à travers le lieu de ponction 
pour permettre au sang de former des bulles et de l’empêcher de circuler dans les sillons 
des empreintes digitales.   
 
e) La lancette doit être mise de côté pendant  le test. Après le test, la lancette doit être placée 
dans un sac à déchets dangereux avec le reste du matériel utilisé pour le prélèvement de 
sang.  
 
 
Étape  4 : Prélèvement de(s) échantillon(s) de sang 
 
a) Lorsque le sang apparaît, utilisez une compresse de 
gaze stérile pour essuyer la première goutte de sang 
(Figure 5). La seconde goutte sera utilisée pour le 
test.   
 
b) Si le sang s’arrête de couler avant qu’une quantité 
suffisante n’ait été prélevée, la procédure de ponction 
de la peau peut être répétée après que la femme ait 
 
 
Figure 4: Utiliser la lancette pour  piquer le 
doigt 
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donné son consentement pour une ponction à un doigt différent en respectant les 
procédures décrites aux étapes 1 à 3. Ne réutilisez aucun instrument/ matériel utilisé 
lors du premier test. 
 
 
REALISATION DU TEST RAPIDE DIAGNOSTIC SEROLOGIQUE DE LA 
SYPHILIS PAR LE TEST RAPIDE ALERETM DETERMINETM  
SYPHILIS TP 
 
Mode opératoire 
Préparation du test 
- Ramener réactif et échantillon à la température de la salle 30 minutes avant utilisation  
- Sortir le nombre de tests à utiliser de leur pochette (Une fois la protection plastique 
retirée chaque test, le dosage doit être effectué dans les 2 heures) 
- Réaliser le test à la température de la salle 
 
 Mode opératoire 
1- Enlever la protection plastique de chaque test 
2- Distribuer 50 µl de sang total à l’aide de micro pipette  ou tube capillaire sur la zone 
de dépôt de l’échantillon (symbolisé par la  flèche). 
3- Attendre que le sang soit absorbé par la zone de dépôt, puits distribuer une goutte de 
tampon de fixation sur la zone de dépôt de l’échantillon. 
4- Attendre 15 minutes (maximum : 24 h) 
5- Lire le résultat 
 
3-4-5 interprétation et validation des résultats 
Le test est validé lorsqu’une bande rouge apparaît dans la zone « contrôle » 
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a- résultat positif (deux barres) 
Apparition de bandes rouges dans la fenêtre-contrôle et dans la fenêtre-patient (une bande 
par fenêtre) sur la bandelette. Toute couleur rouge visible dans la fenêtre-patient doit être 
interprétée comme un résultat positif. 
 
 
  
                                                                                  Bande-contrôle 
 
  
                                                                                 Bande-patient 
 
b- Résultat négatif                                 
Apparition d’une bande rouge dans la fenêtre-contrôle. La bande rouge de la fenêtre-
patient n’apparaissant pas. 
 
                Bande contrôle 
 
 
c- Résultat non valide 
Absence de bande rouge dans la fenêtre-contrôle. Le test doit être recommencé. 
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                                                      Bande-patient                             
 
               INVALIDE            INVALIDE 
 
 
Stopper le saignement au lieu de ponction 
 
a) Après le prélèvement sanguin, essuyez le sang qui s’écoule du lieu de ponction avec une 
compresse de gaze stérile.   
 
b) Après avoir vérifié que le sang ne coule plus, prenez un pansement adhésif et placez-le 
sur le lieu de ponction.  
Se débarrassez des déchets bio-medicaux   
 
Mettez tous les déchets bio-medicaux (comme les lancettes, les tampons alcoolisés, les 
compresses et les gants) dans un sac à déchets destiné à collecter tous les déchets bio-
médicaux qui doivent être éliminés.  En fin de journée, éliminer ces déchets selon les 
procédures décrites. 
 
PRECAUTIONS A PRENDRE POUR LE PRELEVEMENT DES 
ECHANTILLONS 
 
Cette section traite des précautions les plus importantes que les agents doivent observer 
quand ils effectuent des prélèvements d’échantillons sanguins, pour se protéger eux-
mêmes ainsi que les sujets qui se prêtent au test contre les blessures ou les infections qui 
peuvent se transmettre et pour éviter de contaminer les prélèvements. 
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Précautions universelles en prélevant les échantillons 
 
Cette section traite des précautions universelles que les agents doivent observer quand ils 
effectuent des prélèvements pour les tests de la syphilis et. Les agents chargés du 
prélèvement sanguin pour les tests doivent prendre des précautions pour prévenir 
l’exposition parentérale, dermique et des muqueuses aux infections transmises par le 
sang, comme l’hépatite B ou le Virus de l’Immuno déficience Humaine (VIH). Pour se 
conformer aux précautions universelles, les directives suivantes doivent être suivies pour 
éviter de contracter ces infections qui peuvent se transmettre par le sang
1
.  
 
 Portez des gants. Les gants empêchent votre peau et les membranes muqueuses 
d’être en contact avec le sang du sujet. Les gants doivent être portés pendant le 
prélèvement du sang pour les tests de la syphilis jusqu’à ce que l’échantillon soit 
prélevé et que tous les déchets aient été évacués. À ce moment-là, les gants utilisés 
doivent être considérés comme des déchets bio-dangereux. Une nouvelle paire de 
gants doit être utilisée avec chaque sujet. Ne jamais réutilisez de gants! 
 Évitez les blessures perforantes. Les gants permettent de se protéger de la contagion 
sanguine qui peut se produire à la suite de contact avec la peau, qu’elle soit intacte ou 
non, mais ils ne permettent pas d’éviter les blessures perforantes causées par des 
instruments utilisés pour les piqûres au bout du doigt. Les lancettes rétractables qui 
sont utilisées par les agents réduisent les risques de blessures pénétrantes. 
 
Les lancettes ne doivent pas être utilisées à des fins autres que piquer le doigt pour 
prélever le sang pour les tests de la syphilis. Les lancettes ne doivent pas être cassées ou 
détruites par curiosité ou pour des raisons qui n’ont rien à voir avec les prélèvements. 
Immédiatement après la fin du test, les lancettes doivent être  placées dans un sac pour les 
déchets bio-dangereux résistant aux piqûres. 
Si un accident se produit, toute partie de la peau contaminée ou ayant été en contact avec 
le sang, doit être immédiatement lavée. 
 
                                                 
1
 Pour les précautions universelles concernant les agents pathogènes qui se transmettent par le sang, voir les directives du 
U.S. Centers for Disease Control and Prevention et les standards de l’U.S. Occupational Safety and Health Administration 
(OSHA).  
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 Ne jamais manger ou boire au cours des prélèvements.  Comme manger, boire ou 
se maquiller peut être cause de distraction pendant la procédure, cela n’est pas 
autorisé pendant les tests.  
 
 Se débarrasser correctement de tous les déchets biodangereux.  Après utilisation, tout 
équipement qui a été en contact avec le sang doit être placé dans un sac à déchets 
biodangereux  
 
Faites attention à bien ramasser tous les déchets des tests avant d’en commencer un 
nouveau. 
Après avoir terminé les tests de tous les sujets éligibles, vérifiez bien l’endroit où vous 
avez effectué les tests pour être sûr de n’avoir pas laissé traîner de déchets. Attachez bien 
le sac pour éviter que quelque chose ne puisse tomber.   
N’oubliez pas que vous êtes responsable de l’évacuation des déchets. Ne donnez jamais le 
sac à une personne qui n’est pas un membre de l’équipe pour le jeter. Si un des autres 
membres de l’équipe vous aide à vous débarrassez des déchets, assurez-vous qu’il a 
compris qu’il doit jeter lui-même le sac et ne pas le donner à quelqu’un d’autre. 
 
 
Règles particulières à observer au cours des prélèvements pour les tests De la 
syphilis 
 
Il y a un certain nombre de règles particulières que l’ agent doit observer au cours des 
prélèvements pour les tests de syphilis.  Ces règles comprennent :  
 
 Ne jamais « traire » le doigt. L’agent doit appliquer une faible pression en utilisant 
son pouce, son index et son majeur pour faire un « bourrelet » au site de ponction. 
Cela rendra plus poreux le tissu conjonctif sous-jacent à la peau et permettra au sang 
capillaire de couler plus facilement après l'incision. 
 
 Ne jamais mélanger l'alcool avec le sang. L’alcool utilisé pour nettoyer le lieu de 
ponction peut se mélanger au sang et causer des erreurs de lecture du taux 
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d'hémoglobine. Pour éviter ce problème, il faut essuyer et attendre que le doigt soit 
complètement sec avant d'effectuer la ponction. 
 
 Obstruction du flux sanguin. Il est important de bien tenir le doigt pour permettre 
l’accumulation de sang dans le lieu de ponction. Il ne faut cependant pas le tenir trop 
serré car cela peut obstruer le débit sanguin vers le doigt. 
 
Concernant le test de la syphilis, les règles suivantes sont particulièrement importantes :  
 
 Ne pas ouvrir le test unitaire sans être sûr de l’utiliser dans les 30 minutes qui 
suivent.  
 
 Ne jamais toucher les cercles de dépôt de l’échantillon sur la cassette test.  Evitez 
de toucher la zone à l’intérieur des cercles de dépôt de sang  sur le test, avant le 
prélèvement.  
 
 Protéger les cassettes de test des contaminations. Ne laissez jamais de l’eau ou 
autre élément contaminant enter en contact avec la cassette de test avant l’utilisation. 
 
REJET DES DECHETS BIO-DANGEREUX 
 
Tout matériel qui entre en contact avec le sang (par exemple, lancettes, tampons alcoolisés, 
gazes et gants, etc.) est considéré comme dangereux, c’est-à-dire dangereux pour les autres 
êtres humains. Il est très important d’éliminer correctement ces déchets biomédicaux de façon 
adéquate pour empêcher la transmission des maladies transmissibles par le sang, telles que 
l'hépatite B et le VIH.. 
 
A la fin des tests de chaque sujet, tous les déchets bio-dangereux qui ont été produits 
pendant la procédure du test doivent être placés dans un sac poubelle,  pour « déchets 
biodangereux ».  
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PREMIERS SOINS EN CAS D’ACCIDENT D’EXPOSITION AU SANG 
 
Exposition percutanée 
 
En cas de blessure par du matériel contaminé par du sang, ou à la suite d'un contact entre une 
blessure cutanée et du sang ou un fluide corporel : 
 laisser saigner la blessure, nettoyer immédiatement la blessure et la peau qui l'entoure 
à l'eau et au savon, puis rincer ; 
 désinfecter la blessure et la peau qui l'entoure avec un des produits suivants : 
o de l'alcool à 70% ......................................................... pendant 5 minutes. 
o une solution de chlore 12° chlorométrique ……..…… pendant 5 minutes, 
(diluée à 1/10ème, 0,1% de chlore actif)  
ou 
o polyvidone iodée 10% (Bétadine) ……………..……….. pendant 5 minutes, 
ou 
La chlorhexidine cetrimide étant active contre le VIH mais sans effet contre le VHB n'est pas 
recommandée pour les personnes qui ne sont pas vaccinées contre le VHB. 
 
Exposition affectant les yeux ou des membranes muqueuses 
Rincer immédiatement la zone exposée au moyen d'une solution saline isotonique pendant 10 
minutes ou passer l'œil sous le robinet d'eau courante. Des gouttes oculaires antiseptiques 
peuvent également être appliquées sur les yeux exposés. Si aucune de ces solutions n'est 
disponible, utiliser de l'eau propre. 
 
 
APRES TOUS CES PREMIERS SOINS REALISABLES IMMEDIATEMENT, 
CHERCHER A ENTRER EN CONTACT DANS LES 24 HEURES AVEC UNE 
FORMATION SANITAIRE DE REFERENCE POUR UNE MEILLEURE PRISE EN 
CHARGE 
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Schéma récapitulatif  
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Introduction
Despite several advances in treatment and management, syphilis remains 
a major public health problem. The World Health Organization (WHO) 
estimates that there are twelve million new cases of syphilis worldwide 
each year [1]. Ninety percent of syphilis cases occur in low income 
countries [1] and the prevalence ranges from less than 1% to 10%. 
African studies show prevalence during pregnancy of 2% in Mali [2], 3% 
in Nigeria [3], 5% in Botswana [4], and 7.3% in Tanzania [5]. In Burkina 
Faso, Kirakoya-Samadoulougou et al found a low prevalence of syphilis 
during pregnancy at national level but with important regional variations 
[6]. For instance, in Kaya District the prevalence was 7.5 in 2009 whereas 
in Ouagadougou it was 1% [7].
 
Syphilis in pregnancy poses major health risks for the mother and the 
fetus and also increases the risk for HIV transmission [8]. The World 
Health Organization (WHO) estimates that two million pregnant women 
each year are infected with syphilis globally [2]. The risk of vertical 
transmission could be up to 80% in early latent syphilis [2]. Approximately 
1.2 million pregnant women with syphilis transmit the infection to their 
newborn every year [9]. It is estimated that 492 000 infants in sub-
Saharan Africa die annually from congenital syphilis [10]. In Tanzania, a 
clinic-based study found that a quarter of women with high-titer active 
syphilis infection had stillbirths compared with 1% among seronegative 
women [11].
 
Maternal syphilis is detectable by serological screening and entirely 
treatable with penicillin. Therefore, screening and treatment for syphilis 
has been recommended as a routine part of antenatal care [12,13]. In 
Burkina Faso, syphilis screening is recommended for premarital tests 
and during pregnancy [14]. Unfortunately, antenatal syphilis screening 
is often poorly implemented in many sub-Saharan African countries [15]. 
Currently, only 30% of women with syphilis are screened and treated 
in developing countries [16]. The influence of health systems issues on 
timely prenatal syphilis screening has been observed in several countries, 
including Bolivia, Kenya and South Africa [17]. In West African countries 
such as Burkina Faso, barriers to syphilis screening are understudied.
 
In this study, we sought to identify and understand barriers affecting 
health system performance for syphilis screening among pregnant 
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women in Burkina Faso. Existing literature on syphilis screening among 
pregnant women suggests that antenatal care (ANC) is the cornerstone 
for the control of maternal syphilis. Thus, factors affecting attendance 
to ANC are likely to affect syphilis screening for pregnant women. We 
therefore explored various factors at policy, health provider, patient, and 
community levels that are likely to drive syphilis screening levels.  
Methods
Study design
 
We conducted a Multilevel Assessment (MLA) [18] comprising of qualitative 
interviews and observations, as well as a review of existing data. For the 
latter, we assessed health information systems records, policy documents, 
service provider guidelines, training manuals, monitoring and evaluation 
reports and other relevant research reports and published literature. 
These data enabled us to investigate how the syphilis screening policy 
was implemented at facility level, the available indicators of its health 
outcomes, and any documented barriers to its implementation to date. The 
in-depth interviews were held with health providers, district managers, 
facility managers, traditional healers, pregnant women, community 
health workers, and representatives of national and international Non 
Governmental Organizations (NGOs) which work on maternal and child 
health issues to explore barriers and constraints which affect the effective 
delivery of maternal syphilis screening. During data collection, the first 
author also observed interactions between health workers and clients in 
selected health facilities.
 
Study setting
 
The study was conducted in the Kaya health district, based in the central 
north region of Burkina Faso. Kaya district has 484 932 inhabitants, 40 
primary health facilities and is a sentinel site for the national AIDS and 
STI control program. We conducted this research in Kaya District because 
of the high syphilis prevalence relative to the national average. Figure 1
presents the trend of syphilis prevalence among pregnant women from 
2004 to 2009 in Kaya district and nationally. The study was nested in the 
Kaya Health and Demographic Surveillance System (Kaya HDSS), which 
was launched in 2007 by the Health Sciences Research Institute (IRSS). 
Kaya HDSS covers seven semi-urban areas and 18 villages of the district 
with a population of 48,131 inhabitants. In 2011, there were seven public 
primary health facilities that offered ANC, one faith-based health center 
and one regional hospital. The faith-based facility and the hospital did 
not offer ANC but their laboratories offer the venereal diseases research 
laboratory (VDRL) test and Treponame pallidum hoemagglutination 
assay (TPHA). One pharmacy offered a rapid test for syphilis. The health 
facilities selected for the study were all located within Kaya HDSS area.
 
Study population and sampling
 
The study population consisted of health providers, district managers, 
facility managers, traditional healers, pregnant women, community 
health workers, and NGO managers (Table 1). 
The healthcare providers included doctors, midwives, nurses, laboratory 
personnel, and pharmacists. Participants were purposively selected to 
capture a range of perspectives across different actors with varying 
roles and responsibilities. In each health facility, five pregnant women 
were approached as they queued to receive antenatal services and 
informed about the study. For those who consented, the interview was 
held at the end of their visit. Although we initially planned to have focus 
group discussions (FGDs) with pregnant women, the number of women 
available for the FGDs was too small because data collection occurred 
during the rainy season.
 
Data collection
 
Data were collected using interview guides that were adapted for each 
profile of respondent. The interview with pregnant women explored 
experiences of ANC, satisfaction with ANC, knowledge and perceptions 
of sexually transmitted infections (STIs) including syphilis, perceptions of 
existing point-of-care tests, opinion on the introduction of additional test. 
We sought to find out key informants’ perception of ANC, management 
of STI during pregnancy, knowledge and perceptions of syphilis, barriers 
and constraints which affect the effective delivery of maternal syphilis 
screening, organizational and managerial issues, experience with point-
of-care tests, and introduction of a rapid diagnostic test (RDT) for syphilis 
screening.
Data tools were pre-tested and appropriate modifications made before the 
final data collection. Data collection was conducted by the first author and 
two research assistants who are familiar with qualitative studies and have 
a social sciences background. Research assistants were trained on the 
study objectives, data collection tools, and processes before embarking on 
field data collection. Interviews with health providers, district managers, 
facility managers, and NGO managers were conducted in French while 
those with pregnant women, traditional healers and community workers 
were conducted in Mooré the local language. Appointments were made 
with community health workers, traditional healers, health providers, 
district managers, facility managers and NGO managers. All interviews 
were recorded using a digital recorder and files downloaded to a laptop 
the same day. Transcription was done by two transcribers. Interviews in 
Mooré were translated into French and transcribed.
 
Data analysis
 
Interviews were transcribed into a text program and then uploaded on 
Nvivo software. An analytical grid of key themes was developed based on 
the list of possible barriers in our conceptual framework, the objectives of 
the research and familiarization with the first few transcripts. Additional 
themes that emerged during the process of re-reading of transcripts 
were coded. Thematic content analysis was employed to systematically 
analyze the content of each theme.
 
Ethical issues
 
Ethical clearance was obtained from the University of Western Cape, 
the National Ethics Committee for Health in Burkina Faso and the Ethics 
Committee Review of the WHO. In addition, the study team obtained 
permission to conduct the research from the District authorities. Written 
informed consent was obtained from all participants.
Results
Although the guidelines on the management of STIs recommend syphilis 
screening for all pregnant women, we found no information on the 
proportion of pregnant women routinely tested for syphilis at district, 
regional and national level. Our study findings highlight considerable 
weaknesses within operational systems for syphilis screening. In tracking 
a woman’s journey from antenatal care (ANC) through to laboratory, the 
study documented several barriers at health provider and community 
levels.
 
Barriers at health provider level
 
The first barrier to routine syphilis screening among pregnant women 
was related to providers’ perception that syphilis in pregnancy was not 
an important issue relative to other diseases. In addition, health workers 
also felt that syphilis prevalence was low because most women who 
undertook the test were seronegative. As one auxiliary midwife who had 
worked in an urban facility since 2009 stated, “I have never found a 
positive test, all were negative.” Related to this, some health workers felt 
that syphilis was more prevalent in urban areas and thus, screening was 
more systematic in urban-based facilities. One district manager noted 
“For syphilis screening it is not really systematic and I know that in urban 
facilities health workers prescribe it to all women but at rural facilities 
it is not systematic.” Overall, we noted an absence of interventions and 
information on maternal syphilis in the district.
 
The second barrier to routine syphilis screening among pregnant women 
was related to the availability of screening equipment, which was 
particularly a challenge for rural facilities. One facility manager in a rural-
based facility noted that, “I do not systematically prescribe syphilis test 
because we have no laboratory here.” A mapping of thefacilities in the 
district indicated that three facilities (one public and two private) offered 
the syphilis test. All three facilities were urban-based. The public facility 
hosts the laboratory of the regional hospital and performs rapid plasma 
reagin (RPR) and Treponema pallidum particle agglutination assay (TPHA) 
tests. Between August 2011 and August 2012, this facility had performed 
279 RPR tests and 260 TPHA tests. Among the two private that offered 
screening, one was a pharmacy offering a point of care test, while the 
second was a faith based facility offering the RPR and TPHA test. At the 
private pharmacy, only four clients had requested a syphilis test between 
June 2011 and June 2012. At the faith based facility, 50 RPR tests and 
10 TPHA tests were performed between August 2011 and August 2012.
The third barrier was related to health workers’ inability to communicate 
the need for syphilis screening to pregnant women. Health workers 
noted that it was difficult to convince women about the importance of 
screening for syphilis. This challenge was partly related to the need to 
collect multiple blood samples from women for an HIV test, as part of 
the PMTCT program, as well as for the syphilis test. According to one 
health worker, women did not understand the need for multiple blood 
tests: “when we do an HIV test, you get a blood sample. We said that 
they need to go to the laboratory and have another blood test to know if 
they have other diseases, they said no, it is the same blood you got here 
and tested it is not necessary to have another sample.” Health workers 
acknowledged that they did not explain the importance of some of the 
examinations. For example, one manager in an urban-based facility 
noted that “Most of the time it is a lack of communication at our level, 
we do not tell to the women the importance of some exams, why this 
prescription...” The narratives from pregnant women corroborated this 
observation. One pregnant woman in a rural area stated “One day the 
health worker took blood from my left finger but I did not know if it is HIV 
test or not ...) I don’t know because until now they have said nothing.” 
The poor communication between health workers and pregnant woman 
may be related to the lack of routine training as the health workers 
stated that they had no specific training, except for a course on syphilis 
management during their professional training.
 
A fourth barrier was the fragmentation of services in a setting where 
geographic distance was already a barrier. Often women have to be 
referred to an external laboratory for the syphilis screening. According to 
health workers, many women live in rural areas and have to travel long 
distances to health facilities that offer screening services. One health 
worker commented, “we observe that most women are from villages 
around Kaya, they walk from their house to our facility and we ask them to 
do the test the day after. The distance from their house to the laboratory 
is same to our facility. Thus the majority do not go.” We observed that 
traveling from the nearest urban primary health facilities to the public 
laboratory would take about 1 hour by foot or 20 minutes by bicycle. Due 
to this situation, one urban health center had a lab technician who came 
to the facility to collect blood samples, but few women did the test.
 
Barriers at community level
 
The cost of the syphilis test was reported to be a barrier for many women. 
At the public laboratory, RPR and TPHA cost the equivalent of USD 2-3. 
The point of care test cost more in the pharmacy (USD 3) compared 
with the faith based facility (USD 2). Although the cost of syphilis tests 
in the public sector is subsidized by the government, many women are 
not screened because of the cost of the test. One auxiliary nurse stated 
“There are women who keep the exam prescription until delivery because 
they said that they have no money for the exams.”
 
Our findings also indicate that a pregnant woman’s husband or partner 
plays a key role in the decision to be screened for syphilis. Due to 
exemption of fees, women do not carry a lot of money when they go for 
their ANC visit. When they receive a prescription for additional medical 
examinations, such as the syphilis test, they have to go back home and 
get money from their husband. Sometimes, women need approval from 
their husbands as illustrated by this quote from a midwife in an urban 
facility, “sometimes, until the delivery they (women) kept the prescription 
in their health card, when you ask them why, they explain that they gave 
it to the head of the family but he did nothing.”
 
Findings also show that poor knowledge about syphilis was also a 
potential barrier to testing. For example, although many women could 
describe the symptoms of sexually transmitted infections (STIs) (itches, 
pimples, and vaginal discharge), many were unaware about syphilis or 
the consequences of untreated syphilis for the mother and child.
 
Finally, perceptions about syphilis also affected screening rates. In 
particular, the stigma surrounding sexually transmitted diseases was noted 
as a barrier to screening particularly in certain settings like pharmacies. 
One facility manager noted “the pharmacy advertised and gave the prices 
but you know women, it is difficult for them to go to the pharmacy and do 
an exam related to sex. They prefer to go to the laboratory of the hospital 
if they have money because it is a public service.” 
Discussion
Syphilis screening is recommended for premarital tests and during 
pregnancy [14]. Although a policy that promotes syphilis screening in 
pregnant women exists in Burkina Faso, screening is very limited. Our 
findings identified several barriers to the uptake of syphilis screening 
among pregnant women in Burkina Faso.
 
Syphilis testing is largely dependent on the availability of adequate 
laboratory facilities [19]. However, our results suggest that the 
fragmentation of services is key barrier to the uptake of syphilis screening. 
Health workers often have to refer women to external laboratories and 
many women, particularly those living in rural areas, have to travel long 
distances to access these laboratories. Other studies have also reported 
that long distances to screening facilities are associated with delay or 
failure to screen [20, 21]. Our findings suggest the need to introduce a 
“one-stop” service point that including ANC, PMTCT and syphilis testing.
 
As highlighted in previous studies [22, 23], we found that low motivation 
of healthcare workers to prescribe syphilis screening also contributes to 
low screening. Although the need for continued antenatal screening for 
syphilis may be questionable in areas with low prevalence [24], health 
workers in the current study were not aware about the relatively high 
prevalence of syphilis in their district. Consequently, some health workers 
failed to prescribe the test. Trepka et al [25] also found that a lack of 
provider awareness of the prevalence of syphilis was associated with 
inadequate provision of screening test in the United States. The absence 
of interventions to increase syphilis screening and the lack of information 
on maternal syphilis in the district shows also the low prioritization of 
the problem. Efforts to increase awareness about syphilis are therefore 
warranted in order to enhance syphilis screening levels.
 
The relatively high cost of screening, despite government subsidies, also 
prevents pregnant women from being screened for syphilis. The cost for 
Table 1: Study Sample
Group Number and position
District managers 1 pharmacist
1 information systems specialist
1 reproductive health specialist
Head of District
Head of regional laboratory
Health workers 2 lab technicians
4 midwives
6 auxiliary midwives
Community health workers 4 community care workers
7 drug shop managers
NGO and private 2 NGO managers
1 midwife
1 lab technician
1 pharmacist
Facility manager 7 (Primary health care center)
Community 35 pregnant women
4 traditional healers
 
http://www.panafrican-med-journal.com/content/series/17/1/12/full/tab...
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Figure 1
Trends in syphilis prevalence from 2004 to 2011 in Burkina Faso. Source: report CMLS/Santé, 
2010, 2011
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testing was observed to range between $2 and $3 USD, a prohibitive 
cost in a country where 73% of population lives on less than $2 a day 
[26]. The cost of screening is, therefore, a significant deterrent for many 
women particularly those who are financially dependent on their husband 
or partner. Women’s financial dependency means that pregnant women’s 
husbands or partners play a key role in the decision to be screened. 
Similar findings have been highlighted in previous studies [27-28] and 
underscore the need for male involvement in efforts to increase the 
uptake of syphilis screening among pregnant women.
 
Lack of knowledge about syphilis in the community was identified as a 
reason for not being screened. Most respondents at community level 
do not know the symptoms of syphilis nor its serious consequences 
for the unborn and born child. This misperception may be due to the 
lack of differentiation between STIs [29]. Most of STIs are recognized 
through symptoms and respondents do not realize that a STI could be 
asymptomatic. Community may also not perceive syphilis to be a problem 
because of its lack of visibility [30]. Low knowledge about syphilis might 
therefore pose a barrier to screening since pregnant women do not 
perceive the benefit of testing particularly for asymptomatic infections. 
As reported in a recent meta synthesis, many pregnant women did not 
feel the need to seek professional care when there is nothing wrong with 
their pregnancy [31]. Efforts to enhance awareness of syphilis and other 
STIs are therefore recommended.
 
Our study findings should be interpreted in light of several limitations. 
First, because of the exploratory nature of the study, we relied on 
qualitative methods and therefore our findings cannot be generalized 
to the larger population. Second, community’s perceptions reflected 
mostly health services users. However, study findings highlight potential 
barriers to the uptake of syphilis screening. Further research using a 
more representative sample is warranted. 
Conclusion
Our study suggests that barriers such as distance to health facilities, 
cost of testing, and knowledge about syphilis among health workers and 
communities may limit screening levels and hinder the implementation 
of syphilis screening during pregnancy as recommended in national 
guidelines. Pregnant women often weigh the benefits of syphilis screening 
against the high direct and opportunity costs. Our results have several 
implications for efforts to improve screening levels. First, communication 
between health workers and clients needs to be improved in order to 
facilitate the acceptability of the test. Second, the introduction of point of 
care testing for syphilis during ANC may improve coverage of antenatal 
syphilis screening. 
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Abstract
Background and objective: Little information is available on the rapid diagnostic testing for syphilis in Burkina Faso. The 
objectives of  the study were (i) to assess the sensitivity and specificity of  four on site rapid tests in comparison with Tre-
ponema pallidum haemagglutination assay (TPHA) as a gold standard and (ii) to evaluate the operational characteristics of  
those tests among health workers in a maternity unit.
Methods: Four rapid syphilis tests commercially available in Burkina Faso were evaluated using archived serum samples and 
Treponema pallidum hemagglutination assay (TPHA) as the gold standard. Blood samples were collected between Novem-
ber 2011 and June 2012 from blood donors at the Regional Blood Transfusion Center of  Ouagadougou. The sensitivity and 
specificity of  the tests were calculated. Evaluation of  operational characteristics such as clarity of  pamphlet, complexity of  
technique, duration, was conducted in a first-level healthcare center with health workers in maternity unit. 
Results: Alere DetermineTM Syphilis was the most sensitive of  the four rapid syphilis tests evaluated. It was followed by SD 
Bioline Syphilis 3.0, Cypress Diagnostics Syphilis Quick test and Accu-Tell ® Rapid Anti-TP, which was the least sensitive. 
The four tests demonstrated a good diagnostic specificity for syphilis (95–98%), and healthcare workers found them easy 
to use.
Conclusions: The study allowed confirming the good performance of  three of  four rapid syphilis tests in Burkina Faso. 
More research will be conducted to assess the feasibility of  introducing selected rapid tests for syphilis in antenatal care 
services.  
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Introduction
Syphilis in pregnant women remains a major pub-
lic health problem. The World Health Organization 
(WHO) estimates that 90% of  syphilis cases occur in 
low-income countries1. The prevalence in developing 
countries ranges from less than 1% to 10%. In a re-
cent review among studies in 1990-2011, prevalence 
estimates were 4.5% (3.9%-5.1%) in East and southern 
Africa and 3.5% (1.8%-5.2%)  in  West and Central Af-
rica 2. In Burkina Faso, prevalence in pregnant women 
is low, with notable regional variations3,4. According to 
WHO estimates, each year, maternal syphilis is respon-
sible for at least 50,000 spontaneous abortions or still-
births and 500,000 premature births of  babies infected 
with congenital syphilis or who have low birth weight 1. 
However, rates of  congenital syphilis are generally un-
derestimated5. Congenital syphilis is an avoidable dis-
ease that prenatal testing and early treatment of  infect-
ed pregnant women could eliminate6. 
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In response to this situation, the scientific and tech-
nical consulting group of  the WHO’s Department of  
Reproductive Health and Research adopted a strategy 
for the global elimination of  congenital syphilis by 2015 
1. Consequently, many countries have included syphilis 
testing as part of  a minimum package of  tests conduct-
ed during prenatal visits. 
Unfortunately syphilis diagnosis in peripheral clinics 
(CSPSs) in Burkina Faso is conducted using a syndro-
mic approach, while the majority of  syphilis cases are 
asymptomatic. In hospital laboratories (Medical Centers 
with Surgical Services (CMA), regional hospitals (CHR), 
national hospitals (CHU)), testing is conducted with a 
venereal diseases research laboratory (VDRL) test or 
with a Treponema pallidum hemagglutination assay 
(TPHA). Although these tests present certain advan-
tages in that they allow for the differentiation between 
an old or treated syphilis infection and active syphilis, 
as well as an analysis of  treatment adherence, their use 
requires qualified personnel, laboratory equipment, and 
a source of  electricity, which limits their utility to pe-
ripheral clinics (CSPSs). 
Currently, there are several available specific, rapid 
syphilis tests that are simple to use and could be im-
plemented in CSPSs. When compared to the diagnostic 
tests currently being used (VDRL and TPHA), rapid 
treponemic tests have several advantages, including the 
rapid availability of  results ( less than 30 minutes) and 
the fact that their usage does not require electricity or 
highly qualified laboratory staff7. Simultaneous point-
of-care treponemal and non-treponemal are available 
with good performance11 and are undergoing wide 
adoption for their benefits.  However, despite reports 
of  diagnostic performance provided by the manufac-
turers of  rapid syphilis tests, data on test effectiveness 
and operational characteristics in the field remain lim-
ited in West Africa and non-existent in Burkina Faso. 
Against that background, we conducted a study to eval-
uate the diagnostic laboratory performance and opera-
tional characteristics of  four rapid tests for Treponema 
pallidum available in Burkina Faso.  The objectives of  
the study were; to assess the sensitivity and specificity 
of  four on site rapid tests in comparison with Trepone-
ma pallidum haemagglutination assay (TPHA) as a gold 
standard and to evaluate the operational characteristics 
of  the tests. 
 
Methods 
Study populations
We evaluated rapid syphilis tests commercially avail-
able in Burkina Faso using archived serum samples 
and TPHA as the gold standard. Rapid syphilis tests 
were defined as Treponema pallidum tests (i) capable 
of  giving a result within 30 minutes and (ii) that could 
be used at service delivery points without any need for 
special storage or transport7. Only rapid syphilis tests 
with market authorization in Burkina Faso (currently 
valid or in the process of  renewing validity with the 
Ministry of  Health) were considered. In total, four tests 
were selected. These were 1) Accu-Tell® Rapid An-
ti-TP (Treponema pallidum / Syphilis) (Accu Biotech 
Co Ltd, China), 2) AlereTM DetermineTM Syphilis TP 
(AlereTM Médical Co Ltd, UK), 3) Syphilis Cypress 
Diagnostics (Cypress Diagnostics, Belgium), and 4) SD 
Bioline syphilis 3.0 (Standard Diagnostics INC, Korea). 
The characteristics of  the tests according to the manu-
facturers are listed in Table 1. 
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Table 1 Characteristics of the tests according to the manufacturers.  
Characteristics 
Accu-Tell ® 
Rapid Anti-TP 
Alere Determine™ 
Syphilis TP  
Cypress Diagnostics 
Syphilis Quick test 
Diagnostics 
SD Bioline Syphilis 
3.0 test 
Manufacturer Accu Biotech Co Ltd 
Alere TM 
Medical Co Ltd Cypress Diagnostics 
Standard 
Diagnostics INC 
Product code ABT-STD-B17 7D2443 353 Syphilis Quick Test 06FK11 
Lot used 2011071312  
14448k100 
 
25094 
 
32052 
 
Type of 
antigen 
Immunochrom
atographic 
TP 
Ag1, Ag2 
Immunochromatogr
aphic 
 
Ag Treponema 
pallidum 
Immunochromatogr
aphic 
Ag 17, 15 KDa 
Treponema pallidum 
Immunochromatogr
aphic 
Ag recombinant 
pale (17, 15 kDa) 
Specimen Serum or plasma  
Serum, plasma or 
whole blood 
Serum, plasma or 
whole blood 
Serum, plasma or 
whole blood 
Time needed 
for results 15 minutes 
15 minutes 
24 hours maximum 5–20 minutes 5–20 minutes 
Stable result 20 minutes 24 hours 20 minutes 20 minutes 
Storage 
conditions 2–30°C 2–30°C 8–30°C 2–30°C 
 
Blood samples were collected between November 2011 
and June 2012 from blood donors at the Regional Blood 
Transfusion Center (CRTS) of  Ouagadougou, Burkina 
Faso. A total of  120 serum samples were considered 
for the evaluation. There were 60 samples positive for 
syphilis (50 samples were TPHA and VDRL positive: 
active syphilis, and 10 were TPHA positive and VDRL 
negative: previous or primary case of  syphilis) and 60 
samples negative for syphilis (50 samples were TPHA 
negative and VDRL negative, and 10 were TPHA neg-
ative and VDRL positive). The comparative analysis 
was conducted in the laboratory of  the Institut de Re-
cherche en Science de la Santé (IRSS) in Ouagadougou, 
Burkina Faso.
For the evaluation of  the operational characteristics, 
the study was conducted in a primary healthcare cen-
tre (CSPS) located in Ouagadougou the capital city of  
Burkina Faso. In total sixteen healthcare profession-
als (midwives, birth attendants, and auxiliary birth at-
tendants) working in the maternity ward of  an urban 
first-level healthcare were trained in the use of  the four 
tests. Their seniority in the maternity ward was between 
6 months and 18 years, although none had previously 
used a rapid syphilis test. However, they had used HIV 
and malaria rapid tests. 
Sample collection
After obtaining the blood donor’s consent, approxi-
mately 10 mL of  blood was taken from the blood col-
lection bag, put in a dry BD Vacutainer® tube (Becton, 
Dickinson and Company; USA) without anticoagulant 
and kept at +4°C for approximately four hours while 
waiting for the results of  the syphilis test. 
For the operational characteristics study, during the rou-
tine prenatal consultations, each healthcare worker used 
each rapid syphilis test on 5 pregnant women who con-
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sented to a blood-draw by finger prick. A self-adminis-
tered questionnaire was made available to the healthcare 
workers for the data collection. The operational charac-
teristics were appreciated following: (i) the clarity of  the 
manufacturers’ pamphlets, mainly the description of  
use, in terms of  level of  comprehension, (ii) the com-
plexity of  technique, (iii) the length of  time required 
to complete the entire testing process, (iv) the time of  
apparition of  line result, and (v) the interpretation of  
result.  For each criterion, measures were defined.
The clarity of  the manufacturer’s pamphlets was appre-
ciated regarding comprehension of  the text if  it was 
very clear, moderately clear or difficult to understand.
The complexity of  technique was looked if  the tech-
nique for utilization (from blood collection to the avail-
ability of  the result) was complex (very difficult), mod-
erately complex (difficult) or very easy in comparison 
with other rapid tests they had already used such as 
HIV test. The length of  time required for a test (from 
blood collection to the availability of  the result) was 
compared to the duration of  other rapid tests they had 
used following the modalities of  long, equivalent or 
short duration. The time for apparition of  line result 
was compared to what was written in the pamphlet of  
each test. Finally the ease in interpretation of  the result, 
in terms of  visibility and readability of  line result, was 
compared to other used rapid tests following the mo-
dalities of  very easy or moderately easy to interpret.  All 
these criteria were used to appreciate if  a test has good 
operational characteristics or not.
Laboratory methods
After blood collection from blood donors, syphilis test 
was conducted by CRTS using the ARCHITECT Syph-
ilis TP automated treponemal antibody test (Abbott Di-
agnostic, USA). This is a two-step immunoassay for the 
qualitative detection of  anti-TP antibodies in human se-
rum or plasma. It uses chemiluminescent microparticle 
immunoassay (CMIA) technology with flexible dosage 
protocols called Chemiflex. The microparticles are cov-
ered with recombinant TP antigens (TpN15, TpN17, 
and TpN47). Once the syphilis status of  the blood do-
nor was determined by CRTS, we chose positive and 
negative samples for syphilis for our evaluation. At the 
end of  the collection day, the samples were centrifuged 
at 3000 rpm for 10 minutes and then submitted to com-
bine VDRL/TPHA (BIOLABO SA, France) testing in 
the serologic laboratory of  the Institut de Recherche en 
Sciences de la Santé (IRSS) to confirm the syphilis sta-
tus. After confirmation, the serum was aliquoted in two 
cryotubes of  2 mL, labeled, and stored at -20°C until 
beginning of  the next stage of  the evaluation. Hemo-
lytic samples were excluded.
The evaluation of  the rapid syphilis tests performance 
was conducted at the laboratory of  IRSS in July 2012 
using the stock of  serum samples from CRTS. The 
evaluation followed the manufacturers’ instructions 
and used good laboratory practices.  First the frozen 
serum samples were brought to ambient temperature 
before use. Then each test was used in series. To avoid 
the comparison of  results between tests during the lab-
oratory analysis, each rapid test was used on all samples 
before moving to the next test. There was a blind in-
terpretation of  test results, independent of  the results 
of  the reference test (TPHA). TPHA (BIOLABO SA, 
http://www.biolabo.fr/pdfs/noticesFR/Syphilis) was 
used as the gold standard (reference test). It is an in-
direct hemagglutination assay (IHA) for the identifica-
tion of  Treponema pallidum antibodies circulating in 
human plasma and regularly used for the diagnosis of  
syphilis in a laboratory.
Statistical data analysis
For each test, the laboratory evaluation results were 
compared to the reference test (TPHA) and catego-
rized as true positive, false positive, true negative, or 
false negative. The data were entered with Epidata and 
analyzed using SPSS version 15 and R version 2-12.1. 
The performance characteristics, such as sensitivity 
and specificity were calculated relative to the reference 
standard TPHA results obtained for each serum spec-
imen.  
Ethical issues
The research protocol received the approval of  the 
Health Research Ethics Committee (CERS), Ministry 
of  Health, Burkina Faso.  
 
Results 
Performance of  diagnostic tests 
A total of  120 samples were tested for the evaluation 
of  the performance.  The sensitivity of  the tests was 
compared to the gold standard used (TPHA). Analysis 
of  the sensitivity of  the tests showed that Alere Deter-
mineTM syphilis TP had the highest sensitivity (93%) 
among the four selected rapid tests. The sensitivity of  
Cypress syphilis and SD Bioline Syphilis 3.0 was 90%. 
Accu-Tell ® Rapid Anti-TP had a sensitivity of  78%. 
In terms of  specificity, Alere DetermineTM syphilis TP, 
Accu-Tell ® Rapid Anti-TP and SD Bioline Syphilis 3.0 
had the same result (98%), while Cypress syphilis had a 
specificity of  95%. (Table 2) 
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Table 2 Results of the diagnostic performances of rapid syphilis tests.  
 
Accu-Tell ® Rapid 
Anti-TP (Accu 
Biotech Co Ltd) 
Alere Determine™ 
Syphilis TP 
(AlereTM 
Médical Co Ltd) 
Cypress Diagnostics 
Syphilis Quick test 
(Cypress 
Diagnostics) 
SD Bioline Syphilis 
3.0 test (Standard 
Diagnostics INC) 
Sensitivity 
(95% CI) 78% (66 - 87) 93% (84-97) 90% (79-95) 90% (80-95) 
Specificity 
(95% CI) 98% (91-100) 98% (91-100) 95% (86-98) 98% (91-100) 
     
     
CI = confidence interval 
Operational characteristics of  the four tests ac-
cording to healthcare professionals 
The results of  the evaluation of  the operational charac-
teristics of  the four tests by 16 healthcare professionals 
are summarized in Table 3. The pamphlet of  the test 
was clearly comprehensible by 12 of  the 16 respondents 
for Accu-Tell ® Rapid Anti-TP, by 11 respondents for 
SD Bioline syphilis 3.0, by 9 respondents for Cypress 
Diagnostics Syphilis Quick test, and by 7 respondents 
for Alere DetermineTM syphilis TP. 
As a whole, the healthcare professionals judged the 
technique for utilization of  the tests to be very easy. 
Indeed, of  the 16 healthcare professionals who partic-
ipated in the evaluation, 15 found Cypress Diagnostics 
Syphilis Quick test and SD Bioline Syphilis 3.0 to be 
very easy to use, while 14 said the same for Accu-Tell 
® Rapid Anti-TP and Alere DetermineTM syphilis TP.
Overall, the time needed to obtain results was deter-
mined to be similar to other tests already used for HIV 
and malaria. Specifically, 10 respondents found Alere 
DetermineTM syphilis TP and Cypress Diagnostics 
Syphilis Quick test to be similar to the previously used 
tests, and approximately 50% found this for Accu-Tell 
® Rapid Anti-TP (9/16) and SD Bioline syphilis 3.0 
(8/16). 
For the majority of  respondents, the time required to 
obtain results matched the time indicated by the manu-
facturer for Accu-Tell ® Rapid Anti-TP, Cypress Diag-
nostics Syphilis Quick test and SD Bioline syphilis 3.0 
(Table 3). 
The interpretation of  results was found to be very easy 
by 14 of  16 respondents for Accu-Tell ® Rapid An-
ti-TP and SD Bioline syphilis 3.0 and by 12 of  16 re-
spondents for Alere DetermineTM syphilis TP. As for 
Cypress Diagnostics Syphilis Quick test, only 9 of  16 
found the results to be easy to interpret.
The realization of  the tests requires the use of  equip-
ment not provided in the kit. Specific and non-specific 
equipment are needed. Specific equipment, such as cap-
illary tubes with EDTA for Alere Determine™ Syphilis 
TP and pipettes for Cypress Diagnostics Syphilis Quick 
test and SD Bioline syphilis 3.0 Accu-Tell® are need-
ed. Rapid Anti-TP does not require specific equipment. 
Non-specific equipment, including alcohol swabs and 
lancets, was required for the four tests. 
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Table 3 Operational characteristics of syphilis diagnostic tests.  
   Characteristics evaluated 
Accu-Tell ® 
Rapid Anti-
TP 
Alere 
Determine™ 
Syphilis TP 
(AlereTM 
Médical Co 
Ltd) 
Cypress 
Diagnostics 
Syphilis 
Quick test 
SD Bioline 
Syphilis 3.0 
test  
(Standard 
Diagnostics 
INC) 
Clarity of the test pamphlet  (n=16) (n=16) (n=16) (n=16) 
            Difficult to understand                                            2 2 1 1 
             Moderately clear 2 7 6 4 
                Very clear 12 7 9 11 
    
  Complexity of technique (n=16) (n=16) (n=16) (n=16) 
Complex 1 0 0 0 
              Moderately complex 1 2 1 1 
Very easy 14 14 15 15 
Time needed for performing  (n=16) (n=16) (n=16) (n=16) 
Long 0 4 0 0 
Equivalent 9 10 10 8 
Short 7 2 6 8 
 
Time need for results  
 
(n=16) 
 
(n=16) 
 
(n=16) 
 
(n=16) 
Time indicated in pamphlet 15 14 15 15 
Time indicated plus 5 minutes 1 2 1 1 
 
Ease of result interpretation 
 
(n=16) 
 
(n=16) 
 
(n=16) 
 
(n=16) 
Moderately easy 2 4 7 2 
Very easy 14 12 9 14 
 
Discussion
This is the first evaluation of  the performance and the 
characteristics of  commercially available rapid diag-
nostic syphilis tests for Burkina Faso, and it allows the 
identification of  the test that is  adapted to the context 
of  the country. To our knowledge, two of  the tests, Cy-
press Diagnostics Syphilis Quick test and Accu-Tell ® 
Rapid Anti-TP, were for the first time compared to oth-
er rapid tests for syphilis in West Africa.
All the tests used an immunochromatographic detec-
tion of  anti-Treponema pallidum antibodies. These 
tests used one or more of  several similar recombinant 
Treponema pallidum antigens, although their diagnostic 
performances in our study were different. With a sen-
sitivity of  93%, Alere DetermineTM Syphilis was the 
most sensitive of  the four rapid syphilis tests. It was fol-
lowed by SD Bioline Syphilis 3.0 and Cypress Diagnos-
tics Syphilis Quick test (Se = 90%), with Accu-Tell ® 
Rapid Anti-TP being the least sensitive (Se =78%). In 
general, the four tests demonstrated a good diagnostic 
specificity for syphilis (95 – 98%). Taking into account 
the two diagnostic criteria of  sensitivity and specificity, 
our study showed that Alere DetermineTM Syphilis had 
higher diagnostic performance than the four evaluated 
tests (Se = 93%, Sp = 98%) followed by SD Bioline 
Syphilis 3.0 (Se = 90%, Sp = 98%). The good diagnos-
tic performance of  these rapid tests compared to other 
tests has been reported in the literature10–13. However, 
few data exist regarding the performances of  Cypress 
Diagnostics Syphilis Quick test and Accu-Tell ® Rapid 
Anti-TP.
The performance of  the tests was different than what 
was indicated in the manufacturers’ pamphlets. Our 
results showed lower values than those reported for 
Cypress Diagnostics Syphilis Quick test (99.3% and 
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99.5%), Alere DetermineTM syphilis TP (100% with 
serum), and SD Bioline syphilis 3.0  (99.3% and 99.5%). 
The pamphlet for Accu-Tell ® Rapid Anti-TP did not 
give any indication of  performance. This data, which is 
crucial in the choice of  diagnostic tests, is unavailable 
in the current published literature. This result calls into 
question the criteria used for obtaining market author-
ization from the Ministry of  Health to sell rapid tests 
in Burkina Faso. Additionally, this result emphasizes the 
need to evaluate available tests on the local market to 
properly inform policy decision makers.  
The performances of  Cypress Diagnostics Syphilis 
Quick test, Alere DetermineTM syphilis TP, and SD 
Bioline syphilis in this study were in accordance with 
the threshold set by the WHO7, which recommends a 
minimum sensitivity of  85% and a minimum specific-
ity of  95%. The low sensitivity of  Accu-Tell ® Rapid 
Anti-TP (78%) when compared to the WHO threshold 
shows that this test is inappropriate for syphilis testing 
in Burkina Faso. 
The sensitivities found for Alere DetermineTM syphilis 
TP and SD Bioline syphilis 3.0 are below those found 
by Herring et al.14 using stored serum samples in Gam-
bia (100%), Tanzania (96% and 94%), and South Africa 
(96% and 94%). However, their specificities are higher 
than those found by Herring et al. and Mabey et al.13 
and similar to the results obtained in China. This varia-
tion in performance could be explained not only by am-
bient storage conditions and use of  the different tests 
but also by the use of  fluorescent treponemal antibody, 
absorbed (FTA-ABS) as reference test and the type of  
specimen used. This study, whose objective was to eval-
uate rapid syphilis tests commercially available in Burki-
na Faso, used tests bought or received by intermediaries 
of  local distributors. A direct order of  rapid tests from 
the manufacturer would have permitted the traceability 
of  the tests evaluated.  
Regarding the evaluation of  operational characteristics, 
no test was found to be easier to use than any other. We 
found all four tests to have very good operational char-
acteristics. In fact, the majority of  respondents found 
that the results were very easy to interpret, and the time 
required to use the tests was similar to that of  existing 
tests for HIV and malaria. These results are corrobo-
rated by Herring et al. for Alere DetermineTM syphilis 
TP and SD Bioline syphilis 3.0. Other studies have also 
shown rapid diagnostic syphilis tests to be easy to use15 
but this criterion is not the most important in choosing 
a diagnostic test. Although perceived favorably by the 
healthcare professionals, the four test kits were missing 
equipment. This equipment, such as alcohol swabs, lan-
cets, pipettes, and capillary tubes, is necessary to use the 
tests in the field. We recommend that the distributors 
include them in the kits to ensure correct use of  the 
tests. 
Of  the four tests, three can be performed using whole 
blood. Studies have documented the performance of  
Alere DetermineTM syphilis TP in both the laboratory 
as well as in real-world situations13. Given its simplici-
ty and its good performance in our study, which is in 
agreement with data collected in previous studies by 
other research teams, Alere DetermineTM syphilis TP 
seems to be adapted to syphilis testing in Burkina Faso. 
While our study presented the laboratory performance 
of  these tests when used with serum  samples, their 
performance with whole blood will be different16. In 
addition, providing diagnostic tests to CSPSs would al-
low for the collection of  more information on the ef-
fects of  storage conditions on test performance when 
used in rural settings. Moreover, we did not evaluate 
the effects that additional infections, such as HIV or 
malaria, could have on the performance of  these tests 
in real-world situations with whole blood.
Conclusion
Rapid syphilis tests in limited-resource countries can 
help diagnose syphilis in CSPSs that, until now, have 
used a syndromic approach to STI diagnosis. Our study 
allowed us first to confirm the good performance of  
three of  four rapid syphilis tests in Burkina Faso. Ad-
ditionally, it allowed us to identify Alere DetermineTM 
Syphilis TP as the test that is adapted to Burkina Faso. 
More research on the feasibility and acceptability of  
these rapid syphilis tests in first-level healthcare centers 
should allow for the effective implementation of  the 
recommendation for systematic testing of  pregnant 
women.
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